Supplement

Supplementary Table 1 Specification and explanation of inclusion criteria

|  |  |  |
| --- | --- | --- |
| Inclusion Criterion | Specification | Explanation |
| HTA-report | - Report that includes an evaluation of a health technology  - Main objective is to inform medical decision making | Several definitions exist for HTA (e. g. [42-44]). We therefore included all reports that fulfilled the specified criteria as theses were included in all definitions. |
| Systematic review of health economic evaluation (SR-HE) | - Report contains economic aspects of the technology under assessment  - Author state that a literature review of economic evaluations in at least one database was conducted | We applied this rather broad definition as only a small number of systematic reviews are conducted within the economic domain in HTA and we aimed to provide a wide overview of the methods. |
| Language | English, German, French, or Spanish | We included any report that were written in a language familiar to a least one reviewer. |

Supplementary Table 2 Data extraction form for the analysis of methods applied in systematic reviews of health economic evidence

|  |  |
| --- | --- |
| Report/ Manual | |
| Institution |  |
| **Scope of the systematic review** | |
| Scope of SR-HE (only SR-HE/SR-HE and primary CEA/SR-HE to inform primary CEA) |  |
| **Statement of research question and formulated eligibility criteria** | |
| Research question (not stated/stated, recommended/not stated for manuals) |  |
| Eligibility criteria (PICOS + further) |  |
| Economic study types included |  |
| **Literature search strategy** | |
| Information sources (Databases, reference lists of relevant records etc.) |  |
| Search terms/filters  + Explanation when economic terms missing (e.g. joint SR for clinical and economic effectiveness/for all domains) |  |
| Search limits (time period, language, publication type, etc.) |  |
| **Study selection** | |
| Flow of study selection (yes/no) |  |
| Study Selection illustrated in Flow Chart (yes/no) |  |
| Duplicate study selection (yes/no/unclear) + method (e.g. all independently/quality assurance of sample) + mechanism to resolve disagreement) |  |
| **Data extraction** | |
| Data extraction method (e.g. standardized data extraction form) |  |
| Duplicate data extraction (yes/no/unclear) + method (e.g. all independently/quality assurance of sample) + mechanism to resolve disagreement |  |
| Data items extracted |  |
| **Assessment of methodological study quality** | |
| Assessment of methodological study quality on study level (yes/no/unclear) + assessment tool |  |
| Duplicate quality assessment (yes/no/unclear) + method (e.g. all independently/quality assurance of sample) + mechanism to resolve disagreement |  |
| **Assessment of generalizability/transferability/applicability** | |
| Assessment of generalizability/transferability/applicability (yes/no/unclear) + assessment tool |  |
| Duplicate generalizability/transferability/applicability assessment (yes/no/unclear) + method (e.g. all independently/quality assurance of sample) + mechanism to resolve disagreement |  |
| **Presentation of cost data** | |
| Presentation of cost data (as reported/inflated/currency converted) |  |
| **Method for data synthesis** | |
| Data synthesis |  |
| Further remarks |  |

Supplementary Table 3 Agencies with included HTA-reports

| Agency | Country | Number of reports included |
| --- | --- | --- |
| Agencia de Evaluación de Tecnologías Sanitarias de Andalucía (AETSA) | Spain | 6 |
| Agenzia nazionale per i servizi sanitari regionali (Agenas) | Italy | 3 |
| Adelaide Health Technology Assessment (AHTA) | Australia | 1 |
| Alberta Health Technologies Decision Process (AHTDP) | Canada | 1 |
| Canadian Agency for Drugs and Technologies in Health (CADTH) | Canada | 4 |
| Comité d’évaluation et de diffusion des innovations technologiques (CEDIT) | France | 2 |
| European Network for Health Technology Assessment (EUnetHTA) | Europe | 1 |
| Health Policy Advisory Committee on Technology (HealthPACT) | Australia | 2 |
| Health Information and Quality Authority (HIQA) | Ireland | 4 |
| Healthcare Improvement Scotland (HIS) | Scotland | 8 |
| Health Quality Ontario (HQO) | Canada | 10 (of 21 identified) |
| Hauptverband der österreichischen Sozialversicherung (HVB) | Austria | 1 |
| Institute for Clinical and Economic Review (ICER) | USA | 9 |
| Institute of Health Economics (IHE) | Canada | 1 |
| Institut national d’excellence en santé et en services sociaux (INESSS) | Canada | 7 |
| Belgian Health Care Knowledge Centre (KCE) | Belgium | 8 |
| Ludwig Boltzmann Institut (LBI) | Austria | 1 |
| National Institute for Health Research (NIHR) | England | 10 (of 59 identified) |
| Servicio de Evaluación del Servicio Canario de la Salud (SESCS) | Spain | 4 |

Supplementary Table 4 Reports included

| Agency | Report | Rapid report |
| --- | --- | --- |
| Agencia de Evaluación de Tecnologías Sanitarias de Andalucía (AETSA) | Agencia de Evaluación de Tecnologías Sanitarias de Andalucía. Eculizumab en el tratamiento del síndrome hemolítico urémico atípico. 2015. Available from: http://www.juntadeandalucia.es/salud/servicios/contenidos/nuevaaetsa/up/AETSA\_2015\_18\_Eculizumab%20SHUa\_def.pdf. [Accessed 02.07.2016]. |  |
| Agencia de Evaluación de Tecnologías Sanitarias de Andalucía. Tallos de crecimiento electromagnéticos para el tratamiento de la escoliosis de aparición precoz de diversa etiología. 2015. Available from: http://www.juntadeandalucia.es/salud/servicios/contenidos/nuevaaetsa/up/09\_AETSA\_Tallos%20de%20crecimiento%20electromagnetico\_DEF\_NIPO.pdf. [Accessed 02.07.2016]. |  |
| Agencia de Evaluación de Tecnologías Sanitarias de Andalucía. Terapia focal del cáncer de próstata localizado: electroporación irreversible, ultrasonidos focalizados de alta intensidad y láser de holmio. 2015. Available from: http://www.juntadeandalucia.es/salud/servicios/contenidos/nuevaaetsa/up/2014\_04\_AETSA\_Cancer\_prostata\_DEF.pdf. [Accessed 02.07.2016]. |  |
| Agencia de Evaluación de Tecnologías Sanitarias de Andalucía. Eficacia, seguridad y eficiencia del sistema de terapia de presión negativa V.A.C. en heridas traumáticas y postquirúrgicas: Revisión sistemática. 2016. [Accessed 02.07.2016]. |  |
| Agencia de Evaluación de Tecnologías Sanitarias de Andalucía. Seguimiento del cáncer de mama en Atención Primaria. 2016. Available from: http://www.juntadeandalucia.es/salud/servicios/contenidos/nuevaaetsa/up/01\_AETSA\_Seguimiento\_Cancer\_de\_mama\_DEF\_NIPO.pdf. [Accessed 02.07.2016]. |  |
| Agencia de Evaluación de Tecnologías Sanitarias de Andalucía. Termoplastia bronquial en pacientes con asma bronquial severo o grave. Eficacia, seguridady eficiencia. 2016. Available from: http://www.juntadeandalucia.es/salud/servicios/contenidos/nuevaaetsa/up/03\_AETSA\_Termoplastia\_DEF\_NIPO.pdf. [Accessed 02.07.2016]. |  |
| Agenzia nazionale per i servizi sanitari regionali (Agenas) | Gillespie F, Abraha I, Amicosante A, et al. HTA REPORT: “Implantable LVAD (Left Ventricular Assist Device) in addition to guideline directed medical therapy (GDMT) in end stage heart failure”. 2015. Available from: http://www.salute.gov.it/imgs/C\_17\_pagineAree\_1202\_listaFile\_itemName\_10\_file.pdf. [Accessed 02.07.2016]. |  |
| Migliore A, Corio M, Perrini M, et al. Rapid HTA Report: Transcatheter implantable devices for mitral valve repair in adults with chronic mitral valve regurgitation 2015. Available from: http://www.salute.gov.it/imgs/C\_17\_pagineAree\_1202\_listaFile\_itemName\_11\_file.pdf. [Accessed 02.07.2016]. | x |
| Paone S, Migliore A, Abraha I, et al. Rapid HTA Report: Sutureless aortic valve replacement for aortic valve stenosis. 2015. Available from: http://www.salute.gov.it/imgs/C\_17\_pagineAree\_1202\_listaFile\_itemName\_9\_file.pdf. [Accessed 02.07.2016]. | x |
| Adelaide Health Technology Assessment (AHTA) | SJM K, JK M, R M, et al. Testing for hereditary mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: Assessment report. 2015. Available from: http://www.msac.gov.au/internet/msac/publishing.nsf/Content/B1083E11E4A3006BCA257BCB0081849E/$File/1216-MSAC-CA-CFTR.pdf. [Accessed 02.07.2016]. |  |
| Alberta Health Technologies Decision Process (AHTDP) | The Health Technology Assessment Unit; University of Calgary. Hepatitis C Screening in Alberta: A Health Technology Assessment 2016. Available from: http://www.health.alberta.ca/documents/AHTDP-HepatitisC-Screening-HTA-Report-2016.pdf. [Accessed 02.07.2016]. |  |
| Canadian Agency for Drugs and Technologies in Health (CADTH) | Canadian Agency for Drugs and Technologies in Health (CADTH). Comparative Value of Erythrocyte Sedimentation Rate (ESR) and C-Reactive Protein (CRP) Testing in Combination Versus Individually for the Diagnosis of Undifferentiated Patients With Suspected Inflammatory Disease or Serious Infection: A Systematic Review and Economic Analysis - CADTH health technology assessment; no.140. 2015. Available from: https://www.cadth.ca/sites/default/files/pdf/HT0006-OP0516\_ESRandCRP\_e.pdf. [Accessed 08.07.2016]. |  |
| Canadian Agency for Drugs and Technologies in Health (CADTH). Costs of Contact Tracing Activities Aimed at Reducing the Transmission of Measles in Canada. 2015. Available from: https://www.cadth.ca/sites/default/files/pdf/CP0010\_Measles\_Contact\_Tracing\_Report.pdf. [Accessed 08.07.2016]. |  |
| Canadian Agency for Drugs and Technologies in Health (CADTH). Capnography for Monitoring End-Tidal CO2 in Hospital and Pre-hospital Settings: A Health Technology Assessment - CADTH health technology assessment; no.142. 2016. Available from: https://www.cadth.ca/sites/default/files/pdf/HT0007\_End-Tidal\_CO2\_Review.pdf. [Accessed 08.07.2016]. |  |
| Canadian Agency for Drugs and Technologies in Health (CADTH). Cognitive Processing Therapy for Post-traumatic Stress Disorder: A Systematic Review and Meta-analysis - CADTH health technology assessment; no.141. 2016. Available from: https://www.cadth.ca/sites/default/files/pdf/RE0031\_HT009\_CPT\_for\_PTSD.pdf. [Accessed 08.07.2016]. |  |
| Comité d’évaluation et de diffusion des innovations technologiques (CEDIT) | Barna A, Charpentier E, Fahlgren B, et al. Traçabilité individuelle des instruments de chirurgie - Avis du CEDIT. 2016. Available from: http://recherche.aphp.fr/wp-content/blogs.dir/85/files/2016/03/Traçabilité-des-instruments-final-23-mars.pdf. [Accessed 08.07.2016]. |  |
| Charpentier E, Barna A, Guillevin L, et al. Fully bioresorbable drug-eluting coronary scaffolds: A review. Archives of Cardiovascular Diseases. 2015 6//; 108(6–7):385-97. |  |
| European Network for Health Technology Assessment (EUnetHTA) | Agenzia nazionale per i servizi sanitari regionali (Agenas). Structured telephone support (STS) for adult patients with chronic heart failure [Core HTA]. 2015. Available from: http://meka.thl.fi/htacore/ViewCover.aspx?id=305. [Accessed 14.09.2016]. |  |
| Health Policy Advisory Committee on Technology (HealthPACT) | Health Policy Advisory Committee on Technology (HealthPACT). New and Emerging Health Technologies for Diabetes: New and Emerging Health Technology Report. 2015. Available from: https://www.health.qld.gov.au/healthpact/docs/briefs/wp228-diabetes-nehtr.pdf. [Accessed 03.08.2016]. |  |
| Health Policy Advisory Committee on Technology (HealthPACT). Cell salvage as a patient blood management strategy: New and Emerging Health Technology Report. 2015. Available from: https://www.health.qld.gov.au/healthpact/docs/briefs/WP176.pdf. [Accessed 03.08.2016]. |  |
| Health Information and Quality Authority (HIQA) | Health Information and Quality Authority (HIQA). Health technology assessment of chronic disease self-management support interventions. 2015. Available from: https://www.hiqa.ie/publications/health-technology-assessment-chronic-disease-self-management-support-interventions. [Accessed 03.08.2016]. |  |
| Health Information and Quality Authority (HIQA). Health technology assessment of a selective BCG vaccination programme. 2015. Available from: https://www.hiqa.ie/publications/health-technology-assessment-selective-bcg-vaccination-programme. [Accessed 03.08.2016]. |  |
| Health Information and Quality Authority (HIQA). Health technology assessment (HTA) of a national screening programme for atrial fibrillation in primary care. 2015. Available from: https://www.hiqa.ie/publications/health-technology-assessment-hta-national-screening-programme-atrial-fibrillation-prima. [Accessed 03.08.2016]. |  |
| Health Information and Quality Authority (HIQA). Health technology assessment of the use of information technology for early warning and clinical handover systems. 2015. Available from: https://www.hiqa.ie/publications/health-technology-assessment-use-information-technology-early-warning-and-clinical-hand. [Accessed 03.08.2016]. |  |
| Healthcare Improvement Scotland (HIS) | Healthcare Improvement Scotland. Antimicrobial wound dressings for chronic wounds: HTA report 13 2015. Available from: http://www.healthcareimprovementscotland.org/our\_work/technologies\_and\_medicines/shtg\_-\_hta/hta13\_antimicrobial\_dressings.aspx. [Accessed 03.08.2016]. |  |
| Healthcare Improvement Scotland. Magnetic resonance guided focused ultrasound surgery (MRgFUS) for painful bone metastases: evidence note 56. 2015. Available from: http://www.healthcareimprovementscotland.org/our\_work/technologies\_and\_medicines/shtg\_-\_evidence\_notes/evidence\_note\_56.aspx. [Accessed 03.08.2016]. | x |
| Healthcare Improvement Scotland. Patient self-monitoring oral anticoagulation therapy: evidence note 57. 2015. Available from: http://www.healthcareimprovementscotland.org/our\_work/technologies\_and\_medicines/shtg\_-\_evidence\_notes/evidence\_note\_57.aspx. [Accessed 03.08.2016]. | x |
| Healthcare Improvement Scotland. Magnetic resonance guided focused ultrasound surgery (MRgFUS) for the treatment of uterine fibroids: evidence note 55. 2015. Available from: http://www.healthcareimprovementscotland.org/our\_work/technologies\_and\_medicines/shtg\_-\_evidence\_notes/evidence\_note\_55.aspx. [Accessed 03.08.2016]. | x |
| Healthcare Improvement Scotland. Endovascular therapy using mechanical thrombectomy devices for patients with acute ischaemic stroke: evidence note 61. 2016. Available from: http://www.healthcareimprovementscotland.org/our\_work/technologies\_and\_medicines/shtg\_-\_evidence\_notes/evidence\_note\_61.aspx. [Accessed 03.08.2016]. | x |
| Healthcare Improvement Scotland. Home health monitoring compared with usual care for patients with moderate to severe chronic obstructive pulmonary disease: evodence note 60. 2016. Available from: http://www.healthcareimprovementscotland.org/our\_work/technologies\_and\_medicines/shtg\_-\_evidence\_notes/evidence\_note\_60.aspx. [Accessed 03.08.2016]. | x |
| Healthcare Improvement Scotland. Home health monitoring devices compared with usual care for patients with hypertension; evidence note 59. 2016. Available from: http://www.healthcareimprovementscotland.org/our\_work/technologies\_and\_medicines/shtg\_-\_evidence\_notes/evidence\_note\_59.aspx. [Accessed 03.08.2016]. | x |
| Healthcare Improvement Scotland. MitraClip® transcatheter mitral valve repair system: evidence note 58. 2016. Available from: http://www.healthcareimprovementscotland.org/our\_work/technologies\_and\_medicines/shtg\_-\_evidence\_notes/evidence\_note\_58.aspx. [Accessed 03.08.2016]. | x |
| Health Quality Ontario (HQO) | Health Quality Ontario. Mitral Valve Clip for Treatment of Mitral Regurgitation: An Evidence-Based Analysis. 2015. Available from: http://www.hqontario.ca/Portals/0/Documents/evidence/reports/eba-mitral-valve-clip-1505-en.pdf. [Accessed 05.08.2016]. |  |
| Health Quality Ontario. Prostate-Specific Antigen (PSA)–Based Population Screening for Prostate Cancer: An Economic Analysis. 2015. Available from: http://www.hqontario.ca/Portals/0/Documents/evidence/reports/economic-analysis-psa-screening-1505-en.pdf. [Accessed 05.08.2016]. |  |
| Health Quality Ontario. Effect of Increased Intensity of Physiotherapy on Patient Outcomes After Stroke: An Economic Literature Review and Cost-Effectiveness Analysis. 2015. Available from: http://www.hqontario.ca/Portals/0/Documents/evidence/reports/economic-analysis-increased-intensity-pt-1503-en.pdf. [Accessed 05.08.2016]. |  |
| Health Quality Ontario. Magnetic Resonance-Guided High-Intensity Focused Ultrasound (MRgHIFU) for Treatment of Symptomatic Uterine Fibroids: An Economic Analysis. 2015. Available from: http://www.hqontario.ca/Portals/0/Documents/evidence/reports/economic-analysis-mrghifu-1503-en.pdf. [Accessed 05.08.2016]. |  |
| Health Quality Ontario. Cost-Effectiveness of Urgent Care for Transient Ischemic Attack: An Economic Rapid Review. 2015. Available from: http://www.hqontario.ca/Portals/0/Documents/evidence/rapid-reviews/cost-effective-analysis-transient-ischemic-attack-20152302-en.pdf. [Accessed 05.08.2016]. | x |
| Health Quality Ontario. Ultrasound as an Adjunct to Mammography for Breast Cancer Screening: A Health Technology Assessment. 2016. Available from: http://www.hqontario.ca/Portals/0/Documents/evidence/reports/hta-screening-breast-ultrasound-en-1607.pdf. [Accessed 04.08.2016]. |  |
| Health Quality Ontario. Retinal Prosthesis System for Advanced Retinitis Pigmentosa: A Health Technology Assessment. 2016. Available from: http://www.hqontario.ca/Portals/0/Documents/evidence/reports/hta-retinal-prosthetics-en-1606.pdf. [Accessed 04.08.2016]. |  |
| Health Quality Ontario. Vertebral Augmentation Involving Vertebroplasty or Kyphoplasty for Cancer-Related Vertebral Compression Fractures: An Economic Analysis. 2016. Available from: http://www.hqontario.ca/Portals/0/Documents/evidence/reports/econ-kyphoplasty-en-1605.pdf. [Accessed 04.08.2016]. |  |
| Health Quality Ontario. Skin Testing for Allergic Rhinitis: A Health Technology Assessment. 2016. Available from: http://www.hqontario.ca/Portals/0/Documents/evidence/reports/hta-rhinitis-testing-en-1605.pdf. [Accessed 04.08.2016]. |  |
| Health Quality Ontario. Intrathecal Drug Delivery Systems for Cancer Pain: A Health Technology Assessment. 2016. Available from: http://www.hqontario.ca/Portals/0/Documents/evidence/reports/eba-cancer-pain-1601-en.pdf. [Accessed 04.08.2016]. |  |
| Hauptverband der österreichischen Sozialversicherung (HVB) | Hauptverband der österreichischen Sozialversicherung. Strukturierte telefonische Unterstützung (structured telephone support, STS) als Telemonitoring Intervention. Bei Patienten mit chronischer Herzinsuffizienz. 2016. Available from: <http://www.hauptverband.at/cdscontent/load?contentid=10008.631035&version=1464592804>. [Accessed 05.08.2016]. |  |
| Institute for Clinical and Economic Review (ICER) | Institute for Clinical and Economic Review. Bariatric Surgery. 2015. Available from: <https://icer-review.org/wp-content/uploads/2016/02/bariatric_final_rpt_040315.pdf>. [Accessed 06.08.2016]. |  |
| Institute for Clinical and Economic Review. The Comparative Clinical Effectiveness and Value of Novel Combination Therapies for the Treatment of Patients with Genotype 1 Chronic Hepatitis C Infection. 2015. Available from: https://icer-review.org/wp-content/uploads/2016/01/CTAF\_HCV2\_Final\_Report\_013015.pdf. [Accessed 06.08.2016]. |  |
| Institute for Clinical and Economic Review. Integrating Behavioral Health into Primary Care. 2015. Available from: https://icer-review.org/wp-content/uploads/2016/01/BHI\_Final\_Report\_0602151.pdf. [Accessed 06.08.2016]. |  |
| Institute for Clinical and Economic Review. Controversies in Obesity Management. 2015. Available from: https://icer-review.org/wp-content/uploads/2016/02/CTAF\_OM\_Final\_Report\_081015.pdf. [Accessed 06.08.2016]. |  |
| Institute for Clinical and Economic Review. CardioMEMS™ HF System (St. Jude Medical, Inc.) and Sacubitril/Valsartan (Entresto™, Novartis AG) for Management of Congestive Heart Failure: Effectiveness, Value, and Value-Based Price Benchmarks. 2015. Available from: https://icer-review.org/wp-content/uploads/2016/01/CHF\_Final\_Report\_120115.pdf. [Accessed 06.08.2016]. |  |
| Institute for Clinical and Economic Review. Diabetes Prevention Programs: Effectiveness and Value. 2016. Available from: https://icer-review.org/wp-content/uploads/2016/07/CTAF\_DPP\_Final\_Evidence\_Report\_072516.pdf. [Accessed 06.08.2016]. |  |
| Institute for Clinical and Economic Review. Palliative Care in the Outpatient Setting. 2016. Available from: https://icer-review.org/wp-content/uploads/2016/04/NECEPAC\_Palliative\_Care\_Final\_Report\_060616.pdf. [Accessed 06.08.2016]. |  |
| Institute for Clinical and Economic Review. Mepolizumab (Nucala®, GlaxoSmithKline plc.) for the Treatment of Severe Asthma with Eosinophilia: Effectiveness, Value, and ValueBased Price Benchmarks. 2016. Available from: https://icer-review.org/wp-content/uploads/2016/03/CTAF\_Mepolizumab\_Final\_Report\_031416.pdf. [Accessed 06.08.2016]. |  |
| Institute for Clinical and Economic Review. Extracorporeal Membrane Oxygenation (ECMO). 2016. Available from: https://icer-review.org/wp-content/uploads/2016/02/ecmo\_final\_report\_0212161.pdf. [Accessed 06.08.2016]. |  |
| Institute of Health Economics (IHE) | Institute of Health Economics. Post policy implementation review (PPIR) of rapid fetal fibronectin testing for preterm labour in Alberta. 2015. Available from: http://www.ihe.ca/advanced-search/post-policy-implementation-review-ppir-of-rapid-fetal-fibronectin-testing-for-preterm-labour-in-alberta. [Accessed 06.08.2016]. |  |
| Institut national d’excellence en santé et en services sociaux (INESSS) | Institut national d’excellence en santé et en services sociaux (INESSS). Avis sur l’accès équitable aux services de psychothérapie. Volet I – Examen des données probantes sur l’efficacité et le coût de la psychothérapie comparativement à ceux de la pharmacothérapie dans le traitement des adultes atteints de troubles anxieux et dépressifs. 2015. Available from: <http://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/PsychiatriePsychologie/INESSS_Psychotherapie_VoletI_cout_psycho_compare_cout_pharmaco.pdf>. [Accessed 06.08.2016]. |  |
| Institut national d’excellence en santé et en services sociaux (INESSS). Les pompes à insuline dans le traitement du diabète de type 1. 2015. Available from: <http://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/MaladiesChroniques/INESSS_Pompesinsuline.pdf>. [Accessed 06.08.2016]. |  |
| Institut national d’excellence en santé et en services sociaux (INESSS). Avis sur les centres de jour en soins palliatifs. 2015. Available from: <http://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/Geriatrie/INESSS-Avis_CentresdeJour_SoinsPalliatifs.pdf>. [Accessed 06.08.2016]. |  |
| Institut national d’excellence en santé et en services sociaux (INESSS). Efficacité de la radiothérapie peropératoire. 2015. Available from: <http://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/Oncologie/INESSS_Efficacite_de_la_radiotherapie_peroperatoire.pdf>. [Accessed 06.08.2016]. |  |
| Institut national d’excellence en santé et en services sociaux (INESSS). La photophérèse extracorporelle. 2016. Available from: <http://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/Oncologie/INESSS_Photophereese_extracorporelle.pdf>. [Accessed 06.08.2016]. |  |
| Institut national d’excellence en santé et en services sociaux (INESSS). Utilisation du test Oncotype DXMD aux fins de décision thérapeutique dans le contexte du traitement du cancer du sein infiltrant. 2016. Available from: <http://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/Oncologie/INESSS_Test_Oncotype_CancerduSein.pdf>. [Accessed 06.08.2016]. |  |
| Institut national d’excellence en santé et en services sociaux (INESSS). Utilisation de la bille radioactive pour la localisation préopératoire de tumeurs mammaires non palpables. 2016. Available from: <http://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/Oncologie/INESSS_Billes_radioactives.pdf>. [Accessed 06.08.2016]. |  |
| Belgian Health Care Knowledge Centre (KCE) | De Laet C, Thiry N, Holdt Henningsen K, et al. Percutaneous Vertebroplasty and Balloon Kyphoplasty: KCE Reports 255. 2015. Available from: <https://kce.fgov.be/sites/default/files/page_documents/KCE_255_Percutaneaous_vertebroplasty_Report.pdf>. [Accessed 08.07.2016]. |  |
| Desomer A, Gerkens S, Vinck I, et al. Cardiovascular pre-participation screening in young athletes: KCE Reports 241. 2015. Available from: <https://kce.fgov.be/sites/default/files/page_documents/KCE_241_Sportscreening_Report_2_0.pdf>. [Accessed 08.07.2016]. |  |
| Holdt Henningsen K, Thiry N, De Laet C, et al. Cervical and lumbar total disc replacements: KCE Reports 254. 2015. Available from: <https://kce.fgov.be/sites/default/files/page_documents/KCE_254_Total_disc_replacements_Report_0.pdf>. [Accessed 08.07.2016]. |  |
| Neyt M, Leroy R, Devos C, et al. Left ventricular assist devices in the treatment of end-stage heart failure: KCE Reports 264. 2016. Available from: <https://kce.fgov.be/sites/default/files/page_documents/KCE_264_LVAD_report.pdf>. [Accessed 08.07.2016]. |  |
| Roberfroid D, San Miguel L, D P. Non-invasive markers of subclinical atherosclerosis for predicting a primary cardiovascular event: a rapid systematic review: KCE Reports 244. 2015. Available from: <https://kce.fgov.be/sites/default/files/page_documents/KCE_244_markers_of_atherosclerosis_Report.pdf>. [Accessed 08.07.2016]. |  |
| San Miguel L, Benahmed N, Devos C, et al. The role of biomarkers in ruling out cerebral lesions in mild cranial trauma: KCE Reports 261. 2016. Available from: <https://kce.fgov.be/sites/default/files/page_documents/KCE_261_brain_trauma_Scientific_Report.pdf>. [Accessed 08.07.2016]. |  |
| San Miguel L, Vlayen J, C DL. Gene expression profiling and immunohistochemistry tests for personalised management of adjuvant chemotherapy decisions in early breast cancer – a Rapid Assessment: KCE Reports 237. 2015. Available from: <https://kce.fgov.be/sites/default/files/page_documents/KCE_237_Gene%20expression%20profiling_Report.pdf>. [Accessed 08.07.2016]. |  |
| Van den Bulcke M, San Miguel L, Salgado R, et al. Next generation sequencing gene panels for targeted therapy in oncology and haemato-oncology: KCE Reports 240. 2015. Available from: <https://kce.fgov.be/sites/default/files/page_documents/KCE_240_NGS_targeted_therapy_Report.pdf>. [Accessed 08.07.2016]. |  |
| Ludwig Boltzmann Institut (LBI) | Ludwig Boltzmann Institut. PET/PET-CT Evidenz zum Bedarf und zur Planung (bei onkologischen Indikationen). 2015. Available from: <http://eprints.hta.lbg.ac.at/1045/1/HTA-Projektbericht_Nr.77.pdf>. [Accessed 10.08.2016]. |  |
| National Institute for Health Research (NIHR) | Adams J, Bateman B, Becker F, et al. Effectiveness and acceptability of parental financial incentives and quasi-mandatory schemes for increasing uptake of vaccinations in preschool children: systematic review, qualitative study and discrete choice experiment. Health Technol Assess. 2015 2015/11/10; 19(94). |  |
| Bruce I, Harman N, Williamson P, et al. The management of Otitis Media with Effusion in children with cleft palate (mOMEnt): a feasibility study and economic evaluation. Health Technol Assess. 2015 2015/09/01; 19(68). |  |
| Clarke A, Pulikottil-Jacob R, Grove A, et al. Total hip replacement and surface replacement for the treatment of pain and disability resulting from end-stage arthritis of the hip (review of technology appraisal guidance 2 and 44): systematic review and economic evaluation. Health Technol Assess. 2015 2015/02/03; 19(10). |  |
| Corbett M, Soares M, Jhuti G, et al. Tumour necrosis factor-α inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation. Health Technol Assess. 2016 2016/02/08; 20(9). |  |
| Edwards S, Mavranezouli I, Osei-Assibey G, et al. VivaScope® 1500 and 3000 systems for detecting and monitoring skin lesions: a systematic review and economic evaluation. Health Technology Assessment 2016; 20(58). |  |
| Grant SW, Sperrin M, Carlson E, et al. Calculating when elective abdominal aortic aneurysm repair improves survival for individual patients: development of the Aneurysm Repair Decision Aid and economic evaluation. Health Technol Assess. 2015 2015/04/30; 19(32). |  |
| Pickett K, Loveman E, Kalita N, et al. Educational interventions to improve quality of life in people with chronic inflammatory skin diseases: systematic reviews of clinical effectiveness and cost-effectiveness. Health Technol Assess. 2015 2015/10/27; 19(86). |  |
| Shepherd J, Cooper K, Harris P, et al. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation. Health Technol Assess. 2016 2016/05/04; 20(34). |  |
| Uttley L, Scope A, Stevenson M, et al. Systematic review and economic modelling of the clinical effectiveness and cost-effectiveness of art therapy among people with non-psychotic mental health disorders. Health Technol Assess. 2015 2015/03/09; 19(18). |  |
| Wade R, Sideris E, Paton F, et al. Graduated compression stockings for the prevention of deep-vein thrombosis in postoperative surgical patients: a systematic review and economic model with a value of information analysis. Health Technol Assess. 2015 2015/11/30; 19(98). |  |
| Servicio de Evaluación del Servicio  Canario de la Salud (SESCS) | Ministerio de Sanidad; Servicios Sociales e Igualdad, Servicio Canario de la Salud. Alternativas a las técnicas isotópicas en la detección del ganglio linfático centinela en el cáncer de mama 2015. Available from: <http://www3.gobiernodecanarias.org/sanidad/scs/content/fb7bb583-cb57-11e5-a9c5-a398589805dc/SESCS%202015_Ganglio%20centinela.pdf>. [Accessed 12.08.2016]. |  |
| Ministerio de Sanidad; Servicios Sociales e Igualdad, Servicio de Evaluación del Servicio Canario de la Salud. Efectividad, seguridad y coste-efectividad de la adhesiolisis epidural para el tratamiento del síndrome de cirugía fallida de espalda. 2015. Available from: <http://www3.gobiernodecanarias.org/sanidad/scs/content/c2d76f0f-cb57-11e5-a9c5-a398589805dc/SESCS%202015_adhesiolisis%20epidural.pdf>. [Accessed 12.08.2016]. |  |
| Ministerio de Sanidad; Servicios Sociales e Igualdad, Servicio de Evaluación del Servicio Canario de la Salud. Efectividad, seguridad y coste-efectividad de la colecistectomía frente al tratamiento conservador para la colelitiasis sintomática no complicada o colecistitis aguda. 2015. Available from: <http://www3.gobiernodecanarias.org/sanidad/scs/content/f03e0df9-cb57-11e5-a9c5-a398589805dc/SESCS%202015_Colelitiasis.pdf>. [Accessed 12.08.2016]. |  |
| Ministerio de Sanidad; Servicios Sociales e Igualdad, Servicio de Evaluación del Servicio Canario de la Salud. Efectividad, seguridad y coste-efectividad de los sistemas de monitorización continua de glucosa intersticial en tiempo real (SMCG-TR) para la Diabetes Mellitus tipo 1 y 2. 2015. Available from: <http://www3.gobiernodecanarias.org/sanidad/scs/content/228d3c31-cb58-11e5-a9c5-a398589805dc/SESCS%202015_SMCG-TR.pdf>. [Accessed 12.08.2016]. |  |

Supplementary Table 5 Reports randomly excluded form agencies with more than 10 eligible reports

| Report |
| --- |
| 1. Beale S, Sanderson D, Sanniti A, et al. A scoping study to explore the cost-effectiveness of next-generation sequencing compared with traditional genetic testing for the diagnosis of learning disabilities in children. Health Technol Assess. 2015 2015/06/30; 19(46):128.  2. Bhui K, Aslam RW, Palinski A, et al. Interventions designed to improve therapeutic communications between black and minority ethnic people and professionals working in psychiatric services: a systematic review of the evidence for their effectiveness. Health Technol Assess. 2015 2015/04/29; 19(31).  3. Brazzelli M, Cruickshank M, Tassie E, et al. Collagenase clostridium histolyticum for the treatment of Dupuytren’s contracture: systematic review and economic evaluation. Health Technol Assess. 2015 2015/11/02; 19(90):176.  4. Crossan C, Tsochatzis EA, Longworth L, et al. Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation. Health Technol Assess. 2015 2015/02/03; 19(9).  5. Dretzke J, Blissett D, Dave C, et al. The cost-effectiveness of domiciliary non-invasive ventilation in patients with end-stage chronic obstructive pulmonary disease: a systematic review and economic evaluation. Health Technol Assess. 2015 2015/10/19; 19(81).  6. Dretzke J, Riley RD, Lordkipanidzé M, et al. The prognostic utility of tests of platelet function for the detection of ‘aspirin resistance’ in patients with established cardiovascular or cerebrovascular disease: a systematic review and economic evaluation. Health Technol Assess. 2015 2015/05/19; 19(37).  7. Edwards SJ, Barton S, Thurgar E, et al. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation. Health Technol Assess. 2015 2015/01/28; 19(7).  8. Edwards SJ, Karner C, Trevor N, et al. Dual-chamber pacemakers for treating symptomatic bradycardia due to sick sinus syndrome without atrioventricular block: a systematic review and economic evaluation. Health Technol Assess. 2015 2015/08/24; 19(65).  9. Freeman K, Connock M, Cummins E, et al. Fluorouracil plasma monitoring: systematic review and economic evaluation of the My5-FU assay for guiding dose adjustment in patients receiving fluorouracil chemotherapy by continuous infusion. Health Technol Assess. 2015 2015/11/09; 19(91).  10. Greenhalgh J, Bagust A, Boland A, et al. Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis. Health Technol Assess. 2015 2015/04/21; 19(29).  11. Greenhalgh J, Bagust A, Boland A, et al. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation. Health Technol Assess. 2015 2015/07/01; 19(47).  12. Halligan S, Dadswell E, Wooldrage K, et al. Computed tomographic colonography compared with colonoscopy or barium enema for diagnosis of colorectal cancer in older symptomatic patients: two multicentre randomised trials with economic evaluation (the SIGGAR trials). Health Technol Assess. 2015 2015/07/22; 19(54).  13. Harnan SE, Tappenden P, Essat M, et al. Measurement of exhaled nitric oxide concentration in asthma: a systematic review and economic evaluation of NIOX MINO, NIOX VERO and NObreath. Health Technol Assess. 2015 2015/10/20; 19(82).  14. Hayhurst K, Leitner M, Davies L, et al. The effectiveness and cost-effectiveness of diversion and aftercare programmes for offenders using class A drugs: a systematic review and economic evaluation. Health Technol Assess. 2015 2015/01/26; 19(6).  15. Health Quality Ontario. Paclitaxel Drug-Eluting Stents in Peripheral Arterial Disease: A Health Technology Assessment. 2015. Available from: <http://www.hqontario.ca/Portals/0/Documents/evidence/reports/hta-drug-eluting-stent-en-1511.pdf>. [Accessed 05.08.2016].  16. Health Quality Ontario. Transient Elastography and Controlled Attenuation Parameter for Diagnosing Liver Fibrosis and Steatosis in Ontario: An Economic Analysis. 2015. Available from: <http://www.hqontario.ca/Portals/0/Documents/evidence/reports/economic-analysis-transient-elastography-1511-en.pdf>. [Accessed 05.08.2016].  17. Health Quality Ontario. Colon Capsule Endoscopy for the Detection of Colorectal Polyps: An Economic Analysis. 2015. Available from: <http://www.hqontario.ca/Portals/0/Documents/evidence/reports/economic-analysis-colon-capsule-endoscopy-1507-en.pdf>. [Accessed 05.08.2016].  18. Health Quality Ontario. Capsule Endoscopy in the Assessment of Obscure Gastrointestinal Bleeding: An Economic Analysis. 2015. Available from: <http://www.hqontario.ca/Portals/0/Documents/evidence/reports/economic-analysis-capsule-endoscopy-1502-en.pdf>. [Accessed 05.08.2016].  19. Huxley N, Jones-Hughes T, Coelho H, et al. A systematic review and economic evaluation of intraoperative tests [RD-100i one-step nucleic acid amplification (OSNA) system and Metasin test] for detecting sentinel lymph node metastases in breast cancer. Health Technol Assess. 2015 2015/01/14; 19(2).  20. Jordan RE, Majothi S, Heneghan NR, et al. Supported self-management for patients with moderate to severe chronic obstructive pulmonary disease (COPD): an evidence synthesis and economic analysis. Health Technol Assess. 2015 2015/05/19; 19(36).  21. Long L, Briscoe S, Cooper C, et al. What is the clinical effectiveness and cost-effectiveness of conservative interventions for tendinopathy? An overview of systematic reviews of clinical effectiveness and systematic review of economic evaluations. Health Technol Assess. 2015 2015/02/03; 19(8).  22. Loveman E, Copley VR, Colquitt J, et al. The clinical effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: a systematic review and economic evaluation. Health Technol Assess. 2015 2015/03/12; 19(20).  23. McMillan A, Bratton D, Faria R, et al. A multicentre randomised controlled trial and economic evaluation of continuous positive airway pressure for the treatment of obstructive sleep apnoea syndrome in older people: PREDICT. Health Technol Assess. 2015 2015/06/11; 19(40).  24. Morgan H, Hoddinott P, Thomson G, et al. Benefits of Incentives for Breastfeeding and Smoking cessation in pregnancy (BIBS): a mixed-methods study to inform trial design. Health Technol Assess. 2015 2015/04/21; 19(30).  25. Nicholson A, Mahon J, Boland A, et al. The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation. Health Technol Assess. 2015 2015/10/28; 19(87).  26. Pandor A, Thokala P, Goodacre S, et al. Pre-hospital non-invasive ventilation for acute respiratory failure: a systematic review and cost-effectiveness evaluation. Health Technol Assess. 2015 2015/06/29; 19(42).  27. Picot J, Copley V, Colquitt J, et al. The INTRABEAM® Photon Radiotherapy System for the adjuvant treatment of early breast cancer: a systematic review and economic evaluation. Health Technol Assess. 2015 2015/09/01; 19(69):140.  28. Richardson M, Moore DA, Gwernan-Jones R, et al. Non-pharmacological interventions for attention-deficit/hyperactivity disorder (ADHD) delivered in school settings: systematic reviews of quantitative and qualitative research. Health Technol Assess. 2015 Jun; 19(45):1-470.  29. Richardson R, Trépel D, Perry A, et al. Screening for psychological and mental health difficulties in young people who offend: a systematic review and decision model. Health Technol Assess. 2015 2015/01/12; 19(1).  30. Royle P, Mistry H, Auguste P, et al. Pan-retinal photocoagulation and other forms of laser treatment and drug therapies for non-proliferative diabetic retinopathy: systematic review and economic evaluation. Health Technol Assess. 2015 2015/07/15; 19(51).  31. Sharma P, Boyers D, Scott N, et al. The clinical effectiveness and cost-effectiveness of open mesh repairs in adults presenting with a clinically diagnosed primary unilateral inguinal hernia who are operated in an elective setting: systematic review and economic evaluation. Health Technol Assess. 2015 2015/11/10; 19(92).  32. Sharma P, Scotland G, Cruickshank M, et al. The clinical effectiveness and cost-effectiveness of point-of-care tests (CoaguChek system, INRatio2 PT/INR monitor and ProTime Microcoagulation system) for the self-monitoring of the coagulation status of people receiving long-term vitamin K antagonist therapy, compared with standard UK practice: systematic review and economic evaluation. Health Technol Assess. 2015 2015/07/02; 19(48).  33. Tsertsvadze A, Gurung T, Court R, et al. Clinical effectiveness and cost-effectiveness of elemental nutrition for the maintenance of remission in Crohn’s disease: a systematic review and meta-analysis. Health Technol Assess. 2015 2015/03/31; 19(26).  34. Westwood M, Ramaekers B, Whiting P, et al. Procalcitonin testing to guide antibiotic therapy for the treatment of sepsis in intensive care settings and for suspected bacterial infection in emergency department settings: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2015 2015/11/16; 19(96).  35. Westwood M, van Asselt T, Ramaekers B, et al. High-sensitivity troponin assays for the early rule-out or diagnosis of acute myocardial infarction in people with acute chest pain: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2015 2015/06/30; 19(44):145.  36. Whiting P, Al M, Westwood M, et al. Viscoelastic point-of-care testing to assist with the diagnosis, management and monitoring of haemostasis: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2015 2015/07/28; 19(58).  37. Wright B, Barry M, Hughes E, et al. Clinical effectiveness and cost-effectiveness of parenting interventions for children with severe attachment problems: a systematic review and meta-analysis. Health Technol Assess. 2015 2015/07/16; 19(52).  38. Archer R, Tappenden P, Ren S, et al. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model. Health Technol Assess. 2016 2016/05/24; 20(39):300.  39. Auguste P, Tsertsvadze A, Pink J, et al. Accurate diagnosis of latent tuberculosis in children, people who are immunocompromised or at risk from immunosuppression and recent arrivals from countries with a high incidence of tuberculosis: systematic review and economic evaluation. Health Technol Assess. 2016 2016/05/23; 20(38).  40. Bhattacharya D, Aldus C, Barton G, et al. The feasibility of determining the effectiveness and cost-effectiveness of medication organisation devices compared with usual care for older people in a community setting: systematic review, stakeholder focus groups and feasibility randomised controlled trial. Health Technology Assessment 2016; 20(50).  41. Crathorne L, Huxley N, Haasova M, et al. The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model. Health Technol Assess. 2016 2016/02/24; 20(13).  42. Cruickshank M, Henderson L, MacLennan G, et al. Alpha-2 agonists for sedation of mechanically ventilated adults in intensive care units: a systematic review. Health Technol Assess. 2016 2016/04/04; 20(25).  43. Ensor J, Riley RD, Jowett S, et al. Prediction of risk of recurrence of venous thromboembolism following treatment for a first unprovoked venous thromboembolism: systematic review, prognostic model and clinical decision rule, and economic evaluation. Health Technol Assess. 2016 2016/02/16; 20(12).  44. Health Quality Ontario. Fecal Microbiota Therapy for Clostridium difficile Infection: A Health Technology Assessment. 2016. Available from: <http://www.hqontario.ca/Portals/0/Documents/evidence/reports/hta-fecal-microbiota-therapy-en-1607.pdf>. [Accessed 04.08.2016].  45. Health Quality Ontario. Composite Tissue Transplant of Hand or Arm: A Health Technology Assessment. 2016. Available from: <http://www.hqontario.ca/Portals/0/Documents/evidence/reports/hta-limb-transplant-en-1606.pdf>. [Accessed 04.08.2016].  46. Health Quality Ontario. Minimal Residual Disease Evaluation in Childhood Acute Lymphoblastic Leukemia: An Economic Analysis. 2016. Available from: <http://www.hqontario.ca/Portals/0/Documents/evidence/reports/economic-analysis-mrd-1603-en.pdf>. [Accessed 04.08.2016].  47. Health Quality Ontario. Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression: An Economic Analysis. 2016. Available from: <http://www.hqontario.ca/Portals/0/Documents/evidence/reports/economic-analysis-rtms-en.pdf>. [Accessed 04.08.2016].  48. Health Quality Ontario. Mechanical Thrombectomy in Patients With Acute Ischemic Stroke: A Health Technology Assessment. 2016. Available from: <http://www.hqontario.ca/Portals/0/Documents/evidence/reports/hta-mechanical-thrombectomy-1602-en.pdf>. [Accessed 04.08.2016].  49. Health Quality Ontario. Left Ventricular Assist Devices for Destination Therapy: A Health Technology Assessment. 2016. Available from: <http://www.hqontario.ca/Portals/0/Documents/evidence/reports/hta-lvad-1602-en.pdf>. [Accessed 04.08.2016].  50. Health Quality Ontario. Intrathecal Drug Delivery Systems for Noncancer Pain: A Health Technology Assessment. 2016. Available from: <http://www.hqontario.ca/Portals/0/Documents/evidence/reports/eba-noncancer-pain-1602-en.pdf>. [Accessed 04.08.2016].  51. Morrell CJ, Sutcliffe P, Booth A, et al. A systematic review, evidence synthesis and meta-analysis of quantitative and qualitative studies evaluating the clinical effectiveness, the cost-effectiveness, safety and acceptability of interventions to prevent postnatal depression. Health Technol Assess. 2016 2016/05/16; 20(37).  52. National Institute for Health Research. Enzalutamide for treating metastatic hormone-relapsed prostate cancer not previously treated with chemotherapy. 2016. Available from: <http://www.nets.nihr.ac.uk/__data/assets/pdf_file/0008/159983/ERGReport-13-131-01.pdf>. [Accessed 12.08.2016].  53. National Institute for Health Research. Edoxaban tosylate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism 2016. Available from: <http://www.nets.nihr.ac.uk/__data/assets/pdf_file/0010/159985/ERGReport-14-60-01.pdf>. [Accessed 12.08.2016].  54. National Institute for Health Research. Apremilast for treating active psoriatic arthritis. 2016. Available from: <http://www.nets.nihr.ac.uk/__data/assets/pdf_file/0004/159979/ERGReport-13-169-01.pdf>. [Accessed 12.08.2016].  55. Paton F, Wright K, Ayre N, et al. Improving outcomes for people in mental health crisis: a rapid synthesis of the evidence for available models of care. Health Technol Assess. 2016 2016/01/18; 20(3).  56. Perez Nyssen O, Taylor SJC, Wong G, et al. Does therapeutic writing help people with long-term conditions? Systematic review, realist synthesis and economic considerations. Health Technol Assess. 2016 2016/04/13; 20(27).  57. Riemsma R, Corro Ramos I, Birnie R, et al. Integrated sensor-augmented pump therapy system [the MiniMed® Paradigm™ Veo system and the Vibe™ and G4® PLATINUM CGM (continuous glucose monitoring) system] for managing blood glucose levels in type 1 diabetes: a systematic review and economic evaluation. Health Technol Assess. 2016 2016/03; 20(17).  58. Stevenson M, Archer R, Tosh J, et al. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. Health Technol Assess. 2016 2016/05/04; 20(35).  59. Thurgar E, Barton S, Karner C, et al. Clinical effectiveness and cost-effectiveness of interventions for the treatment of anogenital warts: systematic review and economic evaluation. Health Technol Assess. 2016 2016/04/04; 20(24).  60. Whitaker R, Hendry M, Aslam R, et al. Intervention Now to Eliminate Repeat Unintended Pregnancy in Teenagers (INTERUPT): a systematic review of intervention effectiveness and cost-effectiveness, and qualitative and realist synthesis of implementation factors and user engagement. Health Technol Assess. 2016 2016/03/01; 20(16). |

Supplementary Table 6 Reports excluded for not including economic aspects

| Report |
| --- |
| 1. Agencia de Evaluación de Tecnologías Sanitarias, Ministerio de Sanidad; Servicios Sociales e Igualdad. Indicación de ortesis en deformidades de los pies en niños. 2015. Available from: <http://www.juntadeandalucia.es/salud/servicios/contenidos/nuevaaetsa/up/07_AETSA_Indicacion%20de%20ortesis%20en%20deformidades%20de%20los%20pies%20en%20ni%C3%B1os_DEF_NIPO.pdf>. [Accessed 12.08.2016].  2. Agencia de Evaluación de Tecnologías Sanitarias de Andalucía. Dilatación con balón en disfunciones de la trompa de Eustaquio. 2015. Available from: <http://www.juntadeandalucia.es/salud/servicios/contenidos/nuevaaetsa/up/AETSA_2015_Dilatacion_balon.pdf>. [Accessed 02.07.2016].  3. Agencia de Evaluación de Tecnologías Sanitarias de Andalucía. Hígado bioartificial: Revisión Sistemática. 2015. Available from: <http://www.juntadeandalucia.es/salud/servicios/contenidos/nuevaaetsa/up/2015_AETSA_Higado_bioartificial_final.pdf>. [Accessed 02.07.2016].  4. Agencia de Evaluación de Tecnologías Sanitarias de Andalucía. Inmunoterapia activa para el cáncer de pulmón Revisión sistemática. 2015. Available from: <http://www.juntadeandalucia.es/salud/servicios/contenidos/nuevaaetsa/up/AETSA_2014_2_1_Inmunoter_CaPulmon.pdf>. [Accessed 02.07.2016].  5. Agencia de Evaluación de Tecnologías Sanitarias de Andalucía. Simeprevir en el tratamiento de la Hepatitis C Crónica: evaluación comparada de la eficacia y seguridad. 2015. Available from: <http://www.juntadeandalucia.es/salud/servicios/contenidos/nuevaaetsa/up/AETSA_2015_Simeprevir_HCC_def.pdf>. [Accessed 02.07.2016].  6. Andrea Skelly, Robin Hashimoto, Sana Al-Khatib, et al. Catheter Ablation for Treatment of Atrial Fibrillation. 2015. Available from: <https://www.cms.gov/Medicare/Coverage/DeterminationProcess/Downloads/id99TA.pdf>. [Accessed 02.07.2016].  7. Blyth M, Anthony I, Francq B, et al. Diagnostic accuracy of the Thessaly test, standardised clinical history and other clinical examination tests (Apley’s, McMurray’s and joint line tenderness) for meniscal tears in comparison with magnetic resonance imaging diagnosis. Health Technol Assess. 2015 2015/08/04; 19(62).  8. Cooper K, Chatters R, Kaltenthaler E, et al. Psychological and psychosocial interventions for cannabis cessation in adults: a systematic review short report. Health Technol Assess. 2015 2015/07/22; 19(56).  9. Cooper K, Martyn-St James M, Kaltenthaler E, et al. Interventions to treat premature ejaculation: a systematic review short report. Health Technol Assess. 2015 2015/03/16; 19(21).  10. Dunn G, Emsley R, Liu H, et al. Evaluation and validation of social and psychological markers in randomised trials of complex interventions in mental health: a methodological research programme. Health Technol Assess. 2015 2015/11/10; 19(93).  11. Gilbert F, Tucker L, Gillan M, et al. The TOMMY trial: a comparison of TOMosynthesis with digital MammographY in the UK NHS Breast Screening Programme - a multicentre retrospective reading study comparing the diagnostic performance of digital breast tomosynthesis and digital mammography with digital mammography alone. Health Technol Assess. 2015 2015/01/19; 19(4).  12. Hauptverband der österreichischen Sozialversicherung. Katharina-Schroth Therapie bei Skoliose. Ein HTA-Kurzbericht. 2015. Available from: <http://www.hauptverband.at/cdscontent/load?contentid=10008.615720&version=1425627111>. [Accessed 05.08.2016].  13. Hauptverband der österreichischen Sozialversicherung. Manuelle Lymphdrainage / komplexe Entstauungstherapie: Evidenzlage zu Lymphödem. 2015. Available from: <http://www.hauptverband.at/cdscontent/load?contentid=10008.617482&version=1427438642>. [Accessed 05.08.2016].  14. Haute Autorité de Santé. Evaluation de micro-stents de pontage trabéculaire et de leur acte d’implantation: Rapport d'evaluation technologique. 2015. Available from: <http://www.has-sante.fr/portail/upload/docs/application/pdf/2015-12/rapport_evaluation_micro-stents_de_pontage_trabeculaire.pdf>. [Accessed 03.08.2016].  15. Haute Autorité de Santé. Evaluation des tests d’amplification des acides nucléiques recherchant Neisseria gonorrhoeae: Argumentaire. 2015. Available from: <http://www.has-sante.fr/portail/upload/docs/application/pdf/2015-12/taan_gonocoques_argumentaire.pdf>. [Accessed 03.08.2016].  16. Haute Autorité de Santé. Diagnostic par sérologie et/ou par recherche du génome viral de l’infection congénitale à cytomégalovirus: Argumentaire. 2015. Available from: <http://www.has-sante.fr/portail/upload/docs/application/pdf/2015-11/argumentaire_cmv_me_vd.pdf>. [Accessed 03.08.2016].  17. Haute Autorité de Santé. Evaluation de la mesure de la charge virale du cytomégalovirus par amplification génique chez les receveurs d’allogreffes: Argumentaire. 2015. Available from: <http://www.has-sante.fr/portail/upload/docs/application/pdf/2015-08/argumentaire_cmv_vd.pdf>. [Accessed 03.08.2016].  18. Haute Autorité de Santé. Détection du génome des virus Herpès Simplex (HSV) et Zona Varicelle (VZV) dans le liquide cérébro-spinal par amplification génique en cas d’encéphalite: Argumentaire. 2015. Available from: <http://www.has-sante.fr/portail/upload/docs/application/pdf/2015-06/argumentaire_hsv_vzv_vd_2015-06-29_12-06-3_178.pdf>. [Accessed 03.08.2016].  19. Haute Autorité de Santé. Evaluation de la sécurité et des conditions de réalisation de l’autogreffe de tissu adipeux dans la chirurgie reconstructrice, réparatrice et esthétique du sein: Rapport d'evaluation technologique. 2015. Available from: <http://www.has-sante.fr/portail/upload/docs/application/pdf/2015-02/evaluation_de_la_securite_et_des_conditions_de_realisation_de_lautogreffe_de_tissu_adipeux_dans_la_chirurgie_reconstructrice_reparatrice_et_esthetique_du_sein_-_rapport_devaluation_2015-02-20_11-52-13_659.pdf>. [Accessed 03.08.2016].  20. Haute Autorité de Santé. Prothèses de hanche: Rapport d’évaluation. 2015. Available from: <http://www.has-sante.fr/portail/upload/docs/application/pdf/2015-01/rapport_phasecontradictoire_protheseshanche.pdf>. [Accessed 03.08.2016].  21. Haute Autorité de Santé. Actes rares de chirurgie viscérale par coelioscopie: Argumentaire. 2015. Available from: <http://www.has-sante.fr/portail/upload/docs/application/pdf/2015-06/argumentaire_coelio.pdf>. [Accessed 03.08.2016].  22. Haute Autorité de Santé. Colectomies par coelioscopie. Colectomie droite sans rétablissement de la continuité. Colectomie gauche sans libération de l’angle colique gauche, sans rétablissement de continuité: Argumentaire. 2015. Available from: <http://www.has-sante.fr/portail/upload/docs/application/pdf/2015-06/argumentaire_colectomies_vd.pdf>. [Accessed 03.08.2016].  23. Health Quality Ontario. Pancreas Islet Transplantation for Patients With Type 1 Diabetes Mellitus: A Clinical Evidence Review. 2015. Available from: <http://www.hqontario.ca/Portals/0/Documents/evidence/reports/eba-pancreas-islet-transplantation-1509-en.pdf>. [Accessed 05.08.2016].  24. Health Quality Ontario. Positional Magnetic Resonance Imaging for People With Ehlers-Danlos Syndrome or Suspected Craniovertebral or Cervical Spine Abnormalities: An Evidence-Based Analysis. 2015. Available from: <http://www.hqontario.ca/Portals/0/Documents/evidence/reports/eba-positional-magnetic-resonance-imaging-1507-en.pdf>. [Accessed 05.08.2016].  25. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Systemische Therapie bei Erwachsenen als Psychotherapieverfahren: vorläufiger Berichtsplan; Auftrag N14-02. 2015. Available from: <https://www.iqwig.de/download/N14-02_Vorlaeufiger-Berichtsplan_Systemische-Therapie-bei-Erwachsenen.pdf>. [Accessed 23.04.2015].  26. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Screening auf asymptomatische Bakteriurie im Rahmen der Mutterschafts-Richtlinien unter besonderer Berücksichtigung der Testmethoden: Dokumentation und Würdigung der Anhörung zum Vorbericht; Auftrag S13-02. 2015. Available from: <https://www.iqwig.de/download/S13-02_DWA-Vorbericht_Bakteriuriescreening-bei-Schwangeren.pdf>. [Accessed 23.04.2015].  27. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Stammzelltransplantation bei Multiplem Myelom: Update; Rapid Report; Auftrag N14-03. IQWiG-Berichte 2015. 293:[Available from: <https://www.iqwig.de/download/N14-03_Rapid-Report_Stammzelltransplantation-bei-Multiplem-Myelom-Update....pdf>. [Accessed 02.05.2015].  28. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Screening auf asymptomatische Bakteriurie im Rahmen der Mutterschafts-Richtlinien unter besonderer Berücksichtigung der Testmethoden: Abschlussbericht; Auftrag S13-02. IQWiG-Berichte 2015. 279:[Available from: <https://www.iqwig.de/download/S13-02_Abschlussbericht_Bakteriuriescreening-bei-Schwangeren.pdf>. [Accessed 02.05.2015].  29. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Verfahren zur Lungenvolumenreduktion beim schweren Lungenemphysem: vorläufiger Berichtsplan; Auftrag N14-04. 2015. Available from: <https://www.iqwig.de/download/N14-04_vorlaeufiger-Berichtsplan_LVR-beim-schweren-Lungenemphysem.pdf>. [Accessed 02.05.2015].  30. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Screening auf kritische angeborene Herzfehler mittels Pulsoxymetrie bei Neugeborenen: Abschlussbericht; Auftrag S13-01. IQWiG-Berichte 2015. 285:[Available from: <https://www.iqwig.de/download/S13-01_Abschlussbericht_Pulsoxymetrie.pdf>. [Accessed 15.05.2015].  31. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Screening auf kritische angeborene Herzfehler mittels Pulsoxymetrie bei Neugeborenen: Dokumentation und Würdigung der Anhörung zum Vorbericht; Auftrag S13-01. 2015. Available from: <https://www.iqwig.de/download/S13-01_DWA-Vorbericht_Pulsoxymetrie.pdf>. [Accessed 15.05.2015].  32. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Hyperbare Sauerstofftherapie bei diabetischem Fußsyndrom: vorläufiger Berichtsplan; Auftrag N15-02. 2015. Available from: <https://www.iqwig.de/download/N15-02_vorlaeufiger-Berichtsplan_HBO-bei-DFS.pdf>. [Accessed 18.05.2015].  33. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Ultraschall-Screening auf Bauchaortenaneurysmen: Abschlussbericht; Auftrag S13-04. IQWiG-Berichte 2015. 294:[Available from: <https://www.iqwig.de/download/S13-04_Abschlussbericht_Version1-1_Ultraschall-Screening-auf-Bauchaortenaneurysmen.pdf>. [Accessed 03.06.2015].  34. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Ultraschall-Screening auf Bauchaortenaneurysmen: Dokumentation und Würdigung der Anhörung zum Vorbericht; Auftrag S13-04. 2015. Available from: <https://www.iqwig.de/download/S13-04_DWA-Vorbericht_Ultraschall-Screening-auf-Bauchaortenaneurysmen.pdf>. [Accessed 03.06.2015].  35. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Kontinuierliche interstitielle Glukosemessung (CGM) mit Real-Time-Messgeräten bei insulinpflichtigem Diabetes mellitus: Abschlussbericht; Auftrag D12-01. IQWiG-Berichte 2015. 289:[Available from: <https://www.iqwig.de/download/D12-01_Abschlussbericht_Kontinuierliche-Glukosemessung-mit-Real-Time-Messgeraeten.pdf>. [Accessed 03.06.2015].  36. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Kontinuierliche interstitielle Glukosemessung (CGM) mit Real-Time-Messgeräten bei insulinpflichtigem Diabetes mellitus: Dokumentation und Würdigung der Anhörung zum Vorbericht; Auftrag D12-01. 2015. Available from: <https://www.iqwig.de/download/D12-01_DWA-VB_Kontinuierliche-Glukosemessung-mit-Real-Time-Messgeraeten.pdf>. [Accessed 03.06.2015].  37. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Proteomanalyse im Urin zur Erkennung einer diabetischen Nephropathie bei Patientinnen und Patienten mit Diabetes mellitus und arteriellem Hypertonus: Vorbericht (vorläufige Nutzenbewertung); Auftrag D13-01. 2015. Available from: <https://www.iqwig.de/download/D13-01_Vorbericht_Proteomanalyse.pdf>. [Accessed 11.06.2015].  38. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Früherkennung von Sehstörungen bei Kindern bis zur Vollendung des 6. Lebensjahres (Folgeauftrag zu Auftrag S05-02): Rapid Report; Auftrag S14-01; Version 1.1. IQWiG-Berichte 2015. 301:[Available from: <https://www.iqwig.de/download/S14-01_Rapid-Report_Sehscreening-bei-Kindern_V1.1.pdf>. [Accessed 06.07.2015].  39. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Antikörperbeschichtete, medikamentenfreisetzende Stents zur Behandlung von Koronargefäßstenosen: Vorbericht (vorläufige Nutzenbewertung); Auftrag N13-01. 2015. Available from: <https://www.iqwig.de/download/N13-01_Vorbericht_Antikoerperbeschichtete-medikamentenfreisetzende-Stents.pdf>. [Accessed 20.07.2015].  40. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. UV-Vernetzung mit Riboflavin bei Keratokonus: vorläufiger Berichtsplan; Auftrag N15-05. 2015. Available from: <https://www.iqwig.de/download/N15-05_Vorlaeufiger-Berichtsplan_Hornhautvernetzung-bei-Keratokonus.pdf>. [Accessed 20.07.2015].  41. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Hyperbare Sauerstofftherapie bei diabetischem Fußsyndrom: Dokumentation und Würdigung der Anhörung zum Berichtsplan; Auftrag N15-02. 2015. Available from: <https://www.iqwig.de/download/N15-02_DWA-BP_Hyperbare-Sauerstofftherapie-bei-diabetischem-Fusssyndrom.pdf>. [Accessed 20.07.2015].  42. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Hyperbare Sauerstofftherapie bei diabetischem Fußsyndrom: Berichtsplan; Auftrag N15-02. 2015. Available from: <https://www.iqwig.de/download/N15-02_Berichtsplan_Hyperbare-Sauerstofftherapie-bei-diabetischem-Fusssy....pdf>. [Accessed 20.07.2015].  43. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Biomarkerbasierte Tests zur Entscheidung für oder gegen eine adjuvante systemische Chemotherapie beim primären Mammakarzinom: Dokumentation und Würdigung der Anhörung zum Berichtsplan; Auftrag D14-01. 2015. Available from: <https://www.iqwig.de/download/D14-01_DWA-Berichtsplan_Biomarker-bei-Mammakarzinom.pdf>. [Accessed 20.08.2015].  44. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Biomarkerbasierte Tests zur Entscheidung für oder gegen eine adjuvante systemische Chemotherapie beim primären Mammakarzinom: Berichtsplan; Auftrag D14-01. 2015. Available from: <https://www.iqwig.de/download/D14-01_Berichtsplan_Biomarker-bei-Mammakarzinom.pdf>. [Accessed 20.08.2015].  45. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Systemische Therapie bei Erwachsenen als Psychotherapieverfahren: Dokumentation und Würdigung der Anhörung zum Berichtsplan; Auftrag N14-02. 2015. Available from: <https://www.iqwig.de/download/N14-02_DWA-Berichtsplan_Systemische-Therapie-bei-Erwachsenen.pdf>. [Accessed 20.08.2015].  46. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Systemische Therapie bei Erwachsenen als Psychotherapieverfahren: Berichtsplan; Auftrag N14-02. 2015. Available from: <https://www.iqwig.de/download/N14-02_Berichtsplan_Systemische-Therapie-bei-Erwachsenen.pdf>. [Accessed 20.08.2015].  47. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Systematische Behandlung von Parodontopathien: vorläufiger Berichtsplan; Auftrag N15-01. 2015. Available from: <https://www.iqwig.de/download/N15-01_Vorlaeufiger-Berichtsplan_Systematische-Behandlung-von-Parodontopathien.pdf>. [Accessed 22.09.2015].  48. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. UV-Vernetzung mit Riboflavin bei Keratokonus: Dokumentation und Würdigung der Anhörung zum Berichtsplan; Auftrag N15-05. 2015. Available from: <https://www.iqwig.de/download/N15-05_DWA-Berichtsplan_Hornhautvernetzung-bei-Keratokonus.pdf>. [Accessed 09.10.2015].  49. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. UV-Vernetzung mit Riboflavin bei Keratokonus: Berichtsplan; Auftrag N15-05. 2015. Available from: <https://www.iqwig.de/download/N15-05_Berichtsplan_Hornhautvernetzung-bei-Keratokonus.pdf>. [Accessed 09.10.2015].  50. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Verfahren zur Lungenvolumenreduktion beim schweren Lungenemphysem: Dokumentation und Würdigung der Anhörung zum vorläufigen Berichtsplan; Auftrag N14-04. 2015. Available from: <https://www.iqwig.de/download/N14-04_DWA-vBP_LVR-beim-schweren-Lungenemphysem.pdf>. [Accessed 30.11.2015].  51. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Verfahren zur Lungenvolumenreduktion beim schweren Lungenemphysem: Berichtsplan; Auftrag N14-04. 2015. Available from: <https://www.iqwig.de/download/N14-04_Berichtsplan_LVR-beim-schweren-Lungenemphysem.pdf>. [Accessed 30.11.2015].  52. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Extrakorporale Stoßwellentherapie beim Fersenschmerz: vorläufiger Berichtsplan; Auftrag N15-06. 2015. Available from: <https://www.iqwig.de/download/N15-06_Vorlaeufiger-Berichtsplan_ESWT-beim-Fersenschmerz.pdf>. [Accessed 30.11.2015].  53. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Biomarkerbasierte Tests zur Entscheidung für oder gegen eine adjuvante systemische Chemotherapie beim primären Mammakarzinom: Vorbericht (vorläufige Nutzenbewertung); Auftrag D14-01. 2015. Available from: <https://www.iqwig.de/download/D14-01_Vorbericht_Biomarker-bei-Mammakarzinom.pdf>. [Accessed 30.11.2015].  54. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Proteomanalyse im Urin zur Erkennung einer diabetischen Nephropathie bei Patientinnen und Patienten mit Diabetes mellitus und arteriellem Hypertonus: Dokumentation und Würdigung der Anhörung zum Vorbericht; Auftrag D13-01. 2015. Available from: <https://www.iqwig.de/download/D13-01_DWA-Vorbericht_Proteomanalyse-zur-Erkennung-einer-DNP.pdf>. [Accessed 30.11.2015].  55. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Proteomanalyse im Urin zur Erkennung einer diabetischen Nephropathie bei Patientinnen und Patienten mit Diabetes mellitus und arteriellem Hypertonus: Abschlussbericht; Auftrag D13-01. IQWiG-Berichte 2015. 325:[Available from: <https://www.iqwig.de/download/D13-01_Abschlussbericht_Proteomanalyse-zur-Erkennung-einer-DNP.pdf>. [Accessed 30.11.2015].  56. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Neugeborenen-Screening auf Tyrosinämie Typ I mittels Tandem-Massenspektrometrie: vorläufiger Berichtsplan; Auftrag S15-01. 2015. Available from: <https://www.iqwig.de/download/S15-01_Vorlaeufiger-Berichtsplan_Neugeborenen-Screening-auf-Tyrosinaemie-Typ-I.pdf>. [Accessed 30.11.2015].  57. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Antikörperbeschichtete, medikamentenfreisetzende Stents zur Behandlung von Koronargefäßstenosen: Dokumentation und Würdigung der Anhörung zum Vorbericht; Auftrag N13-01. 2015. Available from: <https://www.iqwig.de/download/N13-01_DWA-VB_Antikoerperbeschichtete-medikamentenfreisetzende-Stents.pdf>. [Accessed 30.11.2015].  58. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Antikörperbeschichtete, medikamentenfreisetzende Stents zur Behandlung von Koronargefäßstenosen: Abschlussbericht; Auftrag N13-01. IQWiG-Berichte 2015. 326:[Available from: <https://www.iqwig.de/download/N13-01_Abschlussbericht_Antikoerperbeschichtete-medikamentenfreisetzende%20Stents.pdf>. [Accessed 30.11.2015].  59. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Screening auf schwere kombinierte Immundefekte (SCID-Screening) bei Neugeborenen: vorläufiger Berichtsplan; Auftrag S15-02. 2015. Available from: <https://www.iqwig.de/download/S15-02_vorlaeufiger-Berichtsplan_SCID-Screening.pdf>. [Accessed 15.12.2015].  60. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Messung der myokardialen fraktionellen Flussreserve (FFR) bei koronarer Herzkrankheit: vorläufiger Berichtsplan; Auftrag D15-02. 2015. Available from: <https://www.iqwig.de/download/D15-02_Vorlaeufiger-Berichtsplan_FFR%20bei%20KHK.pdf>. [Accessed 15.12.2015].  61. Institut national d’excellence en santé et en services sociaux (INESSS). Repérage et processus menant au diagnostic de la maladie d’Alzheimer et d’autres troubles neurocognitifs 2015. Available from: <http://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/Geriatrie/INESSS-Rapport_reperage_processus_diagnostic_MA_TNC.pdf>. [Accessed 06.08.2016].  62. Institut national d’excellence en santé et en services sociaux (INESSS). L’efficacité d’outils d’évaluation du risque d’abus physique envers les enfants. 2015. Available from: <http://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/ServicesSociaux/INESSS_Outils_evaluation_risque_abus_physique_enfants.pdf>. [Accessed 06.08.2016].  63. Institut national d’excellence en santé et en services sociaux (INESSS). Efficacité et innocuité de la thérapie par pression négative pour le traitement des plaies complexes. 2015. Available from: <http://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/Traitement/INESSS_TPN_RevueSystematique.pdf>. [Accessed 06.08.2016].  64. Institut national d’excellence en santé et en services sociaux (INESSS). Processus de révision des exigences matricielles pour les établissements de soins aigus du réseau québécois de traumatologie 2015. Available from: <http://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/Traumatologie/INESSS_Rapport_synthese_ExigencesMatricielles.pdf>. [Accessed 06.08.2016].  65. Institut national d’excellence en santé et en services sociaux (INESSS). Innocuité des savons antiseptiques contenant du triclosan pour le lavage des mains en milieu hospitalier. 2015. Available from: <http://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/Infectiologie/INESSS_Triclosan_14-05-15.pdf>. [Accessed 06.08.2016].  66. Institut national d’excellence en santé et en services sociaux (INESSS). Traitement pharmacologique de la maladie d’Alzheimer et des maladies apparentées. 2015. Available from: <http://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/Geriatrie/INESSS-Rapport_ETS_TraitementPharmacoAlzheimer.pdf>. [Accessed 06.08.2016].  67. Institut national d’excellence en santé et en services sociaux (INESSS). Procréation assistée. 2015. Available from: <http://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/ObstetriqueGynecologie/INESSS_ProcreationAssistee.pdf>. [Accessed 06.08.2016].  68. Institute of Health Economics. A systematic review of the measurement properties of self-report instruments that assess presenteeism. 2015. Available from: <http://www.ihe.ca/advanced-search/a-systematic-review-of-the-measurement-properties-of-self-report-instruments-that-assess-presenteeism>. [Accessed 06.08.2016].  69. John R, Henry M, Ritu S, et al. Use of Cardiac Resynchronization Therapy in the Medicare Population 2015. Available from: <https://www.cms.gov/Medicare/Coverage/DeterminationProcess/Downloads/id100TA.pdf>. [Accessed 02.07.2016].  70. Kitchener HC, Gittins M, Desai M, et al. A study of cellular counting to determine minimum thresholds for adequacy for liquid-based cervical cytology using a survey and counting protocol. Health Technol Assess. 2015 2015/03/17; 19(22).  71. Ludwig Boltzmann Institut. Endovascular embolization of unruptured intracranial aneurysms with flow diverters. Systematic Review. 2015. Available from: <http://eprints.hta.lbg.ac.at/1054/1/DSD_83.pdf>. [Accessed 10.08.2016].  72. Ludwig Boltzmann Institut. Ambulante neurologische Rehabilitation: Erreichung der definierten Ziele bei SchlaganfallpatientInnen. Systematischer Review. 2015. Available from: <http://eprints.hta.lbg.ac.at/1071/1/DSD_92.pdf>. [Accessed 10.08.2016].  73. Ludwig Boltzmann Institut. Hadronentherapie bei Kindern. Evidenzsynthese zu 15 pädiatrischen Tumoren. Kontext zum belgischen HTA-Bericht. 2015. Available from: <http://eprints.hta.lbg.ac.at/1049/1/DSD_88.pdf>. [Accessed 10.08.2016].  74. Ludwig Boltzmann Institut. Impfung gegen Humane Papillomaviren (HPV). Entscheidungshilfe zur HPV-Impfung für junge Frauen und Mädchen. 2015. Available from: <http://eprints.hta.lbg.ac.at/1050/1/DSD_79.pdf>. [Accessed 10.08.2016].  75. Ludwig Boltzmann Institut. Intrastromal corneal implants for ectatic corneal disorders. Systematic Review. 2015. Available from: <http://eprints.hta.lbg.ac.at/1055/1/DSD_85.pdf>. [Accessed 10.08.2016].  76. Ludwig Boltzmann Institut. Perkutane transluminale Angioplastie (PTA) peripherer Arterien mit drug-eluting balloon (DEB). Systematischer Review. 1. Update 2015. 2015. Available from: <http://eprints.hta.lbg.ac.at/1057/1/DSD_68_Update2015.pdf>. [Accessed 10.08.2016].  77. Ludwig Boltzmann Institut. Perkutaner Verschluss des linken Vorhofohres zur Thrombembolieprophylaxe bei PatientInnen mit Vorhofflimmern. Systematischer Review. 2. Update 2015  Decision. 2015. Available from: <http://eprints.hta.lbg.ac.at/1056/1/DSD_44_Update2015.pdf>. [Accessed 10.08.2016].  78. Ministerio de Sanidad SSeI. Actualización de la Evidencia Científica sobre Sensibilidad Química Múltiple (SQM). 2015. Available from: <http://www.iacs.aragon.es/awgc/contenido.detalle.do?idContenido=12513&vienede=ZONA_PREDEFINIDAS&numElemento=0>. [Accessed 12.08.2016].  79. Ministerio de Sanidad; Servicios Sociales e Igualdad, Servicio de Evaluación de Tecnologías Sanitarias del País Vasco. Implantes oftalmológicos en cirugía de glaucoma. Análisis de su seguridad y efectividad. 2015. Available from: <http://www.ogasun.ejgv.euskadi.eus/r51-catpub/eu/k75aWebPublicacionesWar/k75aObtenerPublicacionDigitalServlet?R01HNoPortal=true&N_LIBR=051719&N_EDIC=0001&C_IDIOM=es&FORMATO=.pdf>. [Accessed 12.08.2016].  80. National Health and Medical Research Council. Effectiveness of Homeopathy for Clinical Conditions: Evaluation of the Evidence. 2015. Available from: <https://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/cam02j_review_literature_public_submissions.pdf>. [Accessed 11.08.2016].  81. National Health and Medical Research Council. Systematic review of the human health effects of wind farms. 2015. Available from: <https://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/eh54_systematic_review_of_the_human_health_effects_of_wind_farms_december_2013_amended_february_2015.pdf>. [Accessed 11.08.2016].  82. National Institute for Health and Care Excellence. Cyanoacrylate glue occlusion for varicose veins. 2015. Available from: <https://www.nice.org.uk/guidance/ipg526/resources/cyanoacrylate-glue-occlusion-for-varicose-veins-1899871809219781>. [Accessed 15.08.2016].  83. National Institute for Health and Care Excellence. Hysteroscopic metroplasty of a uterine septum for primary infertility. 2015. Available from: <https://www.nice.org.uk/guidance/ipg509/resources/hysteroscopic-metroplasty-of-a-uterine-septum-for-primary-infertility-1899871693326277>. [Accessed 15.08.2016].  84. National Institute for Health and Care Excellence. Implantation of a sphenopalatine ganglion stimulation device for chronic cluster headache. 2015. Available from: <https://www.nice.org.uk/guidance/ipg527/resources/implantation-of-a-sphenopalatine-ganglion-stimulation-device-for-chronic-cluster-headache-1899871810899397>. [Accessed 15.08.2016].  85. National Institute for Health and Care Excellence. Transapical transcatheter mitral valve-in-valve implantation for a failed surgically implanted mitral valve bioprosthesis. 2015. Available from: <https://www.nice.org.uk/guidance/ipg541/resources/transapical-transcatheter-mitral-valveinvalve-implantation-for-a-failed-surgically-implanted-mitral-valve-bioprosthesis-1899871921754053>. [Accessed 15.08.2016].  86. National Institute for Health and Care Excellence. Repetitive transcranial magnetic stimulation for depression. 2015. Available from: <https://www.nice.org.uk/guidance/ipg542/resources/repetitive-transcranial-magnetic-stimulation-for-depression-1899871923433669>. [Accessed 15.08.2016].  87. National Institute for Health and Care Excellence. Radiofrequency ablation for symptomatic interdigital (Morton’s) neuroma. 2015. Available from: <https://www.nice.org.uk/guidance/ipg539/resources/radiofrequency-ablation-for-symptomatic-interdigital-mortons-neuroma-1899871874724805>. [Accessed 15.08.2016].  88. National Institute for Health and Care Excellence. Joint distraction for ankle osteoarthritis. 2015. Available from: <https://www.nice.org.uk/guidance/ipg538/resources/joint-distraction-for-ankle-osteoarthritis-1899871873045189>. [Accessed 15.08.2016].  89. National Institute for Health and Care Excellence. Insertion of a subretinal prosthesis system for retinitis pigmentosa. 2015. Available from: <https://www.nice.org.uk/guidance/ipg537/resources/insertion-of-a-subretinal-prosthesis-system-for-retinitis-pigmentosa-1899871871365573>. [Accessed 15.08.2016].  90. National Institute for Health and Care Excellence. Electrical stimulation of the lower oesophageal sphincter for treating gastro-oesophageal reflux disease. 2015. Available from: <https://www.nice.org.uk/guidance/ipg540/resources/electrical-stimulation-of-the-lower-oesophageal-sphincter-for-treating-gastrooesophageal-reflux-disease-1899871920074437>. [Accessed 15.08.2016].  91. National Institute for Health and Care Excellence. Implantation of a corneal graft–keratoprosthesis for severe corneal opacity in wet blinking eyes. 2015. Available from: <https://www.nice.org.uk/guidance/ipg534/resources/implantation-of-a-corneal-graftkeratoprosthesis-for-severe-corneal-opacity-in-wet-blinking-eyes-1899871866326725>. [Accessed 15.08.2016].  92. National Institute for Health and Care Excellence. Transanal total mesorectal excision of the rectum. 2015. Available from: <https://www.nice.org.uk/guidance/ipg514/resources/transanal-total-mesorectal-excision-of-the-rectum-1899871745394373>. [Accessed 15.08.2016].  93. National Institute for Health and Care Excellence. Hysteroscopic metroplasty of a uterine septum for recurrent miscarriage. 2015. Available from: <https://www.nice.org.uk/guidance/ipg510/resources/hysteroscopic-metroplasty-of-a-uterine-septum-for-recurrent-miscarriage-1899871738675909>. [Accessed 15.08.2016].  94. National Institute for Health and Care Excellence. Open reduction of slipped capital femoral epiphysis. 2015. Available from: <https://www.nice.org.uk/guidance/ipg511/resources/open-reduction-of-slipped-capital-femoral-epiphysis-1899871740355525>. [Accessed 15.08.2016].  95. National Institute for Health and Care Excellence. Implantation of a shock or load absorber for mild to moderate symptomatic medial knee osteoarthritis. 2015. Available from: <https://www.nice.org.uk/guidance/ipg512/resources/implantation-of-a-shock-or-load-absorber-for-mild-to-moderate-symptomatic-medial-knee-osteoarthritis-1899871742035141>. [Accessed 15.08.2016].  96. National Institute for Health and Care Excellence. Insertion of endobronchial nitinol coils to improve lung function in emphysema. 2015. Available from: <https://www.nice.org.uk/guidance/ipg517/resources/insertion-of-endobronchial-nitinol-coils-to-improve-lung-function-in-emphysema-1899871750433221>. [Accessed 15.08.2016].  97. National Institute for Health and Care Excellence. Implantation of a duodenal–jejunal bypass liner for managing type 2 diabetes. 2015. Available from: <https://www.nice.org.uk/guidance/ipg518/resources/implantation-of-a-duodenaljejunal-bypass-liner-for-managing-type2-diabetes-1899871752112837>. [Accessed 15.08.2016].  98. National Institute for Health and Care Excellence. Flexible endoscopic treatment of a pharyngeal pouch. 2015. Available from: <https://www.nice.org.uk/guidance/ipg513/resources/flexible-endoscopic-treatment-of-a-pharyngeal-pouch-1899871743714757>. [Accessed 15.08.2016].  99. National Institute for Health and Care Excellence. Ultrasound‑enhanced, catheter‑directed thrombolysis for pulmonary embolism. 2015. Available from: <https://www.nice.org.uk/guidance/ipg524/resources/ultrasoundenhanced-catheterdirected-thrombolysis-for-pulmonary-embolism-1899871805860549>. [Accessed 15.08.2016].  100. National Institute for Health and Care Excellence. Ultrasound‑enhanced, catheter‑directed thrombolysis for deep vein thrombosis. 2015. Available from: <https://www.nice.org.uk/guidance/ipg523/resources/ultrasoundenhanced-catheterdirected-thrombolysis-for-deep-vein-thrombosis-1899871804180933>. [Accessed 15.08.2016].  101. National Institute for Health and Care Excellence. Insertion of a double balloon catheter for induction of labour in pregnant women without previous caesarean section. 2015. Available from: <https://www.nice.org.uk/guidance/ipg528/resources/insertion-of-a-double-balloon-catheter-for-induction-of-labour-in-pregnant-women-without-previous-caesarean-section-1899871812579013>. [Accessed 15.08.2016].  102. National Institute for Health and Care Excellence. Radiofrequency ablation for gastric antral vascular ectasia. 2015. Available from: <https://www.nice.org.uk/guidance/ipg520/resources/radiofrequency-ablation-for-gastric-antral-vascular-ectasia-1899871799142085>. [Accessed 15.08.2016].  103. National Institute for Health and Care Excellence. Implantation of a left ventricular assist device for destination therapy in people ineligible for heart transplantation. 2015. Available from: <https://www.nice.org.uk/guidance/ipg516/resources/implantation-of-a-left-ventricular-assist-device-for-destination-therapy-in-people-ineligible-for-heart-transplantation-1899871748753605>. [Accessed 15.08.2016].  104. National Institute for Health and Care Excellence. Electrotherapy for the treatment of haemorrhoids. 2015. Available from: <https://www.nice.org.uk/guidance/ipg525/resources/electrotherapy-for-the-treatment-of-haemorrhoids-1899871807540165>. [Accessed 15.08.2016].  105. National Institute for Health and Care Excellence. Joint distraction for knee osteoarthritis without alignment correction. 2015. Available from: <https://www.nice.org.uk/guidance/ipg529/resources/joint-distraction-for-knee-osteoarthritis-without-alignment-correction-1899871814258629>. [Accessed 15.08.2016].  106. National Institute for Health and Care Excellence. Sacral nerve stimulation for idiopathic chronic non-obstructive urinary retention. 2015. Available from: <https://www.nice.org.uk/guidance/ipg536/resources/sacral-nerve-stimulation-for-idiopathic-chronic-nonobstructive-urinary-retention-1899871869685957>. [Accessed 15.08.2016].  107. National Institute for Health and Care Excellence. Preoperative high dose rate brachytherapy for rectal cancer. 2015. Available from: <https://www.nice.org.uk/guidance/ipg531/resources/preoperative-high-dose-rate-brachytherapy-for-rectal-cancer-1899871861287877>. [Accessed 15.08.2016].  108. National Institute for Health and Care Excellence. Insertion of a balloon device to disimpact an engaged fetal head before an emergency caesarean section. 2015. Available from: <https://www.nice.org.uk/guidance/ipg515/resources/insertion-of-a-balloon-device-to-disimpact-an-engaged-fetal-head-before-an-emergency-caesarean-section-1899871747073989>. [Accessed 15.08.2016].  109. National Institute for Health and Care Excellence. Living-donor liver transplantation. 2015. Available from: <https://www.nice.org.uk/guidance/ipg535/resources/livingdonor-liver-transplantation-1899871868006341>. [Accessed 15.08.2016].  110. National Institute for Health and Care Excellence. Transcranial direct current stimulation (tDCS) for depression. 2015. Available from: <https://www.nice.org.uk/guidance/ipg530/resources/transcranial-direct-current-stimulation-tdcs-for-depression-1899871859608261>. [Accessed 15.08.2016].  111. National Institute for Health and Care Excellence. Implanting a baroreceptor stimulation device for resistant hypertension. 2015. Available from: <https://www.nice.org.uk/guidance/ipg533/resources/implanting-a-baroreceptor-stimulation-device-for-resistant-hypertension-1899871864647109>. [Accessed 15.08.2016].  112. National Institute for Health and Care Excellence. Suture fixation of acute disruption of the distal tibiofibular syndesmosis. 2015. Available from: <https://www.nice.org.uk/guidance/ipg521/resources/suture-fixation-of-acute-disruption-of-the-distal-tibiofibular-syndesmosis-1899871800821701>. [Accessed 15.08.2016].  113. National Institute for Health and Care Excellence. Hysteroscopic morcellation of uterine leiomyomas (fibroids). 2015. Available from: <https://www.nice.org.uk/guidance/ipg522/resources/hysteroscopic-morcellation-of-uterine-leiomyomas-fibroids-1899871802501317>. [Accessed 15.08.2016].  114. National Institute for Health and Care Excellence. Insertion of an epiretinal prosthesis for retinitis pigmentosa. 2015. Available from: <https://www.nice.org.uk/guidance/ipg519/resources/insertion-of-an-epiretinal-prosthesis-for-retinitis-pigmentosa-1899871753792453>. [Accessed 15.08.2016].  115. National Institute for Health and Care Excellence. Low energy contact X-ray brachytherapy (the Papillon technique) for early stage rectal cancer. 2015. Available from: <https://www.nice.org.uk/guidance/ipg532/resources/low-energy-contact-xray-brachytherapy-the-papillon-technique-for-early-stage-rectal-cancer-1899871862967493>. [Accessed 15.08.2016].  116. Red Española de Agencias de Evaluación de Tecnologías y Prestaciones del SNS, Agencia de Evaluación de Tecnologías Sanitarias de Galicia, Informes de evaluación de tecnologías sanitarias. Evaluación de las necesidades y elaboración de un documento de información para pacientes con sarcoidosis basado en la evidencia. 2015. Available from: <http://portal.guiasalud.es/contenidos/iframes/documentos/opbe/2015-04/avalia-t201408-InformeSarcoidosis-DEF.pdf>. [Accessed 12.08.2016].  117. Roger Chou, Robin Hashimoto, Janna Friedly, et al. Pain Management Injection Therapies for Low Back Pain 2015. Available from: <https://www.cms.gov/Medicare/Coverage/DeterminationProcess/Downloads/id98TA.pdf>. [Accessed 02.07.2016].  118. Simmonds M, Burch J, Llewellyn A, et al. The use of measures of obesity in childhood for predicting obesity and the development of obesity-related diseases in adulthood: a systematic review and meta-analysis. Health Technol Assess. 2015 2015/06/30; 19(43).  119. Sydne J. N, John D. F, Margaret A. M, et al. Systematic Review for Effectiveness of Hyaluronic Acid in the Treatment of Severe Degenerative Joint Disease (DJD) of the Knee: Technology Assessment Report. 2015. Available from: <https://www.cms.gov/Medicare/Coverage/DeterminationProcess/Downloads/id101TA.pdf>. [Accessed 02.07.2016].  120. Agencia de Evaluación de Tecnologías Sanitarias de Andalucía. Indicación de ortesis en deformidades de los pies en niños. 2016. Available from: <http://www.juntadeandalucia.es/salud/servicios/contenidos/nuevaaetsa/up/07_AETSA_Indicacion%20de%20ortesis%20en%20deformidades%20de%20los%20pies%20en%20ni%C3%B1os_DEF_NIPO.pdf>. [Accessed 02.07.2016].  121. Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS). Pautes per a l'harmonització del tractament farmacològic de la malaltia renal crònica 2016. Available from: <http://catsalut.gencat.cat/web/.content/minisite/catsalut/proveidors_professionals/medicaments_farmacia/phf_apc/protocols/Malaltia_renal/MALATIA-RENAL-CRONICA_Definitiva.pdf.pdf>. [Accessed 02.07.2016].  122. Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS). Proposta d'indicadors per avaluar l'atenció a la cronicitat en el marc de l'Estratègia per a l'Abordatge de la Cronicitat en el Sistema Nacional de Salut. 2016. Available from: <http://aquas.gencat.cat/web/.content/minisite/aquas/publicacions/2015/documents/Propuesta_indicadores_cronicidad_AQuAS_PlaSNS.pdf>. [Accessed 02.07.2016].  123. Basque Office for Health Technology Assessment/Basque Government (OSTEBA). Diseño y Validación de una herramienta de cribado para la Evaluación de Impacto en Salud de las políticas autonómicas. 2016. Available from: <http://www.ogasun.ejgv.euskadi.eus/r51-catpub/es/k75aWebPublicacionesWar/k75aObtenerPublicacionDigitalServlet?R01HNoPortal=true&N_LIBR=051860&N_EDIC=0001&C_IDIOM=es&FORMATO=.pdf>. [Accessed 12.08.2016].  124. Baxter S, Johnson M, Blank L, et al. Non-pharmacological treatments for stuttering in children and adults: a systematic review and evaluation of clinical effectiveness, and exploration of barriers to successful outcomes. Health Technol Assess. 2016 2016/01/18; 20(2).  125. Butler K, Inshaw J, Bernays S, et al. BREATHER (PENTA 16) short-cycle therapy (SCT) (5 days on/2 days off) in young people with chronic human immunodeficiency virus infection: an open, randomised, parallel-group Phase II/III trial. Health Technol Assess. 2016 2016/07/04; 20(49).  126. Frampton GK, Kalita N, Payne L, et al. Accuracy of fundus autofluorescence imaging for the diagnosis and monitoring of retinal conditions: a systematic review. Health Technol Assess. 2016 Apr; 20(31):1-108.  127. Free C, McCarthy O, French RS, et al. Can text messages increase safer sex behaviours in young people? Intervention development and pilot randomised controlled trial. Health Technol Assess. 2016 2016/08/01; 20(57).  128. Hauptverband der österreichischen Sozialversicherung. Extrakorporale Stoßwellentherapie (ESTW). 2016. Available from: <http://www.hauptverband.at/cdscontent/load?contentid=10008.630876&version=1463664704>. [Accessed 05.08.2016].  129. Haute Autorité de Santé. Diagnostic par détection virale et/ou sérologie des infections à virus herpes simplex et varicelle-zona dans le cadre mère-enfant: Argumentaire. 2016. Available from: <http://www.has-sante.fr/portail/upload/docs/application/pdf/2016-05/rapport_hvzv_me_vd.pdf>. [Accessed 03.08.2016].  130. Haute Autorité de Santé. Évaluation des prothèses plurales en extension (bridges cantilever) et des prothèses plurales collées (bridges collés): Rapport d'evaluation technologique. 2016. Available from: <http://www.has-sante.fr/portail/upload/docs/application/pdf/2016-04/rapport_bridges_dentaires_vd.pdf>. [Accessed 03.08.2016].  131. Haute Autorité de Santé. Cahier des charges pour la réalisation des interruptions volontaires de grossesse par méthode instrumentale hors établissement de santé. 2016. Available from: <http://www.has-sante.fr/portail/upload/docs/application/pdf/2016-04/rapport_ivg_vd.pdf>. [Accessed 03.08.2016].  132. Haute Autorité de Santé. Cahier des charges pour la réalisation des interruptions volontaires de grossesse par méthode instrumentale dans les centres de santé. 2016. Available from: <http://www.has-sante.fr/portail/upload/docs/application/pdf/2016-04/cdc_ivg_vd.pdf>. [Accessed 03.08.2016].  133. Haute Autorité de Santé. Alternative(s) à la scintigraphie de perfusion en cas de suspicion d’embolie pulmonaire non massive chez la femme enceinte dans l’hypothèse d’une pénurie complète en technétium-99m: Rapport d'evaluation technologique. 2016. Available from: <http://www.has-sante.fr/portail/upload/docs/application/pdf/2016-03/rapport_tc99.pdf>. [Accessed 03.08.2016].  134. Haute Autorité de Santé. Détection par RT-PCR du virus Zika dans le sang et les urines: Argumentaire. 2016. Available from: <http://www.has-sante.fr/portail/upload/docs/application/pdf/2016-03/argumentaire_zika.pdf>. [Accessed 03.08.2016].  135. Haute Autorité de Santé. Evaluation de l'amplification génique pour le diagnostic des infections à Herpesviridae (cytomégalovirus, virus herpès simplex et varicelle-zona) chez les personnes vivant avec le VIH: Argumentaire. 2016. Available from: <http://www.has-sante.fr/portail/upload/docs/application/pdf/2016-01/argumentaire_herpesviridae_vih.docx.pdf>. [Accessed 03.08.2016].  136. Haute Autorité de Santé. Évaluation de l'amplification génique des Herpesviridae (virus herpès simplex et varicelle-zona) devant des manifestations cutanéomuqueuses et oculaires: Argumentaire. 2016. Available from: <http://www.has-sante.fr/portail/upload/docs/application/pdf/2016-01/argumentaire_herpesviridae_popge.pdf>. [Accessed 03.08.2016].  137. Haute Autorité de Santé. Évaluation de la thermoplastie bronchique pour le traitement de l’asthme sévère non contrôlé: Rapport d'evaluation technologique. 2016. Available from: <http://www.has-sante.fr/portail/upload/docs/application/pdf/2016-01/rapport_thermo_bronch.pdf>. [Accessed 03.08.2016].  138. Heneghan CJ, Onakpoya I, Jones MA, et al. Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data. Health Technol Assess. 2016 2016/05/31; 20(42).  139. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Extrakorporale Stoßwellentherapie (ESWT) beim Fersenschmerz: Dokumentation und Würdigung der Anhörung zum vorläufigen Berichtsplan; Auftrag N15-06. 2016. Available from: <https://www.iqwig.de/download/N15-06_DWA-vBP_ESWT-beim-Fersenschmerz.pdf>. [Accessed 28.04.2016].  140. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Extrakorporale Stoßwellentherapie beim Fersenschmerz: Berichtsplan; Auftrag N15-06. 2016. Available from: <https://www.iqwig.de/download/N15-06_Berichtsplan_ESWT-beim-Fersenschmerz.pdf>. [Accessed 28.04.2016].  141. Institut national d’excellence en santé et en services sociaux (INESSS). Faisabilité et pertinence de déployer des centres atellites de radiothérapie munis d’un seul accélérateur linéaire 2016. Available from: <http://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/Oncologie/INESSS_centres_satellites_radiotherapie.pdf>. [Accessed 06.08.2016].  142. Institut national d’excellence en santé et en services sociaux (INESSS). Les chirurgies des amygdales. 2016. Available from: <http://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/Chirurgie/INESSS_Chirurgie_amygdales.pdf>. [Accessed 06.08.2016].  143. Institut national d’excellence en santé et en services sociaux (INESSS). Modèles de dispensation des soins et services aux personnes présentant des troubles concomitants de santé mentale et de dépendance. 2016. Available from: <http://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/ServicesSociaux/INESSS_Avis_Dispensation_soins_services_troubles_concomitants.pdf>. [Accessed 06.08.2016].  144. Institut national d’excellence en santé et en services sociaux (INESSS). Cancer de la prostate localisé. 2016. Available from: <http://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/Oncologie/INESSS-CHUQuebec_Cancer_de_la_prostate_localise.pdf>. [Accessed 06.08.2016].  145. Institut national d’excellence en santé et en services sociaux (INESSS). Utilisation de la bendamustine pour le traitement du lymphome folliculaire. 2016. Available from: <http://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/Oncologie/INESSS_Outil_aide_decision_Bendamustine.pdf>. [Accessed 06.08.2016].  146. Instituto de Salud Carlos III. Eficacia y seguridad de la braquiterapia de alta tasa de dosis como monoterapia en el tratamiento del cáncer de próstata. 2016. Available from: <http://gesdoc.isciii.es/gesdoccontroller?action=download&id=15/06/2016-d8430dd886>. [Accessed 08.08.2016].  147. Ludwig Boltzmann Institut. Leadless pacemakers for right ventricle pacing. Systematic Review. 2016. Available from: <http://eprints.hta.lbg.ac.at/1094/1/DSD_97.pdf>. [Accessed 10.08.2016].  148. Ludwig Boltzmann Institut. Perkutane transluminale koronare Angioplastie (PTCA) mit drug-eluting balloon (DEB). Systematischer Review. 2. Update 2016. 2016. Available from: <http://eprints.hta.lbg.ac.at/1093/1/DSD_24_Update2016.pdf>. [Accessed 10.08.2016].  149. Ludwig Bolzmann Institut. Thrombektomie bei ischämischem Schlaganfall: Patientencharakteristika, strukturelle Voraussetzungen und (Differential-)Diagnostik. HTA-Projektbericht 87. 2016. Available from: <http://eprints.hta.lbg.ac.at/1084/1/HTA-Projektbericht_Nr.87.pdf>. [Accessed 08.08.2016].  150. Ludwig Bolzmann Institut. Screening, Diagnostik und Ergotherapie-Indikation bei Kindern und Jugendlichen mit umschriebenen motorischen Entwicklungsstörungen. Decision Support Document 96. 2016. Available from: <http://eprints.hta.lbg.ac.at/1092/1/DSD_96.pdf>. [Accessed 08.08.2016].  151. Moga C, Chojecki D. Hysteroscopic tubal sterilization (using the Essure® system) – An update. Alberta STE Report 2016. Available from: <http://www.health.alberta.ca/initiatives/AHTDP-reviews.html>. [Accessed 02.07.2016].  152. National Institute for Health and Care Excellence. Percutaneous endoscopic laser balloon pulmonary vein isolation for atrial fibrillation. 2016. Available from: <https://www.nice.org.uk/guidance/ipg563/resources/percutaneous-endoscopic-laser-balloon-pulmonary-vein-isolation-for-atrial-fibrillation-1899872046045637>. [Accessed 15.08.2016].  153. National Institute for Health and Care Excellence. Transcervical extracorporeal reverse flow neuroprotection for reducing the risk of stroke during carotid artery stenting. 2016. Available from: <https://www.nice.org.uk/guidance/ipg561/resources/transcervical-extracorporeal-reverse-flow-neuroprotection-for-reducing-the-risk-of-stroke-during-carotid-artery-stenting-1899872042686405>. [Accessed 15.08.2016].  154. National Institute for Health and Care Excellence. Ultrasound-guided percutaneous radiofrequency ablation for benign thyroid nodules. 2016. Available from: <https://www.nice.org.uk/guidance/ipg562/resources/ultrasoundguided-percutaneous-radiofrequency-ablation-for-benign-thyroid-nodules-1899872044366021>. [Accessed 15.08.2016].  155. National Institute for Health and Care Excellence. Endovenous mechanochemical ablation for varicose veins. 2016. Available from: <https://www.nice.org.uk/guidance/ipg557/resources/endovenous-mechanochemical-ablation-for-varicose-veins-1899871992297925>. [Accessed 15.08.2016].  156. National Institute for Health and Care Excellence. Biodegradable subacromial spacer insertion for rotator cuff tears. 2016. Available from: <https://www.nice.org.uk/guidance/ipg558/resources/biodegradable-subacromial-spacer-insertion-for-rotator-cuff-tears-1899871993977541>. [Accessed 15.08.2016].  157. National Institute for Health and Care Excellence. Transcutaneous electrical stimulation of the supraorbital nerve for treating and preventing migraine. 2016. Available from: <https://www.nice.org.uk/guidance/ipg559/resources/transcutaneous-electrical-stimulation-of-the-supraorbital-nerve-for-treating-and-preventing-migraine-1899871995657157>. [Accessed 15.08.2016].  158. National Institute for Health and Care Excellence. Microwave ablation for treating liver metastases. 2016. Available from: <https://www.nice.org.uk/guidance/ipg553/resources/microwave-ablation-for-treating-liver-metastases-1899871985579461>. [Accessed 15.08.2016].  159. National Institute for Health and Care Excellence. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. 2016. Available from: <https://www.nice.org.uk/guidance/ipg554/resources/balloon-pulmonary-angioplasty-for-chronic-thromboembolic-pulmonary-hypertension-1899871987259077>. [Accessed 15.08.2016].  160. National Institute for Health and Care Excellence. Percutaneous interlaminar endoscopic lumbar discectomy for sciatica. 2016. Available from: <https://www.nice.org.uk/guidance/ipg555/resources/percutaneous-interlaminar-endoscopic-lumbar-discectomy-for-sciatica-1899871988938693>. [Accessed 15.08.2016].  161. National Institute for Health and Care Excellence. Endovascular aneurysm sealing for abdominal aortic aneurysm. 2016. Available from: <https://www.nice.org.uk/guidance/ipg547/resources/endovascular-aneurysm-sealing-for-abdominal-aortic-aneurysm-1899871931831749>. [Accessed 15.08.2016].  162. National Institute for Health and Care Excellence. Mechanical clot retrieval for treating acute ischaemic stroke. 2016. Available from: <https://www.nice.org.uk/guidance/ipg548/resources/mechanical-clot-retrieval-for-treating-acute-ischaemic-stroke-1899871933511365>. [Accessed 15.08.2016].  163. National Institute for Health and Care Excellence. Corticosteroid-eluting bioabsorbable stent or spacer insertion during endoscopic sinus surgery to treat chronic rhinosinusitis. 2016. Available from: <https://www.nice.org.uk/guidance/ipg551/resources/corticosteroideluting-bioabsorbable-stent-or-spacer-insertion-during-endoscopic-sinus-surgery-to-treat-chronic-rhinosinusitis-1899871982220229>. [Accessed 15.08.2016].  164. National Institute for Health and Care Excellence. Transcutaneous stimulation of the cervical branch of the vagus nerve for cluster headache and migraine. 2016. Available from: <https://www.nice.org.uk/guidance/ipg552/resources/transcutaneous-stimulation-of-the-cervical-branch-of-the-vagus-nerve-for-cluster-headache-and-migraine-1899871983899845>. [Accessed 15.08.2016].  165. National Institute for Health and Care Excellence. Microstructural scaffold (patch) insertion without autologous cell implantation for repairing symptomatic chondral knee defects. 2016. Available from: <https://www.nice.org.uk/guidance/ipg560/resources/microstructural-scaffold-patch-insertion-without-autologous-cell-implantation-for-repairing-symptomatic-chondral-knee-defects-1899872041006789>. [Accessed 15.08.2016].  166. National Institute for Health and Care Excellence. Percutaneous transforaminal endoscopic lumbar discectomy for sciatica. 2016. Available from: <https://www.nice.org.uk/guidance/ipg556/resources/percutaneous-transforaminal-endoscopic-lumbar-discectomy-for-sciatica-1899871990618309>. [Accessed 15.08.2016].  167. National Institute for Health and Care Excellence. Normothermic extracorporeal preservation of hearts for transplantation following donation after brainstem death. 2016. Available from: <https://www.nice.org.uk/guidance/ipg549/resources/normothermic-extracorporeal-preservation-of-hearts-for-transplantation-following-donation-after-brainstem-death-1899871935190981>. [Accessed 15.08.2016].  168. National Institute for Health and Care Excellence. Percutaneous intradiscal radiofrequency treatment of the intervertebral disc nucleus for low back pain. 2016. Available from: <https://www.nice.org.uk/guidance/ipg545/resources/percutaneous-intradiscal-radiofrequency-treatment-of-the-intervertebral-disc-nucleus-for-low-back-pain-1899871928472517>. [Accessed 15.08.2016].  169. National Institute for Health and Care Excellence. Endoscopic carbon dioxide laser cricopharyngeal myotomy for relief of oropharyngeal dysphagia. 2016. Available from: <https://www.nice.org.uk/guidance/ipg550/resources/endoscopic-carbon-dioxide-laser-cricopharyngeal-myotomy-for-relief-of-oropharyngeal-dysphagia-1899871980540613>. [Accessed 15.08.2016].  170. National Institute for Health and Care Excellence. Percutaneous coblation of the intervertebral disc for low back pain and sciatica. 2016. Available from: <https://www.nice.org.uk/guidance/ipg543/resources/percutaneous-coblation-of-the-intervertebral-disc-for-low-back-pain-and-sciatica-1899871925113285>. [Accessed 15.08.2016].  171. National Institute for Health and Care Excellence. Angioplasty and stenting to treat peripheral arterial disease causing refractory erectile dysfunction. 2016. Available from: <https://www.nice.org.uk/guidance/ipg546/resources/angioplasty-and-stenting-to-treat-peripheral-arterial-disease-causing-refractory-erectile-dysfunction-1899871930152133>. [Accessed 15.08.2016].  172. National Institute for Health and Care Excellence. Percutaneous electrothermal treatment of the intervertebral disc annulus for low back pain and sciatica. 2016. Available from: <https://www.nice.org.uk/guidance/ipg544/resources/percutaneous-electrothermal-treatment-of-the-intervertebral-disc-annulus-for-low-back-pain-and-sciatica-1899871926792901>. [Accessed 15.08.2016].  173. Pertl D, Fröschl B, Laschkolnig A. Wirksamkeit eines Lungenkarzinom-Screenings durch Computertomographie mit niedriger Strahlendosis: Kurzrecherche. 2016. Available from: <http://www.goeg.at/cxdata/media/download/ctscreeninglungenkarzinom_kurzrech_2016.pdf>. [Accessed 03.08.2016].  174. Petersen I, McCrea RL, Sammon CJ, et al. Risks and benefits of psychotropic medication in pregnancy: cohort studies based on UK electronic primary care health records. Health Technol Assess. 2016 2016/03/31; 20(23).  175. Stürzlinger H, Antony K, Eisenmann A, et al. Rezente Evidenz zur medikamentösen Therapie von psychischen und Verhaltens-symptomen bei Alzheimer-Demenz: Ein systematischer Review zur Wirksamkeit. 2016. Available from: <http://www.goeg.at/cxdata/media/download/berichte/medikamentsedemenztherapie_endbericht.pdf>. [Accessed 03.08.2016].  176. Stürzlinger H, Eisenmann A, Pertl D, et al. Medikamentöse Schlaganfallprävention bei Vorhofflimmern: Wissenschaftlicher Ergebnisbericht. 2016. Available from: <http://www.goeg.at/cxdata/media/download/berichte/medikamentseschlaganfallprvention_endbericht_0fehler.pdf>. [Accessed 03.08.2016]. |

Supplementary Table 7 Reports excluded for not including a systematic review of economic evaluations

| Report |
| --- |
| 1. Agencia de Evaluación de Tecnologías Sanitarias de Andalucía. Efectividad y seguridad de la stentoplastia para el tratamiento de las fracturas vertebrales osteoporóticas. Revisión Sistemática. 2015. Available from: <http://www.juntadeandalucia.es/salud/servicios/contenidos/nuevaaetsa/up/AETSA_2014_10_Stentoplastia_def.pdf>. [Accessed 02.07.2016].  2. Agencia de Evaluación de Tecnologías Sanitarias de Andalucía. FDG-PET/TC y SPECT para la estadificación oncológica: estadificación del cáncer colorrectal, identificación del nódulo pulmonar solitario y re-estadificación del linfoma. 2015. Available from: <http://www.juntadeandalucia.es/salud/servicios/contenidos/nuevaaetsa/up/2014_8_AETSA_FDG_PET_TC_def.pdf>. [Accessed 02.07.2016].  3. Agencia de Evaluación de Tecnologías Sanitarias de Andalucía. Plataformas genómicas de segunda generación para el pronóstico del cáncer de mama: EndoPredict® y Prosigna™: Revisión Sistemática. 2015. Available from: <http://www.juntadeandalucia.es/salud/servicios/contenidos/nuevaaetsa/up/04_AETSA_Plataformas_genomicas_DEF_NIPO.pdf>. [Accessed 02.07.2016].  4. Agencia de Evaluación de Tecnologías Sanitarias de Andalucía. Utilidad de QF-PCR en el diagnóstico prenatal de aneuploidías fetales. 2015. Available from: <http://www.juntadeandalucia.es/salud/servicios/contenidos/nuevaaetsa/up/05_AETSA_Utilidad%20de%20QF_PCR%20en%20el%20diagnostico%20prenatal%20de%20aneuploidias%20feta_DEF_NIPO.pdf>. [Accessed 02.07.2016].  5. Agencia de Evaluación de Tecnologías Sanitarias de Andalucía. FDG-PET/TC y SPECT para la estadificación oncológica. Estadificación del cáncer colorrectal, identificación del nodulo pulmonar solitario y re-estadificación del linfoma. 2015. Available from: <http://www.juntadeandalucia.es/salud/servicios/contenidos/nuevaaetsa/up/2014_8_AETSA_FDG_PET_TC_def.pdf>. [Accessed 12.08.2016].  6. Agencia de Evaluación de Tecnologías Sanitarias de Andalucía. Efectividad de la quimioterapia con radioterapia frente a cirugía en el tratamiento del cáncer de laringe avanzado: Revisión sistemática 2016. Available from: <http://www.juntadeandalucia.es/salud/servicios/contenidos/nuevaaetsa/up/03_AETSA_CaLaringe_DEF_NIPO.pdf>. [Accessed 02.07.2016].  7. Agencia de Evaluación de Tecnologías Sanitarias de Andalucía. Eficacia y efectividad de las pruebas genéticas para el diagnóstico de la estenosis coronaria: Revisión sistemática. 2016. Available from: <http://www.juntadeandalucia.es/salud/servicios/contenidos/nuevaaetsa/up/08_AETSA_Pruebas%20Geneticas%20de%20Estenosis%20coronaria_DEF_NIPO.pdf>. [Accessed 02.07.2016].  8. Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS). Albiglutida en el tractament de la diabetis mellitus 2. 2015. Available from: <http://catsalut.gencat.cat/web/.content/minisite/catsalut/proveidors_professionals/medicaments_farmacia/phf_apc/informes/albiglutida/Informe_ALBIGLUTIDA_2015.pdf>. [Accessed 02.07.2016].  9. Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS). Avaluació econòmica de la prevenció primària de les fractures de maluc per fragilitat: estimació del risc i cost-efectivitat del tractament. 2015. Available from: <http://aquas.gencat.cat/web/.content/minisite/aquas/publicacions/2015/documents/evaluacion_economica_prevencion_fractura_cadera_aquas2015es.pdf>. [Accessed 02.07.2016].  10. Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS). Canagliflozina en el tractament de la diabetis mellitus tipus 2 2015. Available from: <http://catsalut.gencat.cat/web/.content/minisite/catsalut/proveidors_professionals/medicaments_farmacia/phf_apc/informes/canagliflozina/Informe_CANAGLIFLOZINA_PHFAPC_2015.pdf>. [Accessed 02.07.2016].  11. Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS). Canagliflozina/metformina en el tractament de la diabetis mellitus tipus 2. 2015. Available from: <http://catsalut.gencat.cat/web/.content/minisite/catsalut/proveidors_professionals/medicaments_farmacia/phf_apc/informes/canagliflozina_metformina/Informe_CANAGLIFLOZINA_METFORMINA_2015.pdf>. [Accessed 02.07.2016].  12. Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS). Dapagliflozina en el tractament de la diabetis mellitus tipus 2. 2015. Available from: <http://catsalut.gencat.cat/web/.content/minisite/catsalut/proveidors_professionals/medicaments_farmacia/phf_apc/informes/dapagliflozina/Informe_DAPAGLIFLOZINA_PHFAPC_2015.pdf>. [Accessed 02.07.2016].  13. Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS). Dapagliflozina i metformina en el tractament de la diabetis mellitus tipus 2 2015. Available from: <http://catsalut.gencat.cat/web/.content/minisite/catsalut/proveidors_professionals/medicaments_farmacia/phf_apc/informes/dapaglifozina_metformina/Informe_DAPAGLIFLOZINA_METFORMINA_PHFAPC_2015.pdf>. [Accessed 02.07.2016].  14. Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS). Desvenlafaxina en el tractament del trastorn depressiu major en adults 2015. Available from: <http://catsalut.gencat.cat/web/.content/minisite/catsalut/proveidors_professionals/medicaments_farmacia/phf_apc/informes/desvenlafaxina/Informe_DESVENLAFAXINA_PHFAPC_2015.pdf>. [Accessed 02.07.2016].  15. Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS). Dutasterida/tamsulosina en el tractament de la hiperplàsia benigna de pròstata. 2015. Available from: <http://catsalut.gencat.cat/web/.content/minisite/catsalut/proveidors_professionals/medicaments_farmacia/phf_apc/informes/dutasterida_amsulosina/Informe_DUODART_PHFAPC_2015.pdf>. [Accessed 02.07.2016].  16. Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS). Alogliptina en el tractament de la diabetis mellitus tipus 2 en adults. 2016. Available from: <http://catsalut.gencat.cat/web/.content/minisite/catsalut/proveidors_professionals/medicaments_farmacia/phf_apc/informes/alogliptina/informe_alogliptina.pdf>. [Accessed 02.07.2016].  17. Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS). Bromur d'umeclidini en el tractament broncodilatador de manteniment per alleujar els símptomes de la malaltia pulmonar obstructiva crònica en pacients adults 2016. Available from: <http://aquas.gencat.cat/web/.content/minisite/aquas/publicacions/2015/documents/Bromur-umeclidini_informe_farmacia_AQuAS.pdf>. [Accessed 02.07.2016].  18. Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS). Bromur d'umeclidini/vilanterol en el tractament broncodilatador de manteniment en pacients amb malaltia pulmonar obstructiva crònica (MPOC). 2016. Available from: <http://catsalut.gencat.cat/web/.content/minisite/catsalut/proveidors_professionals/medicaments_farmacia/phf_apc/informes/umeclidini_vilanterol/054-123590-BROMUR-VILANTEROL_per-publicar.pdf>. [Accessed 02.07.2016].  19. Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS). lodaterol en el tractament broncodilatador de manteniment en pacients amb malaltia pulmonar obstructiva crònica (MPOC). 2016. Available from: <http://catsalut.gencat.cat/web/.content/minisite/catsalut/proveidors_professionals/medicaments_farmacia/phf_apc/informes/olodaterol/054-123596-OLODATEROL.pdf>. [Accessed 02.07.2016].  20. Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS). Pautes per a l'harmonització del tractament farmacològic de la malaltia d'Alzheimer. 2016. Available from: <http://catsalut.gencat.cat/web/.content/minisite/catsalut/proveidors_professionals/medicaments_farmacia/phf_apc/protocols/Alzheimer/PAUTES-ALZHEIMER.pdf>. [Accessed 02.07.2016].  21. Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS). Aripiprazol IM depot: tractament de manteniment de l’esquizofrènia. 2016. Available from: <http://catsalut.gencat.cat/web/.content/minisite/catsalut/proveidors_professionals/medicaments_farmacia/phf_apc/informes/aripiprazol_injectable_alliberacio_perllongada/Informe-ARIPIPRAZOL_per-web.pdf>. [Accessed 02.07.2016].  22. Arbyn M, Haelens A, Desomer A, et al. Cervical cancer screening program and Human Papillomavirus (HPV) testing, part II: Update on HPV primary screening: KCE Reports 238. 2015. Available from: <https://kce.fgov.be/sites/default/files/page_documents/KCE__238_HPV_DNA_Testing_Report2_.pdf>. [Accessed 08.07.2016].  23. Azuara-Blanco A, Banister K, Boachie C, et al. Automated imaging technologies for the diagnosis of glaucoma: a comparative diagnostic study for the evaluation of the diagnostic accuracy, performance as triage tests and cost-effectiveness (GATE study). Health Technol Assess. 2016 2016/02/01; 20(8).  24. Barna A, Charpentier E, Fahlgren B, et al. Désinfection du centre de traitement des brûlés de l’AP-HP (Saint-Louis) à l’aide du peroxyde d’hydrogène vaporisé (Bioquell) - Avis du CEDIT. 2015. Available from: <http://recherche.aphp.fr/wp-content/blogs.dir/85/files/2015/07/Bioquell-avis-CEDIT.pdf>. [Accessed  25. Barna A, Charpentier E, Fahlgren B, et al. Intérêt des dispositifs d’oxygénation extracorporelle par membrane (ECMO) pour la prise en charge pré-hospitalière de l’arrêt cardiaque - Avis du CEDIT. 2015. Available from: <http://recherche.aphp.fr/wp-content/blogs.dir/85/files/2015/06/ECMO-préhospitaliere-Avis-du-CEDIT.pdf>. [Accessed  26. Barna A, Charpentier E, Fahlgren B, et al. Surveillance peropératoire non invasive en continu de l'hémoglobinémie (dispositif Masimo Radical-7) - Avis du CEDIT. 2015. Available from: <http://recherche.aphp.fr/wp-content/blogs.dir/85/files/2015/05/Monitorage-Hb-avis-CEDIT.pdf>. [Accessed  27. Barna A, Charpentier E, Fahlgren B, et al. Dispositif STAR™ pour l'ablation par radiofréquence des métastases vertébrales - Avis du CEDIT. 2015. Available from: <http://recherche.aphp.fr/wp-content/blogs.dir/85/files/2015/05/SpineStar-avis-CEDIT.pdf>. [Accessed  28. Barna A, Charpentier E, Fahlgren B, et al. Aquaphérèse : ultrafiltration pour la prise en charge de l’insuffisance cardiaque - Avis du CEDIT. 2015. Available from: <http://recherche.aphp.fr/wp-content/blogs.dir/85/files/2015/04/Aquapherese-avis-CEDIT.pdf>. [Accessed  29. Barna A, Charpentier E, Fahlgren B, et al. Désinfection des sondes d’échographie endocavitaire par rayons ultraviolets C (Antigermix) - Avis du CEDIT. 2015. Available from: <http://recherche.aphp.fr/wp-content/blogs.dir/85/files/2015/03/Antigermix-avis-du-CEDIT.pdf>. [Accessed  30. Barna A, Charpentier E, Fahlgren B, et al. Spirales endobronchiques RePneu® dans le traitement de l’emphysème pulmonaire - Avis du CEDIT. 2016. Available from: <http://recherche.aphp.fr/wp-content/blogs.dir/85/files/2016/01/Spirales-endobronchique-avis-du-CEDIT.pdf>. [Accessed  31. Barna A, Charpentier E, Fahlgren B, et al. Spectros T-Stat™ (Visible light spectroscopy) pour les ischémies intestinales aigües - Avis du CEDIT. 2016. Available from: <http://recherche.aphp.fr/wp-content/blogs.dir/85/files/2016/03/Infarctus-mesenterique-avis-final-20160322.pdf>. [Accessed  32. Barnes TRE, Leeson VC, Paton C, et al. Antidepressant Controlled Trial For Negative Symptoms In Schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trial. Health Technol Assess. 2016 2016/04/19; 20(29).  33. Basque Office for Health Technology Assessment/Basque Government (OSTEBA). Sistemas de e-salud para el apoyo a pacientes oncológicos: propuesta de diseño para futuros estudios evaluativos. 2015. Available from: <http://www.ogasun.ejgv.euskadi.eus/r51-catpub/es/k75aWebPublicacionesWar/k75aObtenerPublicacionDigitalServlet?R01HNoPortal=true&N_LIBR=051726&N_EDIC=0001&C_IDIOM=es&FORMATO=.pdf>. [Accessed 12.08.2016].  34. Basque Office for Health Technology Assessment/Basque Government (OSTEBA). Telemonitorización de pacientes pluripatológicos con enfermedad cardiaca o respiratoria. Evaluación de su implantación en Atención Primaria. 2015. Available from: <http://www.ogasun.ejgv.euskadi.eus/r51-catpub/es/k75aWebPublicacionesWar/k75aObtenerPublicacionDigitalServlet?R01HNoPortal=true&N_LIBR=051619&N_EDIC=0001&C_IDIOM=es&FORMATO=.pdf>. [Accessed 12.08.2016].  35. Basque Office for Health Technology Assessment/Basque Government (OSTEBA). Evaluación de los tiempos de atención del cáncer en las principales localizaciones: colon-recto, pulmón, mama y próstata. 2016. Available from: <http://www.ogasun.ejgv.euskadi.eus/r51-catpub/es/k75aWebPublicacionesWar/k75aObtenerPublicacionDigitalServlet?R01HNoPortal=true&N_LIBR=051878&N_EDIC=0001&C_IDIOM=es&FORMATO=.pdf>. [Accessed 12.08.2016].  36. Basque Office for Health Technology Assessment/Basque Government (OSTEBA). Impacto de la implantación de un programa de cribado poblacional de cáncer de cérvix, siguiendo las recomendaciones europeas (prueba/intervalo)en relación a la situación actual. 2016. Available from: <http://www.ogasun.ejgv.euskadi.eus/r51-catpub/es/k75aWebPublicacionesWar/k75aObtenerPublicacionDigitalServlet?R01HNoPortal=true&N_LIBR=051788&N_EDIC=0001&C_IDIOM=es&FORMATO=.pdf>. [Accessed 12.08.2016].  37. Basque Office for Health Technology Assessment/Basque Government (OSTEBA). Evaluación de la calidad asistencial en el SNS de los trastornos mentales graves en la infancia. Estudio en Salud Mental Infanto-Juvenil. 2016. Available from: <http://www.ogasun.ejgv.euskadi.net/r51-catpub/es/k75aWebPublicacionesWar/k75aObtenerPublicacionDigitalServlet?R01HNoPortal=true&N_LIBR=051612&N_EDIC=0001&C_IDIOM=es&FORMATO=.pdf>. [Accessed 12.08.2016].  38. Baxter S, Johnson M, Blank L, et al. Non-pharmacological treatments for stuttering in children and adults: a systematic review and evaluation of clinical effectiveness, and exploration of barriers to successful outcomes. Health Technol Assess. 2016 2016/01/18; 20(2).  39. Blyth A, Maskrey V, Notley C, et al. Effectiveness and economic evaluation of self-help educational materials for the prevention of smoking relapse: randomised controlled trial. Health Technol Assess. 2015 2015/07/28; 19(59).  40. Blyth M, Anthony I, Francq B, et al. Diagnostic accuracy of the Thessaly test, standardised clinical history and other clinical examination tests (Apley’s, McMurray’s and joint line tenderness) for meniscal tears in comparison with magnetic resonance imaging diagnosis. Health Technol Assess. 2015 2015/08/04; 19(62).  41. Bonell C, Fletcher A, Fitzgerald-Yau N, et al. Initiating change locally in bullying and aggression through the school environment (INCLUSIVE): a pilot randomised controlled trial. Health Technol Assess. 2015 2015/07/20; 19(53).  42. Brittenden J, Cotton SC, Elders A, et al. Clinical effectiveness and cost-effectiveness of foam sclerotherapy, endovenous laser ablation and surgery for varicose veins: results from the Comparison of LAser, Surgery and foam Sclerotherapy (CLASS) randomised controlled trial. Health Technol Assess. 2015 2015/04/13; 19(27).  43. Bunn F, Trivedi D, Alderson P, et al. The impact of Cochrane Reviews: a mixed-methods evaluation of outputs from Cochrane Review Groups supported by the National Institute for Health Research. Health Technol Assess. 2015 2015/04/16; 19(28).  44. Campbell F, Holmes M, Everson-Hock E, et al. A systematic review and economic evaluation of exercise referral schemes in primary care: a short report. Health Technol Assess. 2015 2015/07/29; 19(60).  45. Campbell JL, Fletcher E, Britten N, et al. The clinical effectiveness and cost-effectiveness of telephone triage for managing same-day consultation requests in general practice: a cluster randomised controlled trial comparing general practitioner-led and nurse-led management systems with usual care (the ESTEEM trial). Health Technol Assess. 2015 2015/02/18; 19(13).  46. Carr AJ, Cooper CD, Campbell MK, et al. Clinical effectiveness and cost-effectiveness of open and arthroscopic rotator cuff repair [the UK Rotator Cuff Surgery (UKUFF) randomised trial]. Health Technol Assess. 2015 2015/10/14; 19(80).  47. Cassell JA, Dodds J, Estcourt C, et al. The relative clinical effectiveness and cost-effectiveness of three contrasting approaches to partner notification for curable sexually transmitted infections: a cluster randomised trial in primary care. Health Technol Assess. 2015 2015/01/26; 19(5).  48. Chakravarthy U, Harding SP, Rogers CA, et al. A randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN). Health Technol Assess. 2015 2015/10/07; 19(78).  49. Champaneria R, Shah L, Moss J, et al. The relationship between pelvic vein incompetence and chronic pelvic pain in women: systematic reviews of diagnosis and treatment effectiveness. Health Technol Assess. 2016 2016/01/20; 20(5).  50. Clark AL, Johnson M, Fairhurst C, et al. Does home oxygen therapy (HOT) in addition to standard care reduce disease severity and improve symptoms in people with chronic heart failure? A randomised trial of home oxygen therapy for patients with chronic heart failure. Health Technol Assess. 2015 2015/09/22; 19(75).  51. Clark JT, Middleton LJ, Cooper N AM, et al. A randomised controlled trial of Outpatient versus inpatient Polyp Treatment (OPT) for abnormal uterine bleeding. Health Technol Assess. 2015 2015/07/30; 19(61).  52. Clarke M, Hogan V, Buck D, et al. An external pilot study to test the feasibility of a randomised controlled trial comparing eye muscle surgery against active monitoring for childhood intermittent exotropia [X(T)]. Health Technol Assess. 2015 2015/05/26; 19(39).  53. Claxton K, Martin S, Soares M, et al. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technol Assess. 2015 2015/02/18; 19(14).  54. Comisión de Salud Pública del Consejo Interterritorial del Sistema Nacional de Salud, Ministerio de Sanidad SSeI. Adenda. Actualización en "Revisión del programa de vacunación frente a tos ferina en España". 2015. Available from: <http://www.msssi.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/docs/Adenda_TosFerinaEmbarazo.pdf>. [Accessed 12.08.2016].  55. Comisión de Salud Pública del Consejo Interterritorial del Sistema Nacional de Salud, Ministerio de Sanidad SSeI. Vacunación frente a neumococo en grupos de riesgo. 2015. Available from: <http://www.msssi.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/docs/Neumococo_Gruposriesgo.pdf>. [Accessed 12.08.2016].  56. Coomarasamy A, Williams H, Truchanowicz E, et al. PROMISE: first-trimester progesterone therapy in women with a history of unexplained recurrent miscarriages - a randomised, double-blind, placebo-controlled, international multicentre trial and economic evaluation. Health Technol Assess. 2016 2016/05/25; 20(41):119.  57. Costa ML, Achten J, Plant C, et al. UK DRAFFT: a randomised controlled trial of percutaneous fixation with Kirschner wires versus volar locking-plate fixation in the treatment of adult patients with a dorsally displaced fracture of the distal radius. Health Technol Assess. 2015 2015/02/26; 19(17).  58. Crawford F, Cezard G, Chappell FM, et al. A systematic review and individual patient data meta-analysis of prognostic factors for foot ulceration in people with diabetes: the international research collaboration for the prediction of diabetic foot ulcerations (PODUS). Health Technol Assess. 2015 2015/07/28; 19(57).  59. Cunningham S, Rodriguez A, Boyd KA, et al. Bronchiolitis of Infancy Discharge Study (BIDS): a multicentre, parallel-group, double-blind, randomised controlled, equivalence trial with economic evaluation. Health Technol Assess. 2015 2015/09/14; 19(71).  60. Dennis M, Sandercock P, Graham C, et al. The Clots in Legs Or sTockings after Stroke (CLOTS) 3 trial: a randomised controlled trial to determine whether or not intermittent pneumatic compression reduces the risk of post-stroke deep vein thrombosis and to estimate its cost-effectiveness. Health Technol Assess. 2015 2015/09/29; 19(76).  61. Dobbie F, Hiscock R, Leonardi-Bee J, et al. Evaluating Long-term Outcomes of NHS Stop Smoking Services (ELONS): a prospective cohort study. Health Technol Assess. 2015 2015/11/16; 19(95).  62. Drobniewski F, Cooke M, Jordan J, et al. Systematic review, meta-analysis and economic modelling of molecular diagnostic tests for antibiotic resistance in tuberculosis. Health Technol Assess. 2015 2015/05/10; 19(34).  63. EUnetHTA WP5 Joint Action 2. Sorafenib for the treatment of progressive, locally advanced or metastatic, diffenetiated (papillary/follicular/hüthle cell) thyroid carcinoma, refractory to radioactive iodine. ID: SA-[3]. 2015. Available from: <http://www.eunethta.eu/sites/5026.fedimbo.belgium.be/files/Sorafenib%20for%20the%20treatment%20of%20thyroid%20carcinoma_Rapid%20REA_Final_Mar%202015_0.pdf>. [Accessed 14.09.2016].  64. EUnetHTA WP5 Joint Action 2. Rapid relative effectiveness assessment of new pharmaceuticals for the treatment of chronic hepatits C. Pilot ID: WP5‐SA‐6. 2015. Available from: <http://www.eunethta.eu/sites/5026.fedimbo.belgium.be/files/New%20Pharmaceuticals%20for%20the%20treatment%20of%20chronic%20Hepatitis%20C_Rapid%20REA_Final_Dec%202015_1.pdf>. [Accessed 14.09.2016].  65. EUnetHTA WP5 Joint Action 2. Ramucirumab in combination with paclitaxel as second-line treatment for adult patients with advanced gastric or gastro-oesophageal junction adenocarcinoma. Pilot ID: WP5 – SA4. 2015. Available from: <http://www.eunethta.eu/sites/5026.fedimbo.belgium.be/files/Ramucirumab%20for%20the%20treatment%20of%20gastric%20cancer_Rapid%20REA_Final_Mar2015.pdf>. [Accessed 14.09.2016].  66. EUnetHTA WP5 Joint Action 2. Vorapaxar for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI). Pilot ID: WP5 - SA-5 2015. Available from: <http://www.eunethta.eu/sites/5026.fedimbo.belgium.be/files/Vorapaxar%20for%20the%20reduction%20of%20thrombotic%20cardivascular%20events_Rapid%20REA_Final_Jun%202015_0.pdf>. [Accessed 14.09.2016].  67. EUnetHTA WP5 Joint Action 2. Balloon Eustachian tuboplasty for the treatment of Eustachian tube dysfunction. Pilot ID: SB-13. 2015. Available from: <http://www.eunethta.eu/sites/5026.fedimbo.belgium.be/files/Balloon%20Eustachian%20Tuboplasty%20for%20treatment%20of%20Eustachian%20tube%20dysfunction_Rapid%20REA_Final_Feb%202015.pdf>. [Accessed 14.09.2016].  68. EUnetHTA WP5 Joint Action 2. Biodegradable stents for the treatment of refractory or recurrent benign oesophageal stenosis. Pilot ID: SB-14. 2015. Available from: <http://www.eunethta.eu/sites/5026.fedimbo.belgium.be/files/Biodegradable%20Stents%20for%20benign%20refractory%20esophageal%20stenosis_Rapid%20REA_Final_May%202015_0.pdf>. [Accessed 14.09.2016].  69. EUnetHTA WP5 Joint Action 2. Transcatheter implantable devices for mitral valve repair in adults with chronic mitral valve regurgitation. Pilot ID: SB-15. 2015. Available from: <http://www.eunethta.eu/sites/5026.fedimbo.belgium.be/files/Transcatheter%20Implantable%20Devices%20for%20mitral%20valve%20repair%20in%20adults%20with%20chronic%20mitral%20valve%20regurgitation_Rapid%20REA_Final_Sep%202015_0.pdf>. [Accessed 14.09.2016].  70. EUnetHTA WP5 Joint Action 2. Endovascular therapy using mechanical thrombectomy devices for acute ischaemic stroke. Pilot ID: WP5-SB-16. 2016. Available from: <http://www.eunethta.eu/sites/5026.fedimbo.belgium.be/files/Mechanical%20thrombectomy%20devices%20for%20acute%20ischaemic%20stroke_Rapid%20REA_Updated%20and%20Final%20Feb%202016.pdf>. [Accessed 14.09.2016].  71. Everard ML, Hind D, Ugonna K, et al. Saline in Acute Bronchiolitis RCT and Economic evaluation: hypertonic saline in acute bronchiolitis - randomised controlled trial and systematic review. Health Technol Assess. 2015 2015/08/24; 19(66):142.  72. Field JK, Duffy SW, Baldwin DR, et al. The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer. Health Technol Assess. 2016 2016/05/24; 20(40):177.  73. Fortnum H, Ukoumunne OC, Hyde C, et al. A programme of studies including assessment of diagnostic accuracy of school hearing screening tests and a cost-effectiveness model of school entry hearing screening programmes. Health Technol Assess. 2016 2016/05/11; 20(36).  74. Foster NE, Bishop A, Bartlam B, et al. Evaluating Acupuncture and Standard carE for pregnant women with Back pain (EASE Back): a feasibility study and pilot randomised trial. Health Technol Assess. 2016 2016/05/03; 20(33).  75. Francis NA, Ridd MJ, Thomas-Jones E, et al. A randomised placebo-controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study. Health Technol Assess. 2016 2016/03/02; 20(19).  76. Gerkens S, Van De Sande S, Leroy R, et al. Autologous breast reconstruction techniques after mammary resection: time measurements for a potential reevaluation of the surgeon fee: KCE Reports 251. 2015. Available from: <https://kce.fgov.be/sites/default/files/page_documents/KCE_251_Cost_breast_reconstruction_Report.pdf>. [Accessed 08.07.2016].  77. Gillett M, Brennan A, Watson P, et al. The cost-effectiveness of testing strategies for type 2 diabetes: a modelling study. Health Technol Assess. 2015 2015/05/10; 19(33).  78. Graves N, Wloch C, Wilson J, et al. A cost-effectiveness modelling study of strategies to reduce risk of infection following primary hip replacement based on a systematic review. Health Technology Assessment 2016; 20(54).  79. Gregson BA, Rowan EN, Francis R, et al. Surgical Trial In Traumatic intraCerebral Haemorrhage (STITCH): a randomised controlled trial of Early Surgery compared with Initial Conservative Treatment. Health Technol Assess. 2015 2015/09/08; 19(70).  80. Griffin D, Wall P, Realpe A, et al. UK FASHIoN: feasibility study of a randomised controlled trial of arthroscopic surgery for hip impingement compared with best conservative care. Health Technol Assess. 2016 2016/04/27; 20(32).  81. Guo B, Tjosvold L. Endovenous thermal ablation interventions for symptomatic varicose veins of the legs – An update. Alberta STE Report 2016. Available from: <http://www.health.alberta.ca/initiatives/AHTDP-reviews.html>. [Accessed 02.07.2016].  82. Gupta JK, Daniels JP, Middleton LJ, et al. A randomised controlled trial of the clinical effectiveness and cost-effectiveness of the levonorgestrel-releasing intrauterine system in primary care against standard treatment for menorrhagia: the ECLIPSE trial. Health Technol Assess. 2015 2015/10/28; 19(88).  83. Guthrie S, Bienkowska-Gibbs T, Manville C, et al. The impact of the National Institute for Health Research Health Technology Assessment programme, 2003-13: a multimethod evaluation. Health Technol Assess. 2015 Aug; 19(67):1-291.  84. Handoll H, Brealey S, Rangan A, et al. The ProFHER (PROximal Fracture of the Humerus: Evaluation by Randomisation) trial - a pragmatic multicentre randomised controlled trial evaluating the clinical effectiveness and cost-effectiveness of surgical compared with non-surgical treatment for proximal fracture of the humerus in adults. Health Technol Assess. 2015 2015/03/31; 19(24).  85. Harron K, Mok Q, Dwan K, et al. CATheter Infections in CHildren (CATCH): a randomised controlled trial and economic evaluation comparing impregnated and standard central venous catheters in children. Health Technol Assess. 2016 2016/03/02; 20(18).  86. Harvey SE, Parrott F, Harrison DA, et al. A multicentre, randomised controlled trial comparing the clinical effectiveness and cost-effectiveness of early nutritional support via the parenteral versus the enteral route in critically ill patients (CALORIES). Health Technol Assess. 2016 2016/04/19; 20(28).  87. Hauptverband der österreichischen Sozialversicherung. CRC Screening. 2015. Available from: <http://www.hauptverband.at/cdscontent/load?contentid=10008.623215&version=1442491208>. [Accessed 05.08.2016].  88. Hauptverband der österreichischen Sozialversicherung. Tätigkeiten von Pflegefachkräften in der Hausarztpraxis: Internationale Tätigkeitsprofile und Evidenzlage. 2016. Available from: <http://www.hauptverband.at/cdscontent/load?contentid=10008.631038&version=1464598270>. [Accessed 05.08.2016].  89. Hauptverband der österreichischen Sozialversicherung. Sturzprävention für ältere Menschen. 2016. Available from: <http://www.hauptverband.at/cdscontent/load?contentid=10008.615719&version=1425627108>. [Accessed 05.08.2016].  90. Hauptverband der österreichischen Sozialversicherung. Niederenergetischer Ultraschall zur Wundbehandlung. Bei chronischen Wunden. 2016. Available from: <http://www.hauptverband.at/cdscontent/load?contentid=10008.631512&version=1466574777>. [Accessed 05.08.2016].  91. Hauptverband der österreichischen Sozialversicherung. Niederenergetischer Ultraschall und katheterassoziierte Harnwegsinfektionen. 2016. Available from: <http://www.hauptverband.at/cdscontent/load?contentid=10008.631193&version=1464872208> [Accessed 05.08.2016].  92. Haute Autorité de Santé. Evaluation d’un clip de réparation mitrale bord à bord et de son acte d’implantation: Service d'evaluation des dispositifs. 2015. Available from: <http://www.has-sante.fr/portail/upload/docs/application/pdf/2015-04/rapport_devaluation_mitraclip.pdf>. [Accessed 03.08.2016].  93. Haute Autorité de Santé. Mesure du monoxyde d’azote (NO) dans l’air expiré: Argumentaire. 2015. Available from: <http://www.has-sante.fr/portail/upload/docs/application/pdf/2015-06/argumentaire_mesure_no_vd.pdf>. [Accessed 03.08.2016].  94. Haute Autorité de Santé. Crosslinking du collagène cornéen et anneaux intra-cornéens dans le traitement des ectasies cornéennes: Rapport d'evaluation technologique. 2015. Available from: <http://www.has-sante.fr/portail/upload/docs/application/pdf/2015-06/rapport_keratocone.pdf>. [Accessed 03.08.2016].  95. Haute Autorité de Santé. Tests in vitro de dépistage de l’infection tuberculeuse latente par détection de production d’interféron gamma: Argumentaire. 2015. Available from: <http://www.has-sante.fr/portail/upload/docs/application/pdf/2015-06/argumentaire_igra_vd_2015-06-29_11-57-54_758.pdf>. [Accessed 03.08.2016].  96. Haute Autorité de Santé. Évaluation de la sialendoscopie parotidienne et submandibulaire à visée diagnostique et thérapeutique: Rapport d'evaluation technologique. 2015. Available from: <http://www.has-sante.fr/portail/upload/docs/application/pdf/2015-05/rapport_sialendoscopie.pdf>. [Accessed 03.08.2016].  97. Haute Autorité de Santé. Modification de la Nomenclature des actes de biologie médicale pour les actes de recherche du Treponema pallidum (bactérie responsable de la syphilis): Argumentaire. 2015. Available from: <http://www.has-sante.fr/portail/upload/docs/application/pdf/2015-05/argumentaire_syphilis_vd.pdf>. [Accessed 03.08.2016].  98. Haute Autorité de Santé. Alternative(s) à la scintigraphie préopératoire lors du bilan de localisation des glandes parathyroïdes hypersécrétantes dans l’hypothèse d’une pénurie complète en technétium-99m: Rapport d'evaluation technologique. 2015. Available from: <http://www.has-sante.fr/portail/upload/docs/application/pdf/2015-04/rapport_technetium_vd.pdf>. [Accessed 03.08.2016].  99. Haute Autorité de Santé. Mesure de la fraction du flux de réserve coronarien FFR lors d’une coronarographie: Argumentaire. 2015. Available from: <http://www.has-sante.fr/portail/upload/docs/application/pdf/2015-06/argumentaire_ffr_vd.pdf>. [Accessed 03.08.2016].  100. Hay AD, Birnie K, Busby J, et al. The Diagnosis of Urinary Tract infection in Young children (DUTY): a diagnostic prospective observational study to derive and validate a clinical algorithm for the diagnosis of urinary tract infection in children presenting to primary care with an acute illness. Health Technol Assess. 2016 2016/07/11; 20(51).  101. Health Policy Advisory Committee on Technology (HealthPACT). Bioresorbable vascular scaffolds for coronary artery disease: Technology Brief. 2015. Available from: <https://www.health.qld.gov.au/healthpact/docs/briefs/WP220.pdf>. [Accessed 03.08.2016].  102. Health Policy Advisory Committee on Technology (HealthPACT). Leadless Pacemaker: Technology Brief. 2015. Available from: <https://www.health.qld.gov.au/healthpact/docs/briefs/WP222.pdf>. [Accessed 03.08.2016].  103. Health Policy Advisory Committee on Technology (HealthPACT). High-frequency spinal cord stimulation and dorsal root ganglion stimulation for chronic pain: Technology Brief. 2015. Available from: <https://www.health.qld.gov.au/healthpact/docs/briefs/WP221.pdf>. [Accessed 03.08.2016].  104. Health Policy Advisory Committee on Technology (HealthPACT). MRIdian™ system for MRI-guided radiotherapy: Technology Brief. 2015. Available from: <https://www.health.qld.gov.au/healthpact/docs/briefs/WP214.pdf>. [Accessed 03.08.2016].  105. Health Policy Advisory Committee on Technology (HealthPACT). Vagus nerve blocking and gastric artery embolisation for obesity: Extended Technology Brief. 2015. Available from: <https://www.health.qld.gov.au/healthpact/docs/briefs/WP212-extended.pdf>. [Accessed 03.08.2016].  106. Health Policy Advisory Committee on Technology (HealthPACT). The RePneu® Coil System and other bronchoscopic lung volume reduction treatments for advanced emphysema: Extended Technology Brief. 2015. Available from: <https://www.health.qld.gov.au/healthpact/docs/briefs/WP172-extended.pdf>. [Accessed 03.08.2016].  107. Health Policy Advisory Committee on Technology (HealthPACT). Basic fibroblast growth factor (b-FGF) for the treatment of tympanic membrane perforation: Technology Brief Update. 2015. Available from: <https://www.health.qld.gov.au/healthpact/docs/briefs/WP129-update.pdf>. [Accessed 03.08.2016].  108. Health Policy Advisory Committee on Technology (HealthPACT). PleurX® catheter system for the treatment of malignant pleural effusion: Technology Brief Update. 2015. Available from: <https://www.health.qld.gov.au/healthpact/docs/briefs/WP038-update.pdf>. [Accessed 03.08.2016].  109. Health Policy Advisory Committee on Technology (HealthPACT). ROX Coupler for Treatment-resistant Hypertension: Technology Brief. 2015. Available from: <https://www.health.qld.gov.au/healthpact/docs/briefs/WP195.pdf>. [Accessed 03.08.2016].  110. Health Policy Advisory Committee on Technology (HealthPACT). Screening for coronary artery disease using CT calcium scoring: Technology Brief. 2015. Available from: <https://www.health.qld.gov.au/healthpact/docs/briefs/wp227-calcium-scoring.pdf>. [Accessed 03.08.2016].  111. Health Policy Advisory Committee on Technology (HealthPACT). Endovascular clot retrieval with thrombolysis for ischaemic stroke: Technology Brief. 2015. Available from: <https://www.health.qld.gov.au/healthpact/docs/briefs/wp226-mech-thrombectomy.pdf>. [Accessed 03.08.2016].  112. Health Policy Advisory Committee on Technology (HealthPACT). Transcatheter mitral valve replacement for severe mitral regurgitation: Technology Brief. 2015. Available from: <https://www.health.qld.gov.au/healthpact/docs/briefs/wp225-mitral-valve.pdf>. [Accessed 03.08.2016].  113. Health Policy Advisory Committee on Technology (HealthPACT). Ultra-filtration for patients with decompensated heart failure: Technology Brief Update. 2015. Available from: <https://www.health.qld.gov.au/healthpact/docs/briefs/wp148-aquapheresis.pdf>. [Accessed 03.08.2016].  114. Health Policy Advisory Committee on Technology (HealthPACT). Microwave ablation for hepatic tumours: Technology Brief Update. 2015. Available from: <https://www.health.qld.gov.au/healthpact/docs/briefs/WP163.pdf>. [Accessed 03.08.2016].  115. Health Policy Advisory Committee on Technology (HealthPACT). Stem cell therapy for non-haematological (autoimmune) indications: New and Emerging Health Technology Report. 2015. Available from: <https://www.health.qld.gov.au/healthpact/docs/nehtr/nehtr-march2015.pdf>. [Accessed 03.08.2016].  116. Health Policy Advisory Committee on Technology (HealthPACT). MRI screening for prostate cancer: Technology Brief. 2015. Available from: <https://www.health.qld.gov.au/healthpact/docs/briefs/WP203.pdf>. [Accessed 03.08.2016].  117. Health Policy Advisory Committee on Technology (HealthPACT). Blood and stool biomarker testing for colorectal cancer screening: Technology Overview. 2015. Available from: <https://www.health.qld.gov.au/healthpact/docs/briefs/WP151.pdf>. [Accessed 03.08.2016].  118. Health Policy Advisory Committee on Technology (HealthPACT). Pressurised intraperitoneal aerosol chemotherapy: Technology Brief. 2015. Available from: <https://www.health.qld.gov.au/healthpact/docs/briefs/WP223.pdf>. [Accessed 03.08.2016].  119. Health Policy Advisory Committee on Technology (HealthPACT). Circulating tumour DNA assays: Technology Brief. 2015. Available from: <https://www.health.qld.gov.au/healthpact/docs/briefs/WP217.pdf>. [Accessed 03.08.2016].  120. Health Policy Advisory Committee on Technology (HealthPACT). ZIO® XT Patch for diagnosis of cardiac arrhythmia: Technology Brief. 2015. Available from: <https://www.health.qld.gov.au/healthpact/docs/briefs/WP197.pdf>. [Accessed 03.08.2016].  121. Health Policy Advisory Committee on Technology (HealthPACT). Barricaid® prosthesis for partial annulus replacement: Technology Brief. 2015. Available from: <https://www.health.qld.gov.au/healthpact/docs/briefs/WP209.pdf>. [Accessed 03.08.2016].  122. Health Policy Advisory Committee on Technology (HealthPACT). Upper Airway Stimulation for Moderate-to-Severe Sleep Apnoea: Technology Brief. 2015. Available from: <https://www.health.qld.gov.au/healthpact/docs/briefs/WP097(update).pdf>. [Accessed 03.08.2016].  123. Health Policy Advisory Committee on Technology (HealthPACT). Endobronchial valves for patients with advanced heterogeneous emphysema: Technology Brief. 2015. Available from: <https://www.health.qld.gov.au/healthpact/docs/briefs/WP199.pdf>. [Accessed 03.08.2016].  124. Health Policy Advisory Committee on Technology (HealthPACT). InSpace™ biodegradable subacromial spacer for rotator cuff tears: Technology Brief. 2015. Available from: <https://www.health.qld.gov.au/healthpact/docs/briefs/WP211.pdf>. [Accessed 03.08.2016].  125. Health Policy Advisory Committee on Technology (HealthPACT). Magnetic resonance thermometry-guided laser interstitial thermal therapy for intracranial neoplasms: Technology Brief Update. 2016. Available from: <https://www.health.qld.gov.au/healthpact/docs/briefs/WP166-update.pdf>. [Accessed 03.08.2016].  126. Health Policy Advisory Committee on Technology (HealthPACT). Enhanced liver fibrosis test: Technology Brief Update. 2016. Available from: <https://www.health.qld.gov.au/healthpact/docs/briefs/WP177-update.pdf>. [Accessed 03.08.2016].  127. Health Policy Advisory Committee on Technology (HealthPACT). Non-Invasive Open Ventilation (NIOV™) System for Respiratory Insufficiency: Technology Brief. 2016. Available from: <https://www.health.qld.gov.au/healthpact/docs/briefs/WP193.pdf>. [Accessed 03.08.2016].  128. Health Policy Advisory Committee on Technology (HealthPACT). STAR™ Tumor Ablation System: Technology Brief. 2016. Available from: <https://www.health.qld.gov.au/healthpact/docs/briefs/WP196.pdf>. [Accessed 03.08.2016].  129. Health Policy Advisory Committee on Technology (HealthPACT). Stenting versus medical therapy for atherosclerotic renal artery stenosis: Technology Brief. 2016. Available from: <https://www.health.qld.gov.au/healthpact/docs/briefs/WP207.pdf>. [Accessed 03.08.2016].  130. Health Policy Advisory Committee on Technology (HealthPACT). Radiofrequency Ablation for Hypertrophy of the Inferior Nasal Turbinates : Technology Brief. 2016. Available from: <https://www.health.qld.gov.au/healthpact/docs/briefs/WP215.pdf>. [Accessed 03.08.2016].  131. Health Policy Advisory Committee on Technology (HealthPACT). PATHFAST Presepsin chemiluminescent enzyme immunoassay for the diagnosis and prognosis of sepsis: Technology Brief. 2016. Available from: <https://www.health.qld.gov.au/healthpact/docs/briefs/WP229.pdf>. [Accessed 03.08.2016].  132. Health Policy Advisory Committee on Technology (HealthPACT). Gene expression profiling of breast cancer: Technology Brief Update. 2016. Available from: <https://www.health.qld.gov.au/healthpact/docs/briefs/WP039-update.pdf>. [Accessed 03.08.2016].  133. Health Quality Ontario. Caesarean Delivery Rate Review: An Evidence-Based Analysis. 2015. Available from: <http://www.hqontario.ca/Portals/0/Documents/evidence/reports/eba-caesarean-delivery-rate-review-1503-en.pdf>. [Accessed 05.08.2016].  134. Health Quality Ontario. Prostate-Specific Antigen (PSA)–Based Population Screening for Prostate Cancer: An Economic Analysis. 2015. Available from: <http://www.hqontario.ca/Portals/0/Documents/evidence/reports/report-pulmonary-rehab-20150402-en.pdf>. [Accessed 05.08.2016].  135. Healthcare Improvement Scotland. DySIS®: Innovative medical technology overview 005-2015. 2015. Available from: <http://www.healthcareimprovementscotland.org/our_work/technologies_and_medicines/shtg_imto/imto_005-2015.aspx>. [Accessed 03.08.2016].  136. Healthcare Improvement Scotland. Ambulight®: Innovative medical technology overview. 2015. Available from: <http://www.healthcareimprovementscotland.org/our_work/technologies_and_medicines/shtg_imto/imto_004-2015.aspx>. [Accessed 03.08.2016].  137. Healthcare Improvement Scotland. Airsonett®: Innovative medical technology overview 003-2015. 2015. Available from: <http://www.healthcareimprovementscotland.org/our_work/technologies_and_medicines/shtg_imto/imto_003-2015.aspx>. [Accessed 03.08.2016].  138. Hilton P, Armstrong N, Brennand C, et al. INVESTIGATE-I (INVasive Evaluation before Surgical Treatment of Incontinence Gives Added Therapeutic Effect?): a mixed-methods study to assess the feasibility of a future randomised controlled trial of invasive urodynamic testing prior to surgery for stress urinary incontinence in women. Health Technol Assess. 2015 2015/02/25; 19(15).  139. Hollis C, Pennant M, Cuenca J, et al. Clinical effectiveness and patient perspectives of different treatment strategies for tics in children and adolescents with Tourette syndrome: a systematic review and qualitative analysis. Health Technol Assess. 2016 2016/01/20; 20(4).  140. Horrocks EJ, Bremner SA, Stevens N, et al. Double-blind randomised controlled trial of percutaneous tibial nerve stimulation versus sham electrical stimulation in the treatment of faecal incontinence: CONtrol of Faecal Incontinence using Distal NeuromodulaTion (the CONFIDeNT trial). Health Technol Assess. 2015 2015/10/01; 19(77):76.  141. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Lurasidon: Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A14-42. IQWiG-Berichte 2015. 275:[Available from: <https://www.iqwig.de/download/A14-42_Lurasidon_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 10.02.2015].  142. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Vildagliptin: Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A14-46. IQWiG-Berichte 2015. 281:[Available from: <https://www.iqwig.de/download/A14-46_Vildagliptin_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 12.03.2015].  143. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Ledipasvir/Sofosbuvir: Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A14-44. IQWiG-Berichte 2015. 282:[Available from: <https://www.iqwig.de/download/A14-44_Ledipasvir-Sofosbuvir_Nutzenbewertung_35a-SGB-V.pdf>. [Accessed 12.03.2015].  144. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Simoctocog alfa: Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A14-41. IQWiG-Berichte 2015. 277:[Available from: <https://www.iqwig.de/download/A14-41_Simoctocog-alfa_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 12.03.2015].  145. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Nintedanib: Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A15-01. IQWiG-Berichte 2015. 290:[Available from: <https://www.iqwig.de/download/A15-01_Nintedanib_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 02.05.2015].  146. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Tafluprost/Timolol: Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A14-49. IQWiG-Berichte 2015. 292:[Available from: <https://www.iqwig.de/download/A14-49_Tafluprost-Timolol_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 02.05.2015].  147. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Enzalutamid (neues Anwendungsgebiet): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A14-48. IQWiG-Berichte 2015. 291:[Available from: <https://www.iqwig.de/download/A14-48_Enzalutamid-neues-Anwendungsgebiet_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 02.05.2015].  148. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Ledipasvir/Sofosbuvir: Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A14-44. IQWiG-Berichte 2015. 282:[Available from: <https://www.iqwig.de/download/A14-44_Ledipasvir-Sofosbuvir_Nutzenbewertung_35a-SGB-V.pdf>. [Accessed 02.05.2015].  149. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Apremilast: Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A15-09. IQWiG-Berichte 2015. 302:[Available from: <https://www.iqwig.de/download/A15-09_Apremilast_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 18.05.2015].  150. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Insulin degludec (neues Anwendungsgebiet): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A15-10. IQWiG-Berichte 2015. 306:[Available from: <https://www.iqwig.de/download/A15-10_Insulin-degludec-neues-Anwendungsgebiet_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 03.06.2015].  151. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Aflibercept (neues Anwendungsgebiet): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A15-11. IQWiG-Berichte 2015. 308:[Available from: <https://www.iqwig.de/download/A15-11_Aflibercept-neues-Anwendungsgebiet_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 06.07.2015].  152. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Fingolimod: Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A15-12. IQWiG-Berichte 2015. 313:[Available from: <https://www.iqwig.de/download/A15-12_Fingolimod_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 06.07.2015].  153. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Dasabuvir: Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A15-03. IQWiG-Berichte 2015. 296:[Available from: <https://www.iqwig.de/download/A15-03_Dasabuvir_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 06.07.2015].  154. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Ombitasvir/Paritaprevir/Ritonavir: Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A15-04. IQWiG-Berichte 2015. 297:[Available from: <https://www.iqwig.de/download/A15-04_Ombitasvir-Paritaprevir-Ritonavir_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 06.07.2015].  155. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Aclidiniumbromid/Formoterol: Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A15-06. IQWiG-Berichte 2015. 298:[Available from: <https://www.iqwig.de/download/A15-06_Aclidiniumbromid-Formoterol_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 06.07.2015].  156. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Dulaglutid: Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A15-07. IQWiG-Berichte 2015. 299:[Available from: <https://www.iqwig.de/download/A15-07_Dulaglutid_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 06.07.2015].  157. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Ruxolitinib: Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A15-13. IQWiG-Berichte 2015. 314:[Available from: <https://www.iqwig.de/download/A15-13_Ruxolitinib_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 20.07.2015].  158. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Insulin degludec/Liraglutid: Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A15-15. IQWiG-Berichte 2015. 316:[Available from: <https://www.iqwig.de/download/A15-15_Insulin-degludec-Liraglutid_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 20.08.2015].  159. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Vortioxetin: Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A15-16. IQWiG-Berichte 2015. 317:[Available from: <https://www.iqwig.de/download/A15-16_Vortioxetin_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 20.08.2015].  160. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Safinamid: Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A15-18. IQWiG-Berichte 2015. 319:[Available from: <https://www.iqwig.de/download/A15-18_Safinamid_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 20.08.2015].  161. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Afatinib: Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A15-17. IQWiG-Berichte 2015. 318:[Available from: <https://www.iqwig.de/download/A15-17_Afatinib_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 20.08.2015].  162. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Secukinumab: Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A15-20. IQWiG-Berichte 2015. 322:[Available from: <https://www.iqwig.de/download/A15-20_Secukinumab_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 03.09.2015].  163. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Lomitapid: Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A15-23. IQWiG-Berichte 2015. 324:[Available from: <https://www.iqwig.de/download/A15-23_Lomitapid_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 22.09.2015].  164. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Ceritinib: Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A15-24. IQWiG-Berichte 2015. 329:[Available from: <https://www.iqwig.de/download/A15-24_Ceritinib_Nutzenbewertung_35a_SGB-V.pdf>. [Accessed 08.10.2015].  165. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Nivolumab: Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A15-27. IQWiG-Berichte 2015. 331:[Available from: <https://www.iqwig.de/download/A15-27_Nivolumab_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 30.11.2015].  166. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Belatacept: Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A15-25. IQWiG-Berichte 2015. 330:[Available from: <https://www.iqwig.de/download/A15-25_Belatacept_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 30.11.2015].  167. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Edoxaban: Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A15-29. IQWiG-Berichte 2015. 334:[Available from: <https://www.iqwig.de/download/A15-29_Edoxaban_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 30.11.2015].  168. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Pembrolizumab: Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A15-33. IQWiG-Berichte 2015. 339:[Available from: <https://www.iqwig.de/download/A15-33_Pembrolizumab_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 30.11.2015].  169. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Tiotropium/Olodaterol: Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung: Auftrag A15-31. IQWiG-Berichte 2015. 337:[Available from: <https://www.iqwig.de/download/A15-31_Tiotropium-Olodaterol_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 30.11.2015].  170. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Insulin degludec/Liraglutid (neues Anwendungsgebiet): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A15-30. IQWiG-Berichte 2015. 335:[Available from: <https://www.iqwig.de/download/A15-30_Insulin-degludec-Liraglutid-neues-AWG_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 30.11.2015].  171. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Netupitant/Palonosetron: Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A15-28. IQWiG-Berichte 2015. 336:[Available from: <https://www.iqwig.de/download/A15-28_Netupitant-Palonosetron_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 30.11.2015].  172. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Nivolumab (neues Anwendungsgebiet): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A15-32. IQWiG-Berichte 2015. 338:[Available from: <https://www.iqwig.de/download/A15-32_Nivolumab-neues-AWG_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 30.11.2015].  173. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Pertuzumab (neues Anwendungsgebiet): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A15-34. IQWiG-Berichte 2015. 343:[Available from: <https://www.iqwig.de/download/A15-34_Pertuzumab-neues-AWG_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 15.12.2015].  174. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Evolocumab: Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A15-38. IQWiG-Berichte 2015. 345:[Available from: <https://www.iqwig.de/download/A15-38_Evolocumab_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 15.12.2015].  175. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Ibrutinib: Bewertung gemäß § 35a Abs. 1 Satz 10 SGB V; Dossierbewertung; Auftrag G14-11. IQWiG-Berichte 2015. 272:[Available from: <https://www.iqwig.de/download/G14-11_Ibrutinib_Bewertung-35a-Abs-1-Satz10-SGB-V.pdf>. [Accessed 10.02.2015].  176. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Alipogentiparvovec: Bewertung gemäß § 35a Abs. 1 Satz 10 SGB V; Dossierbewertung; Auftrag G14-12. IQWiG-Berichte 2015. 273:[Available from: <https://www.iqwig.de/download/G14-12_Alipogentiparvovec_Bewertung-35a-Abs1-Satz10-SGB-V.pdf>. [Accessed 10.02.2015].  177. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Ataluren: Bewertung gemäß § 35a Abs. 1 Satz 10 SGB V; Dossierbewertung; Auftrag G14-13. IQWiG-Berichte 2015. 280:[Available from: <https://www.iqwig.de/download/G14-13_Ataluren_Bewertung-35a-Abs1-Satz10-SGB-V.pdf>. [Accessed 12.03.2015].  178. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Pasireotid (neues Anwendungsgebiet): Bewertung gemäß § 35a Abs. 1 Satz 10 SGB V; Dossierbewertung; Auftrag G14-14. IQWiG-Berichte 2015. 286:[Available from: <https://www.iqwig.de/download/G14-14_Pasireotid_Bewertung-35a-Abs1-Satz10-SGB-V.pdf>. [Accessed 02.05.2015].  179. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Nintedanib: Bewertung gemäß § 35a Abs. 1 Satz 10 SGB V; Dossierbewertung; Auftrag G15-03. IQWiG-Berichte 2015. 304:[Available from: <https://www.iqwig.de/download/G15-03_Nintedanib_Bewertung-35a-Abs1-Satz10-SGB-V.pdf>. [Accessed 06.07.2015].  180. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Eliglustat: Bewertung gemäß § 35a Abs. 1 Satz 10 SGB V; Dossierbewertung; Auftrag G15-04. IQWiG-Berichte 2015. 310:[Available from: <https://www.iqwig.de/download/G15-04_Eliglustat_Bewertung-35a-Abs1-Satz10-SGB-V.pdf>. [Accessed 06.07.2015].  181. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Ramucirumab: Bewertung gemäß § 35a Abs. 1 Satz 10 SGB V; Dossierbewertung; Auftrag G15-02. IQWiG-Berichte 2015. 295:[Available from: <https://www.iqwig.de/download/G15-02_Ramucirumab_Bewertung-35a-Abs1-Satz10-SGB-V.pdf>. [Accessed 21.07.2015].  182. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Olaparib: Bewertung gemäß § 35a Abs. 1 Satz 10 SGB V; Dossierbewertung; Auftrag G15-05. IQWiG-Berichte 2015. 320:[Available from: <https://www.iqwig.de/download/G15-05_Olaparib_Bewertung-35a-Abs1-Satz10-SGB-V.pdf>. [Accessed 03.09.2015].  183. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Lenvatinib: Bewertung gemäß § 35a Abs. 1 Satz 10 SGB V; Dossierbewertung; Auftrag G15-06. IQWiG-Berichte 2015. 321:[Available from: <https://www.iqwig.de/download/G15-06_Lenvatinib_Bewertung-35a-Abs1-Satz10-SGB-V.pdf>. [Accessed 08.10.2015].  184. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Regorafenib: Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A15-43. IQWiG-Berichte 2016. 352:[Available from: <https://www.iqwig.de/download/A15-43_Regorafenib_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 18.01.2016].  185. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Pomalidomid: Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A15-42. IQWiG-Berichte 2016. 351:[Available from: <https://www.iqwig.de/download/A15-42_Pomalidomid_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 18.01.2016].  186. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Trametinib: Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A15-40. IQWiG-Berichte 2016. 354:[Available from: <https://www.iqwig.de/download/A15-40_Trametinib_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 18.01.2016].  187. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Dabrafenib (neues Anwendungsgebiet): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A15-39. IQWiG-Berichte 2016. 353:[Available from: <https://www.iqwig.de/download/A15-39_Dabrafenib_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 18.01.2016].  188. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Alirocumab: Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A15-47. IQWiG-Berichte 2016. 362:[Available from: <https://www.iqwig.de/download/A15-47_Alirocumab_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 26.02.2016].  189. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Aclidiniumbromid: Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A15-45. IQWiG-Berichte 2016. 355:[Available from: <https://www.iqwig.de/download/A15-45_Aclidiniumbromid_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 26.02.2016].  190. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Aflibercept (neues Anwendungsgebiet): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A15-49. IQWiG-Berichte 2016. 369:[Available from: <https://www.iqwig.de/download/A15-49_Aflibercept-neues-Anwendungsgebiet_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 03.03.2016].  191. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Fingolimod (neues Anwendungsgebiet): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A15-48. IQWiG-Berichte 2016. 368:[Available from: <https://www.iqwig.de/download/A15-48_Fingolimod-neues-Anwendungsgebiet_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 03.03.2016].  192. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Ivacaftor (neues Anwendungsgebiet): Bewertung gemäß § 35a Abs. 1 Satz 10 SGB V; Dossierbewertung; Auftrag G15-13. IQWiG-Berichte 2016. 371:[Available from: <https://www.iqwig.de/download/G15-13_Ivacaftor-neues-Anwendungsgebiet_Bewertung-35a-Abs1-Satz10-SGB-V.pdf>. [Accessed 18.03.2016].  193. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Carfilzomib: Bewertung gemäß § 35a Abs. 1 Satz 10 SGB V; Dossierbewertung; Auftrag G15-16. IQWiG-Berichte 2016. 367:[Available from: <https://www.iqwig.de/download/G15-16_Carfilzomib_Bewertung-35a-Abs1-Satz10-SGB-V.pdf>. [Accessed 25.02.2016].  194. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Secukinumab (neues Anwendungsgebiet): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A15-53. IQWiG-Berichte 2016. 374:[Available from: <https://www.iqwig.de/download/A15-53_Secukinumab-neues-Anwendungsgebiet_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 08.04.2016].  195. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Cobimetinib: Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A15-52. IQWiG-Berichte 2016. 375:[Available from: <https://www.iqwig.de/download/A15-52_Cobimetinib_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 08.04.2016].  196. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Efmoroctocog alfa: Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A15-54. IQWiG-Berichte 2016. 376:[Available from: <https://www.iqwig.de/download/A15-54_Efmoroctocog%20alfa_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 08.04.2016].  197. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Elvitegravir/Cobicistat/ Emtricitabin/ Tenofoviralafenamid: Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A15-61. IQWiG-Berichte 2016. 380:[Available from: <https://www.iqwig.de/download/A15-61_Elvitegravir-CobicistatEmtricitabin-Tenofoviralafenamid_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 08.04.2016].  198. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Sacubitril/Valsartan: Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A15-60. IQWiG-Berichte 2016. 379:[Available from: <https://www.iqwig.de/download/A15-60_Sacubitril-Valsartan_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 08.04.2016].  199. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Crizotinib (neues Anwendungsgebiet): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A15-59. IQWiG-Berichte 2016. 378:[Available from: <https://www.iqwig.de/download/A15-59_Crizotinib-neues-Anwendungsgebiet_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 08.04.2016].  200. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Rilpivirin (neues Anwendungsgebiet): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A15-55. IQWiG-Berichte 2016. 377:[Available from: <https://www.iqwig.de/download/A15-55_Rilpivirin-neues-Anwendungsgebiet_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 08.04.2016].  201. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Ibrutinib: Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A16-04. IQWiG-Berichte 2016. 386:[Available from: <https://www.iqwig.de/download/A16-04_Ibrutinib_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 25.05.2016].  202. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Mepolizumab: Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A16-03. IQWiG-Berichte 2016. 385:[Available from: <https://www.iqwig.de/download/A16-03_Mepolizumab_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 25.05.2016].  203. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Vismodegib: Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A16-09. IQWiG-Berichte 2016. 392:[Available from: <https://www.iqwig.de/download/A16-09_Vismodegib_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 25.05.2016].  204. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Brivaracetam: Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A16-08. IQWiG-Berichte 2016. 391:[Available from: <https://www.iqwig.de/download/A16-08_Brivaracetam_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 25.05.2016].  205. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Ramucirumab (Lungenkarzinom): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A16-11. IQWiG-Berichte 2016. 398:[Available from: <https://www.iqwig.de/download/A16-11_Ramucirumab_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 06.07.2016].  206. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Ramucirumab (Kolorektalkarzinom): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A16-10. IQWiG-Berichte 2016. 401:[Available from: <https://www.iqwig.de/download/A16-10_Ramucirumab_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 06.07.2016].  207. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Empagliflozin: Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A16-12. IQWiG-Berichte 2016. 399:[Available from: <https://www.iqwig.de/download/A16-12_Empagliflozin_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 06.07.2016].  208. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Empagliflozin/Metformin: Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A16-13. IQWiG-Berichte 2016. 400:[Available from: <https://www.iqwig.de/download/A16-13_Empagliflozin-Metformin_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 06.07.2016].  209. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Ticagrelor (Prävention atherothrombotischer Ereignisse nach Myokardinfarkt): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A16-15. IQWiG-Berichte 2016. 405:[Available from: <https://www.iqwig.de/download/A16-15_Ticagrelor_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 06.07.2016].  210. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Necitumumab (Lungenkarzinom): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A16-17. IQWiG-Berichte 2016. 404:[Available from: <https://www.iqwig.de/download/A16-17_Necitumumab_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 06.07.2016].  211. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Idelalisib (chronische lymphatische Leukämie): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A16-18. IQWiG-Berichte 2016. 406:[Available from: <https://www.iqwig.de/download/A16-18_Idelalisib_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 06.07.2016].  212. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Osimertinib (Lungenkarzinom): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A16-14. IQWiG-Berichte 2016. 402:[Available from: <https://www.iqwig.de/download/A16-14_Osimertinib_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 06.07.2016].  213. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Nivolumab (Nierenzellkarzinom): Nutzenbewertung gemäß § 35a SGB V; Auftrag A16-24. IQWiG-Berichte 2016. 415:[Available from: <https://www.iqwig.de/download/A16-24_Nivolumab_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 05.08.2016].  214. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Ospemifen (vulvovaginale Atrophie): Nutzenbewertung gemäß § 35a SGB V; Auftrag A16-21. IQWiG-Berichte 2016. 414:[Available from: <https://www.iqwig.de/download/A16-21_Ospemifen_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 05.08.2016].  215. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Nivolumab (nicht plattenepitheliales NSCLC): Nutzenbewertung gemäß § 35a SGB V; Auftrag A16-25. IQWiG-Berichte 2016. 416:[Available from: <https://www.iqwig.de/download/A16-25_Nivolumab_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 05.08.2016].  216. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Ramucirumab (Magenkarzinom): Nutzenbewertung gemäß § 35a SGB V; Auftrag A16-23. IQWiG-Berichte 2016. 413:[Available from: <https://www.iqwig.de/download/A16-23_Ramucirumab_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 05.08.2016].  217. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Afatinib (NSCLC mit Plattenepithelhistologie): Nutzenbewertung gemäß § 35a SGB V; Auftrag A16-22. IQWiG-Berichte 2016. 411:[Available from: <https://www.iqwig.de/download/A16-22_Afatinib_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 05.08.2016].  218. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Emtricitabin/Tenofoviralafenamid (HIV-Infektion): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A16-30. IQWiG-Berichte 2016. 420:[Available from: <https://www.iqwig.de/download/A16-30_Emtricitabin-Tenofoviralafenamid_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 23.09.2016].  219. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Necitumumab (Lungenkarzinom): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A16-17; Version 1.1. IQWiG-Berichte 2016. 404:[Available from: <https://www.iqwig.de/download/A16-17_Necitumumab_Nutzenbewertung-35a-SGB-V_V1.1.pdf>. [Accessed 23.09.2016].  220. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Migalastat: Bewertung gemäß § 35a Abs. 1 Satz 10 SGB V; Dossierbewertung; Auftrag G16-04. IQWiG-Berichte 2016. 429:[Available from: <https://www.iqwig.de/download/G16-04_Migalastat_Bewertung-35a-Abs1-Satz10-SGB-V.pdf>. [Accessed 23.09.2016].  221. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Elotuzumab (multiples Myelom): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A16-32. IQWiG-Berichte 2016. 426:[Available from: <https://www.iqwig.de/download/A16-32_Elotuzumab_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 23.09.2016].  222. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Eribulin (Liposarkom): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A16-31. IQWiG-Berichte 2016. 427:[Available from: <https://www.iqwig.de/download/A16-31_Eribulin_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 23.09.2016].  223. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Talimogen laherparepvec (Melanom): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A16-37. IQWiG-Berichte 2016. 431:[Available from: <https://www.iqwig.de/download/A16-37_Talimogen-laherparepvec_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 23.09.2016].  224. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Nivolumab (Melanom): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A16-35. IQWiG-Berichte 2016. 432:[Available from: <https://www.iqwig.de/download/A16-35_Nivolumab_Nutzenbewertung-35a-SGB-V.pdf>. [Accessed 23.09.2016].  225. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Asfotase alfa: Bewertung gemäß § 35a Abs. 1 Satz 10 SGB V; Dossierbewertung; Auftrag G15-09. IQWiG-Berichte 2016. 348:[Available from: <https://www.iqwig.de/download/G15-09_Asfotase-alfa_Bewertung-35a-Absatz-1-Satz-10-SGB-V.pdf>. [Accessed 15.01.2016].  226. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Panobinostat: Bewertung gemäß § 35a Abs. 1 Satz 10 SGB V; Dossierbewertung; Auftrag G15-10. IQWiG-Berichte 2016. 349:[Available from: <https://www.iqwig.de/download/G15-10_Panobinostat_Dossierbewertung_35a-Absatz-1-Satz-10-SGB-V.pdf>. [Accessed 15.01.2016].  227. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Idebenon: Bewertung gemäß § 35a Abs. 1 Satz 10 SGB V; Dossierbewertung; Auftrag G15-11. IQWiG-Berichte 2016. 350:[Available from: <https://www.iqwig.de/download/G15-11_Idebenon_Dossierbewertung_35a-Absatz-1-Satz-10-SGB-V.pdf>. [Accessed 15.01.2016].  228. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Sebelipase alfa: Bewertung gemäß § 35a Abs. 1 Satz 10 SGB V; Dossierbewertung; Auftrag G15-08. IQWiG-Berichte 2016. 347:[Available from: <https://www.iqwig.de/download/G15-08_Sebelipase-alfa_Bewertung-35a-Absatz-1-Satz-10-SGB-V.pdf>. [Accessed 18.01.2016].  229. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Isavuconazol: Bewertung gemäß § 35a Abs. 1 Satz 10 SGB V; Dossierbewertung; Auftrag G15-12. IQWiG-Berichte 2016. 360:[Available from: <https://www.iqwig.de/download/G15-12_Isavuconazol_Bewertung-35a-Absatz-1-Satz-10-SGB-V.pdf>. [Accessed 26.02.2016].  230. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Lumacaftor / Ivacaftor: Bewertung gemäß § 35a Abs. 1 Satz 10 SGB V; Dossierbewertung; Auftrag G15-14. IQWiG-Berichte 2016. 372:[Available from: <https://www.iqwig.de/download/G15-14_Lumacaftor-Ivacaftor_Bewertung-35a-Abs1-Satz10-SGB-V.pdf>. [Accessed 18.03.2016].  231. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Blinatumomab: Bewertung gemäß § 35a Abs. 1 Satz 10 SGB V; Dossierbewertung; Auftrag G15-15. IQWiG-Berichte 2016. 366:[Available from: <https://www.iqwig.de/download/G15-15_Blinatumomab_Bewertung-35a-Abs1-Satz10-SGB-V.pdf>. [Accessed 18.03.2016].  232. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Afamelanotid: Bewertung gemäß § 35a Abs. 1 Satz 10 SGB V; Dossierbewertung; Auftrag G16-01. IQWiG-Berichte 2016. 390:[Available from: <https://www.iqwig.de/download/G16-01_Afamelanotid_Bewertung-35a-Abs1-Satz10-SGB-V.pdf>. [Accessed 18.08.2016].  233. Institut national d’excellence en santé et en services sociaux (INESSS). La chirurgie mammaire conservatrice guidée par échographie peropératoire. 2015. Available from: <http://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/Oncologie/INESSS_Chirurgie_mammaire_par_echographie.pdf>. [Accessed 06.08.2016].  234. Institut national d’excellence en santé et en services sociaux (INESSS). Avis sur les mesures relatives au remboursement des bandelettes. 2016. Available from: <http://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/MaladiesChroniques/INESSS_Avis_remb_bandelettes_290716.pdf>. [Accessed 06.08.2016].  235. Institut national d’excellence en santé et en services sociaux (INESSS). Usage optimal à long terme des inhibiteurs de la pompe à protons. 2016. Available from: <http://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/Medicaments/INESSS_Avis_IPP_2016.pdf>. [Accessed 06.08.2016].  236. Institute for Clinical and Economic Review. PCSK9 Inhibitors for Treatment of High Cholesterol: Effectiveness, Value, and ValueBasedPrice Benchmarks. 2015. Available from: <https://icer-review.org/wp-content/uploads/2016/01/Final-Report-for-Posting-11-24-15-1.pdf>. [Accessed 06.08.2016].  237. Institute for Clinical and Economic Review. Obeticholic Acid for the Treatment of Nonalcoholic Steatohepatitis: Comparative Clinical Effectiveness and Value. 2016. Available from: <https://icer-review.org/wp-content/uploads/2016/07/NECEPAC_OCA_NASH_Evidence_Report_FINAL.pdf>. [Accessed 06.08.2016].  238. Institute for Clinical and Economic Review. Obeticholic Acid for the Treatment of Primary Biliary Cholangitis: Comparative Clinical Effectiveness, Value, and Value-Based Price Benchmarks. 2016. Available from: <https://icer-review.org/wp-content/uploads/2016/07/NECEPAC_OCA_PBC_Evidence_Report_FINAL.pdf>. [Accessed 06.08.2016].  239. Institute for Clinical and Economic Review. Treatment Options for Relapsed or Refractory Multiple Myeloma: Effectiveness, Value, and Value-Based Price Benchmarks. 2016. Available from: <https://icer-review.org/wp-content/uploads/2016/06/MWCEPAC_MM_Final_Evidence_Report_061016V3.pdf>. [Accessed 06.08.2016].  240. Institute for Clinical and Economic Review. Insulin Degludec (Tresiba®, Novo Nordisk A/S) for the Treatment of Diabetes: Effectiveness, Value, and Value-based Price Benchmarks. 2016. Available from: <https://icer-review.org/wp-content/uploads/2016/03/CTAF_Degludec_Final_Report_031416.pdf>. [Accessed 06.08.2016].  241. Institute of Health Economics. Newborn blood spot screening for galactosemia, tyrosinemia type I, homocystinuria, sickle cell anemia, sickle cell/beta-thalassemia, sickle cell/hemoglobin C disease, and severe combined immunodeficiency. 2016. Available from: <http://www.ihe.ca/advanced-search/newborn-blood-spot-screening-for-galactosemia-tyrosiemia-type-i-homocystinuria-sickle-cell-anemia-sickle-cell-beta-thalassemia-sickle-cell-hemoglobin-c-disease-and-severe-combined-immunodeficiency>. [Accessed 06.08.2016].  242. Instituto de Evaluación Tecnológica en Salud. Informe rápido regional de evaluación de tecnología sobre la efectividad y seguridad del uso de adalimumab para el tratamiento de pacientes con psoriasis en placa (vulgar) moderada a severa. 2015. Available from: <http://www.omaif.org/images/obsbid/documentos/etregionales/Informe_rapido_regional_del_uso_de_Adalimumab_en_Psoriasis.pdf>. [Accessed 06.08.2016].  243. Instituto de Evaluación Tecnológica en Salud. Informe del análisis económico de costo-efectividad del uso de efavirenz en combinación con tenofovir y emtricitabina para el tratamiento de pacientes mayores de 13 años de edad con infección por VIH, que no han recibido terapia antirretroviral. 2015. Available from: <http://www.omaif.org/images/obsbid/documentos/etregionales/Informe-final-EE-EFVTDFFTC-VIH-20151201-v10-270716.pdf>. [Accessed 06.08.2016].  244. Instituto de Evaluación Tecnológica en Salud. Informe rápido regional de evaluación de tecnología sobre la efectividad y seguridad del uso de sorafenib en el tratamiento de pacientes con carcinoma renal avanzado. 2015. Available from: <http://www.omaif.org/images/obsbid/documentos/etregionales/Informe_rapido_regional_del_uso_Sorafenib_CaRenal.pdf>. [Accessed 06.08.2016].  245. Instituto de Salud Carlos III. Evaluación económica de diferentes estrategias para el cribado de la enfermedad de Chagas en España. 2015. Available from: <http://gesdoc.isciii.es/gesdoccontroller?action=download&id=12/06/2015-6b8c0168be>. [Accessed 08.08.2016].  246. Instituto de Salud Carlos III. Estudios de coste de la diabetes tipo2: Una revisión de la literatura. 2016. Available from: <http://gesdoc.isciii.es/gesdoccontroller?action=download&id=26/05/2015-28ff538b32>. [Accessed 08.08.2016].  247. James N, Pirrie S, Pope A, et al. TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer. Health Technol Assess. 2016 2016/07/18; 20(53).  248. Janet P-R, Leonor V-L, Gerardo Atienza M. Efectividad y seguridad del dispositivo de asistencia ventricular mecánica HeartWare® en el tratamiento de la insuficiencia cardíaca avanzada 2015. Available from: <http://avalia-t.sergas.es/DXerais/551/avalia-t201501HeartwareAsistVentricular_DEF.pdf>. [Accessed 02.07.2016].  249. Janet Puñal R, María del Carmen SG, Gerardo Atienza M. Seguridad y eficacia de la angioplastia con balón liberador de fármaco en la estenosis coronaria: reestenosis intraestent y lesiones de novo. 2015. Available from: <http://avalia-t.sergas.es/DXerais/72/avalia-t201406_ACP_Balon.pdf>. [Accessed 02.07.2016].  250. Kiru G, Bicknell C, Falaschetti E, et al. An evaluation of the effect of an angiotensin-converting enzyme inhibitor on the growth rate of small abdominal aortic aneurysms: a randomised placebo-controlled trial (AARDVARK). Health Technol Assess. 2016 2016/08/03; 20(59).  251. Kunnskapssenteret. A health technology assessment of the new drugs for inoperable or metastatic malignant melanoma patients. 2015. Available from: <http://www.kunnskapssenteret.no/en/publications/A+health+technology+assessment+of+the+new+drugs+for+inoperable+or+metastatic+malignant+melanoma+patients>. [Accessed 12.08.2016].  252. Kunnskapssenteret. Effect of HPV-vaccination of boys. 2015. Available from: <http://www.kunnskapssenteret.no/en/publications/Effect+of+HPV-vaccination+of+boys>. [Accessed 12.08.2016].  253. Kunnskapssenteret. Cost-effectiveness of HPV-vaccination of boys aged 12 in a Norwegian setting. 2015. Available from: <http://www.kunnskapssenteret.no/en/publications/Cost-effectiveness+of+HPV-vaccination+of+boys+aged+12+in+a+Norwegian+setting>. [Accessed 12.08.2016].  254. Kuyken W, Hayes R, Barrett B, et al. The effectiveness and cost-effectiveness of mindfulness-based cognitive therapy compared with maintenance antidepressant treatment in the prevention of depressive relapse/recurrence: results of a randomised controlled trial (the PREVENT study). Health Technol Assess. 2015 2015/09/17; 19(73).  255. Lall R, Hamilton P, Young D, et al. A randomised controlled trial and cost-effectiveness analysis of high-frequency oscillatory ventilation against conventional artificial ventilation for adults with acute respiratory distress syndrome. The OSCAR (OSCillation in ARDS) study. Health Technol Assess. 2015 2015/03/24; 19(23).  256. Lecky F, Russell W, Fuller G, et al. The Head Injury Transportation Straight to Neurosurgery (HITS-NS) randomised trial: a feasibility study. Health Technol Assess. 2016 2016/01/12; 20(1).  257. Leroy R, Benahmed N, Hulstaert F, et al. Hadron therapy in children – an update of the scientific evidence for 15 paediatric cancers: KCE Reports 235. 2015. Available from: <https://kce.fgov.be/sites/default/files/page_documents/KCE_235_Hadron%20Therapy_Report.pdf>. [Accessed 08.07.2016].  258. Lucinda-Paz V, María del Carmen M-R, Leonor V-L. Tratamiento no invasivo del Pectus carinatum mediante ortesis de compresión. 2015. Available from: <http://avalia-t.sergas.es/DXerais/412/avalia-t201503PectusCarinatum_DEF.pdf>. [Accessed 02.07.2016].  259. Ludwig Boltzmann Institut. Ballondilatation der Eustachischen Röhre zur Behandlung der Tubendysfunktion. Deutsche Kurzfassung und Update zum gleichnamigen EUnetHTA Bericht. 2015. Available from: <http://eprints.hta.lbg.ac.at/1073/1/DSD_91.pdf>. [Accessed 10.08.2016].  260. Ludwig Boltzmann Institut. Bevacizumab (Avastin®) in combination with chemotherapy as second-line therapy for HER2-negative, locally recurrent or metastatic breast cancer that has progressed after first-line treatment with Bevacizumab plus chemotherapy. Horizon Scanning in Oncology 2015. Available from: <http://eprints.hta.lbg.ac.at/1066/1/DSD_HSO_Nr.51.pdf>. [Accessed 10.08.2016].  261. Ludwig Boltzmann Institut. Carfilzomib (Kyprolis®) for patients with relapsed multiple myeloma who have received one to three prior lines of therapy. Horizon Scanning in Oncology. 2015. Available from: <http://eprints.hta.lbg.ac.at/1070/1/DSD_HSO_Nr.52.pdf>. [Accessed 10.08.2016].  262. Ludwig Boltzmann Institut. Defibrotide for the treatment and prophylaxis of hepatic veno-occlusive disease. Systematic Review. 2015. Available from: <http://eprints.hta.lbg.ac.at/1061/1/DSD_84.pdf>. [Accessed 10.08.2016].  263. Ludwig Boltzmann Institut. Fully bioresorbable scaffolds for coronary artery disease. Systematic Review. 2015. Available from: <http://eprints.hta.lbg.ac.at/1060/1/DSD_81.pdf>. [Accessed 10.08.2016].  264. Ludwig Boltzmann Institut. Lokale Injektionstherapie mit Bulking Agents bei fäkaler Inkontinenz. Systematischer Review. 2015. Available from: <http://eprints.hta.lbg.ac.at/1059/1/DSD_87.pdf>. [Accessed 10.08.2016].  265. Ludwig Boltzmann Institut. Nivolumab (Nivolumab BMS®) for the second-line therapy of metastatic squamous non-small cell lung cancer. Horizon Scanning in Oncology. 2015. Available from: <http://eprints.hta.lbg.ac.at/1068/1/DSD_HSO_Nr.53.pdf>. [Accessed 10.08.2016].  266. Ludwig Boltzmann Institut. Nivolumab (Opdivo®) as single-agent first-line therapy for unresectable or metastatic melanoma. Horizon Scanning in Oncology. 2015. Available from: <http://eprints.hta.lbg.ac.at/1051/1/DSD_HSO_Nr.50.pdf>. [Accessed 10.08.2016].  267. Ludwig Boltzmann Institut. Pembrolizumab (Keytruda®) for the treatment of advanced melanoma. Horizon Scanning in Oncology. 2015. Available from: <http://eprints.hta.lbg.ac.at/1076/1/DSD_HSO_Nr.55.pdf>. [Accessed 10.08.2016].  268. Ludwig Boltzmann Institut. Perkutane Mitralklappenreparatur bei chronischer Mitralklappeninsuffizienz (Mitraclip®, Carillon®, NeoChord DS1000). Deutsche Kurzfassung zum gleichnamigen EUnetHTA Bericht. 2015. Available from: <http://eprints.hta.lbg.ac.at/1075/1/DSD_93.pdf>. [Accessed 10.08.2016].  269. Ludwig Boltzmann Institut. Ramucirumab in combination with paclitaxel as second-line treatment for adult patients with advanced gastric or gastro-oesophageal junction carcinoma. Horizon Scanning in Oncology. 2015. Available from: <http://eprints.hta.lbg.ac.at/1069/1/DSD_HSO_Nr.54.pdf>. [Accessed 10.08.2016].  270. Ludwig Boltzmann Institut. Resorbierbare Stents zur Behandlung gutartiger refraktärer oder rezidivierender Ösophagus-Stenosen. Deutsche Kurzfassung zum gleichnamigen EUnetHTA Bericht. 2015. Available from: <http://eprints.hta.lbg.ac.at/1067/1/DSD_89.pdf>. [Accessed 10.08.2016].  271. Ludwig Boltzmann Institut. Roboterassistierte Chirurgie. Eine systematische Übersichtsarbeit zu Wirksamkeit und Sicherheit bei ausgewählten Indikationen und anfallenden Kosten. 2015. Available from: <http://eprints.hta.lbg.ac.at/1077/1/HTA-Projektbericht_Nr.84.pdf>. [Accessed 10.08.2016].  272. Ludwig Boltzmann Institut. Stimulation des Ganglion Sphenopalatinum (SPG) bei therapierefraktärem Clusterkopfschmerz. Systematischer Review. 2015. Available from: <http://eprints.hta.lbg.ac.at/1062/1/DSD_86.pdf>. [Accessed 10.08.2016].  273. Ludwig Boltzmann Institut. Transapikale Mitralklappenimplantation (Valve-in-Valve). Systematischer Review. 2015. Available from: <http://eprints.hta.lbg.ac.at/1058/1/DSD_82.pdf>. [Accessed 10.08.2016].  274. Ludwig Boltzmann Institut. Bevacizumab (Avastin®) in addition to standard chemotherapy for the first-line treatment of ovarian cancer. Horizon Scanning in Oncology. 2016. Available from: <http://eprints.hta.lbg.ac.at/1082/1/DSD_HSO_Nr.56.pdf>. [Accessed 10.08.2016].  275. Ludwig Boltzmann Institut. Magnetic sphincter augmentation device (MSAD) in patients with gastroesophageal reflux disease (GERD). Systematic Review. 2016. Available from: <http://eprints.hta.lbg.ac.at/1098/1/DSD_101.pdf>. [Accessed 10.08.2016].  276. Ludwig Boltzmann Institut. Mechanische Thrombektomie bei akutem ischämischem Schlaganfall. Deutsche Kurzfassung zum gleichnamigen EUnetHTA Bericht. 2016. Available from: <http://eprints.hta.lbg.ac.at/1081/1/DSD_94.pdf>. [Accessed 10.08.2016].  277. Ludwig Boltzmann Institut. Ofatumumab (Arzerra®) as maintenance therapy in patients with relapsed chronic lymphocytic leukaemia (CLL). Horizon Scanning in Oncology. 2016. Available from: <http://eprints.hta.lbg.ac.at/1085/1/DSD_HSO_Nr.57.pdf>. [Accessed 10.08.2016].  278. Ludwig Boltzmann Institut. Pembrolizumab (Keytruda®) in previously treated advanced non-small cell lung cancer (NSCLC). Horizon Scanning in Oncology. 2016. Available from: <http://eprints.hta.lbg.ac.at/1086/1/DSD_HSO_Nr.58.pdf>. [Accessed 10.08.2016].  279. Ludwig Boltzmann Institut. Radiofrequency denervation for sacroiliac and facet joint pain. Systematic Review. 2016. Available from: <http://eprints.hta.lbg.ac.at/1096/1/DSD_99.pdf>. [Accessed 10.08.2016].  280. Ludwig Boltzmann Institut. Upper Airway Stimulation for Moderate-to-Severe Sleep Apnea. Systematic Review. 2016. Available from: <http://eprints.hta.lbg.ac.at/1097/1/DSD_100.pdf>. [Accessed 10.08.2016].  281. Ludwig Boltzmann Institut. Single-step scaffold-based cartilage repair in the knee. Systematic Review. 2016. Available from: <http://eprints.hta.lbg.ac.at/1095/1/DSD_98.pdf>. [Accessed 10.08.2016].  282. Ludwig Bolzmann Institut. Afatinib (Giotrif®) in combination therapy for patients with non-small cell lung cancer (NSCLC) who are refractory/resistant to erlotinib/gefitinib and afatinib monotherapy. Horizon Scanning in Oncology. 2016 15.06.2016.  283. Maltoni S, Negro A, Trimaglio F, et al. Implantable device for the treatment of drug-resistant hypertension -Short report n. 8. 2015. Available from: <http://assr.regione.emilia-romagna.it/it/servizi/pubblicazioni/short-report/SR8_ipertensione_en>. [Accessed 02.07.2016].  284. María del Carmen SG, Lisset FdA, Gerardo Atienza M. Ablación por radiofrecuencia en el tratamiento del esófago de Barrett con displasia de alto grado/ carcinoma intramucoso: Revisión sistemática. 2015. Available from: <http://avalia-t.sergas.es/DXerais/305/avalia-t201502_RadiofrecuenciaBarret_DEF.pdf>. [Accessed 02.07.2016].  285. María del Carmen SG, Paula Cantero M, Gerardo Atienza M. Cribado de cáncer de pulmón con tomografía computarizada de baja dosis. 2015. Available from: <http://avalia-t.sergas.es/DXerais/647/avalia-t201505_Cribado%20de%20ca%CC%81ncer%20de%20pulmo%CC%81n.pdf>. [Accessed 02.07.2016].  286. McConachie H, Parr JR, Glod M, et al. Systematic review of tools to measure outcomes for young children with autism spectrum disorder. Health Technol Assess. 2015 2015/06/11; 19(41).  287. McDermott CJ, Bradburn MJ, Maguire C, et al. DiPALS: Diaphragm Pacing in patients with Amyotrophic Lateral Sclerosis - a randomised controlled trial. Health Technol Assess. 2016 2016/06/28; 20(45).  288. McMurran M, Crawford MJ, Reilly J, et al. Psychoeducation with problem-solving (PEPS) therapy for adults with personality disorder: a pragmatic randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of a manualised intervention to improve social functioning. Health Technol Assess. 2016 2016/07/18; 20(52).  289. Metcalfe C, Avery K, Berrisford R, et al. Comparing open and minimally invasive surgical procedures for esophagectomy in the treatment of cancer: the ROMIO (Randomised Oesophagectomy: Minimally Invasive or Open) feasibility study and pilot trial. Health Technol Assess. 2016 2016/06/30; 20(48).  290. Mezey G, Meyer D, Robinson F, et al. Developing and piloting a peer mentoring intervention to reduce teenage pregnancy in looked-after children and care leavers: an exploratory randomised controlled trial. Health Technol Assess. 2015 2015/10/26; 19(85).  291. Michie S, Wood CE, Johnston M, et al. Behaviour change techniques: the development and evaluation of a taxonomic method for reporting and describing behaviour change interventions (a suite of five studies involving consensus methods, randomised controlled trials and analysis of qualitative data). Health Technol Assess. 2015 2015/11/30; 19(99).  292. Ministerio de Sanidad SSeI. Artroscopia con lavado articular en el tratamiento de la artrosis de rodilla. 2015. Available from: <http://www.ogasun.ejgv.euskadi.eus/r51-catpub/es/k75aWebPublicacionesWar/k75aObtenerPublicacionDigitalServlet?R01HNoPortal=true&N_LIBR=051729&N_EDIC=0001&C_IDIOM=es&FORMATO=.pdf>. [Accessed 12.08.2016].  293. Ministerio de Sanidad SSeI. Consejo integral en estilo de vida en Atención Primaria, vinculado con recursos comunitarios en población adulta. 2015. Available from: <http://www.msssi.gob.es/profesionales/saludPublica/prevPromocion/Estrategia/docs/Consejo_Integral_EstiloVida_en_AtencionPrimaria.pdf>. [Accessed 12.08.2016].  294. Ministerio de Sanidad; Servicios Sociales e Igualdad, Servicio de Evaluación de Tecnologías Sanitarias del País Vasco. Análisis coste efectividad de la terapia tópica de presión negativa para el tratamiento de las úlceras venosas de pierna. 2015. Available from: <http://www.ogasun.ejgv.euskadi.eus/r51-catpub/es/k75aWebPublicacionesWar/k75aObtenerPublicacionDigitalServlet?R01HNoPortal=true&N_LIBR=051722&N_EDIC=0001&C_IDIOM=es&FORMATO=.pdf>. [Accessed 12.08.2016].  295. Ministerio de Sanidad; Servicios Sociales e Igualdad, Servicio de Evaluación de Tecnologías Sanitarias del País Vasco. Impacto de la implantación de un programa de cribado poblacional de cáncer de cérvix, siguiendo las recomendaciones europeas (prueba/intervalo) en relación a la situación actual. 2016. Available from: <http://www.ogasun.ejgv.euskadi.eus/r51-catpub/es/k75aWebPublicacionesWar/k75aObtenerPublicacionDigitalServlet?R01HNoPortal=true&N_LIBR=051788&N_EDIC=0001&C_IDIOM=es&FORMATO=.pdf>. [Accessed 12.08.2016].  296. Ministerio de Sanidad; Servicios Sociales e Igualdad, Servicio de Evaluación del Servicio Canario de la Salud. Efectividad y seguridad del acido hialurónico en el tratamiento de la artrosis de rodilla, cadera y otras localizaciones articulares. 2015. Available from: <http://www3.gobiernodecanarias.org/sanidad/scs/content/a4ce884d-cb57-11e5-a9c5-a398589805dc/SESCS%202015_Ac_hialuronico.pdf>. [Accessed 12.08.2016].  297. Ministerio de Sanidad; Servicios Sociales e Igualdad, Servicio de Evaluación del Servicio Canario de la Salud. Red Española de Agencias de Evaluación de Tecnologías y Prestaciones del SNS,  Agencia de Evaluación de Tecnologías Sanitarias de Galicia,. 2015. Available from: <https://libraria.xunta.gal/sites/default/files/downloads/publicacion/avalia-t201406_acp_balon-definitivo.pdf>. [Accessed 12.08.2016].  298. Ministerio de Sanidad; Servicios Sociales e Igualdad, Servicio de Evaluación del Servicio Canario de la Salud. Coste-efectividad del cribado neonatal de la Aciduria 3-hidroxi-3-metilglutárica (HMG). 2015. Available from: <http://www3.gobiernodecanarias.org/sanidad/scs/content/eb78dd95-d62c-11e5-a9c5-a398589805dc/SESCS%202015_CN_HMG_NIPO.pdf>. [Accessed 12.08.2016].  299. Ministry of Health – Manatū Hauora. Review of Mobile Surgical Services and related services 2015. Available from: <http://www.health.govt.nz/system/files/documents/publications/mss-review-report.pdf>. [Accessed 12.08.2016].  300. Ministry of Health – Manatū Hauora. Review of the benefits and costs of water fluoridation in New Zealand 2016. Available from: <http://www.health.govt.nz/system/files/documents/publications/review-benefits-costs-water-fluoridation-new-zealand-apr16.pdf>. [Accessed 12.08.2016].  301. Mouncey PR, Osborn TM, Power GS, et al. Protocolised Management In Sepsis (ProMISe): a multicentre randomised controlled trial of the clinical effectiveness and cost-effectiveness of early, goal-directed, protocolised resuscitation for emerging septic shock. Health Technol Assess. 2015 2015/11/24; 19(97):156.  302. National Health and Medical Research Council. Evaluation of evidence related to exposure to lead. 2015. Available from: <https://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/nhmrc_evaluation_of_evidence_related_to_exposure_to_lead_May_2015_0.pdf>. [Accessed 11.08.2016].  303. National Institute for Health and Care Excellence. Diagnosing prostate cancer: PROGENSA PCA3 assay and Prostate Health Index. 2015. Available from: <https://www.nice.org.uk/guidance/dg17/resources/diagnosing-prostate-cancer-progensa-pca3-assay-and-prostate-health-index-1053634828741>. [Accessed 15.08.2016].  304. National Institute for Health and Care Excellence. Procalcitonin testing for diagnosing and monitoring sepsis (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay and VIDAS BRAHMS PCT assay). 2015. Available from: <https://www.nice.org.uk/guidance/dg18/resources/procalcitonin-testing-for-diagnosing-and-monitoring-sepsis-advia-centaur-brahms-pct-assay-brahms-pct-sensitive-kryptor-assay-elecsys-brahms-pct-assay-liaison-brahms-pct-assay-and-vidas-brahms-pct-ass-1053636508357>. [Accessed 15.08.2016].  305. National Institute for Health and Care Excellence. VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions. 2015. Available from: <https://www.nice.org.uk/guidance/dg19/resources/vivascope-1500-and-3000-imaging-systems-for-detecting-skin-cancer-lesions-1053638187973>. [Accessed 15.08.2016].  306. National Institute for Health and Care Excellence. The TURis system for transurethral resection of the prostate. 2015. Available from: <https://www.nice.org.uk/guidance/mtg23/resources/the-turis-system-for-transurethral-resection-of-the-prostate-64371933166021>. [Accessed 15.08.2016].  307. National Institute for Health and Care Excellence. VibraTip for testing vibration perception to detect diabetic peripheral neuropathy. 2015. Available from: <https://www.nice.org.uk/guidance/mtg22/resources/vibratip-for-testing-vibration-perception-to-detect-diabetic-peripheral-neuropathy-64371931486405>. [Accessed 15.08.2016].  308. National Institute for Health and Care Excellence. The Sherlock 3CG Tip Confirmation System for placement of peripherally inserted central catheters. 2015. Available from: <https://www.nice.org.uk/guidance/mtg24/resources/the-sherlock3cg-tip-confirmation-system-for-placement-of-peripherally-inserted-central-catheters-64371934845637>. [Accessed 15.08.2016].  309. National Institute for Health and Care Excellence. The 3M Tegaderm CHG IV securement dressing for central venous and arterial catheter insertion sites. 2015. Available from: <https://www.nice.org.uk/guidance/mtg25/resources/the-3m-tegaderm-chg-iv-securement-dressing-for-central-venous-and-arterial-catheter-insertion-sites-64371936525253>. [Accessed 15.08.2016].  310. National Institute for Health and Care Excellence. UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia. 2015. Available from: <https://www.nice.org.uk/guidance/mtg26/resources/urolift-for-treating-lower-urinary-tract-symptoms-of-benign-prostatic-hyperplasia-64371938204869>. [Accessed 15.08.2016].  311. National Institute for Health and Care Excellence. Virtual Touch Quantification to diagnose and monitor liver fibrosis in chronic hepatitis B and C. 2015. Available from: <https://www.nice.org.uk/guidance/mtg27/resources/virtual-touch-quantification-to-diagnose-and-monitor-liver-fibrosis-in-chronic-hepatitis-b-and-c-64371939884485>. [Accessed 15.08.2016].  312. National Institute for Health and Care Excellence. Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy. 2015. Available from: <https://www.nice.org.uk/guidance/ta374/resources/erlotinib-and-gefitinib-for-treating-nonsmallcell-lung-cancer-that-has-progressed-after-prior-chemotherapy-82602789240517>. [Accessed 16.08.2016].  313. National Institute for Health and Care Excellence. Elosulfase alfa for treating mucopolysaccharidosis type IVa. 2015. Available from: <https://www.nice.org.uk/guidance/hst2/resources/elosulfase-alfa-for-treating-mucopolysaccharidosis-type-iva-1394897528005>. [Accessed 15.08.2016].  314. National Institute for Health and Care Excellence. Eculizumab for treating atypical haemolytic uraemic syndrome. 2015. Available from: <https://www.nice.org.uk/guidance/hst1/resources/eculizumab-for-treating-atypical-haemolytic-uraemic-syndrome-1394895848389>. [Accessed 15.08.2016].  315. National Institute for Health and Care Excellence. Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears. 2015. Available from: <https://www.nice.org.uk/guidance/ta369>. [Accessed 15.08.2016].  316. National Institute for Health and Care Excellence. Bortezomib for previously untreated mantle cell lymphoma. 2015. Available from: <https://www.nice.org.uk/guidance/ta370>. [Accessed 15.08.2016].  317. National Institute for Health and Care Excellence. Trastuzumab emtansine for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane. 2015. Available from: <https://www.nice.org.uk/guidance/ta371>. [Accessed 15.08.2016].  318. National Institute for Health and Care Excellence. Apremilast for treating active psoriatic arthritis. 2015. Available from: <https://www.nice.org.uk/guidance/ta372>. [Accessed 15.08.2016].  319. National Institute for Health and Care Excellence. Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis 2015. Available from: <https://www.nice.org.uk/guidance/ta373>. [Accessed 15.08.2016].  320. National Institute for Health and Care Excellence. Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy. 2015. Available from: <https://www.nice.org.uk/guidance/ta374>. [Accessed 15.08.2016].  321. National Institute for Health and Care Excellence. Ledipasvir–sofosbuvir for treating chronic hepatitis C. 2015. Available from: <https://www.nice.org.uk/guidance/ta363>. [Accessed 15.08.2016].  322. National Institute for Health and Care Excellence. Daclatasvir for treating chronic hepatitis C. 2015. Available from: <https://www.nice.org.uk/guidance/ta364>. [Accessed 15.08.2016].  323. National Institute for Health and Care Excellence. Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C. 2015. Available from: <https://www.nice.org.uk/guidance/ta365>. [Accessed 15.08.2016].  324. National Institute for Health and Care Excellence. Pembrolizumab for advanced melanoma not previously treated with ipilimumab. 2015. Available from: <https://www.nice.org.uk/guidance/ta366>. [Accessed 15.08.2016].  325. National Institute for Health and Care Excellence. Vortioxetine for treating major depressive episodes. 2015. Available from: <https://www.nice.org.uk/guidance/ta367>. [Accessed 15.08.2016].  326. National Institute for Health and Care Excellence. Apremilast for treating moderate to severe plaque psoriasis. 2015. Available from: <https://www.nice.org.uk/guidance/ta368>. [Accessed 15.08.2016].  327. National Institute for Health and Care Excellence. Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab. 2015. Available from: <https://www.nice.org.uk/guidance/ta357>. [Accessed 15.08.2016].  328. National Institute for Health and Care Excellence. Tolvaptan for treating autosomal dominant polycystic kidney disease. 2015. Available from: <https://www.nice.org.uk/guidance/ta358>. [Accessed 15.08.2016].  329. National Institute for Health and Care Excellence. Idelalisib for treating chronic lymphocytic leukaemia. 2015. Available from: <https://www.nice.org.uk/guidance/ta359>. [Accessed 15.08.2016].  330. National Institute for Health and Care Excellence. Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer. 2015. Available from: <https://www.nice.org.uk/guidance/ta360>. [Accessed 15.08.2016].  331. National Institute for Health and Care Excellence. Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation. 2015. Available from: <https://www.nice.org.uk/guidance/ta355>. [Accessed 15.08.2016].  332. National Institute for Health and Care Excellence. Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy. 2015. Available from: <https://www.nice.org.uk/guidance/ta352>. [Accessed 15.08.2016].  333. National Institute for Health and Care Excellence. Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism. 2015. Available from: <https://www.nice.org.uk/guidance/ta354>. [Accessed 15.08.2016].  334. National Institute for Health and Care Excellence. Naloxegol for treating opioid‑induced constipation. 2015. Available from: <https://www.nice.org.uk/guidance/ta345>. [Accessed 15.08.2016].  335. National Institute for Health and Care Excellence. Aflibercept for treating diabetic macular oedema. 2015. Available from: <https://www.nice.org.uk/guidance/ta346>. [Accessed 15.08.2016].  336. National Institute for Health and Care Excellence. Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer. 2015. Available from: <https://www.nice.org.uk/guidance/ta347>. [Accessed 15.08.2016].  337. National Institute for Health and Care Excellence. Everolimus for preventing organ rejection in liver transplantation. 2015. Available from: <https://www.nice.org.uk/guidance/ta348>. [Accessed 15.08.2016].  338. National Institute for Health and Care Excellence. Dexamethasone intravitreal implant for treating diabetic macular oedema. 2015. Available from: <https://www.nice.org.uk/guidance/ta349>. [Accessed 15.08.2016].  339. National Institute for Health and Care Excellence. Secukinumab for treating moderate to severe plaque psoriasis. 2015. Available from: <https://www.nice.org.uk/guidance/ta350>. [Accessed 15.08.2016].  340. National Institute for Health and Care Excellence. Omalizumab for previously treated chronic spontaneous urticaria. 2015. Available from: <https://www.nice.org.uk/guidance/ta339>. [Accessed 15.08.2016].  341. National Institute for Health and Care Excellence. Ustekinumab for treating active psoriatic arthritis. 2015. Available from: <https://www.nice.org.uk/guidance/ta340>. [Accessed 15.08.2016].  342. National Institute for Health and Care Excellence. Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism. 2015. Available from: <https://www.nice.org.uk/guidance/ta341>. [Accessed 15.08.2016].  343. National Institute for Health and Care Excellence. Vedolizumab for treating moderately to severely active ulcerative colitis. 2015. Available from: <https://www.nice.org.uk/guidance/ta342>. [Accessed 15.08.2016].  344. National Institute for Health and Care Excellence. Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia. 2015. Available from: <https://www.nice.org.uk/guidance/ta343>. [Accessed 15.08.2016].  345. National Institute for Health and Care Excellence. Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia. 2015. Available from: <https://www.nice.org.uk/guidance/ta344>. [Accessed 15.08.2016].  346. National Institute for Health and Care Excellence. Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome. 2015. Available from: <https://www.nice.org.uk/guidance/ta335>. [Accessed 15.08.2016].  347. National Institute for Health and Care Excellence. Empagliflozin in combination therapy for treating type 2 diabetes. 2015. Available from: <https://www.nice.org.uk/guidance/ta336>. [Accessed 15.08.2016].  348. National Institute for Health and Care Excellence. Rifaximin for preventing episodes of overt hepatic encephalopathy. 2015. Available from: <https://www.nice.org.uk/guidance/ta337>. [Accessed 15.08.2016].  349. National Institute for Health and Care Excellence. Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib. 2015. Available from: <https://www.nice.org.uk/guidance/ta338>. [Accessed 15.08.2016].  350. National Institute for Health and Care Excellence. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy. 2015. Available from: <https://www.nice.org.uk/guidance/ta329>. [Accessed 15.08.2016].  351. National Institute for Health and Care Excellence. Sofosbuvir for treating chronic hepatitis C. 2015. Available from: <https://www.nice.org.uk/guidance/ta330>. [Accessed 15.08.2016].  352. National Institute for Health and Care Excellence. Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C. 2015. Available from: <https://www.nice.org.uk/guidance/ta331>. [Accessed 15.08.2016].  353. National Institute for Health and Care Excellence. Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment. 2015. Available from: <https://www.nice.org.uk/guidance/ta333>. [Accessed 15.08.2016].  354. National Institute for Health and Care Excellence. GreenLight XPS for treating benign prostatic hyperplasia. 2016. Available from: <https://www.nice.org.uk/guidance/mtg29/resources/greenlight-xps-for-treating-benign-prostatic-hyperplasia-64371943243717>. [Accessed 15.08.2016].  355. National Institute for Health and Care Excellence. Tests for rapidly identifying bloodstream bacteria and fungi (LightCycler SeptiFast Test MGRADE, SepsiTest and IRIDICA BAC BSI assay). 2016. Available from: <https://www.nice.org.uk/guidance/dg20/resources/tests-for-rapidly-identifying-bloodstream-bacteria-and-fungi-lightcycler-septifast-test-mgrade-sepsitest-and-iridica-bac-bsi-assay-1053683537605>. [Accessed 15.08.2016].  356. National Institute for Health and Care Excellence. Integrated sensor-augmented pump therapy systems for managing blood glucose levels in type 1 diabetes (the MiniMed Paradigm Veo system and the Vibe and G4 PLATINUM CGM system). 2016. Available from: <https://www.nice.org.uk/guidance/dg21/resources/integrated-sensoraugmented-pump-therapy-systems-for-managing-blood-glucose-levels-in-type-1-diabetes-the-minimed-paradigm-veo-system-and-the-vibe-and-g4-platinum-cgm-system-1053685217221>. [Accessed 15.08.2016].  357. National Institute for Health and Care Excellence. Therapeutic monitoring of TNF-alpha inhibitors in Crohn’s disease (LISATRACKER ELISA kits, IDKmonitor ELISA kits, and Promonitor ELISA kits). 2016. Available from: <https://www.nice.org.uk/guidance/dg22/resources/therapeutic-monitoring-of-tnfalpha-inhibitors-in-crohns-disease-lisatracker-elisa-kits-idkmonitor-elisa-kits-and-promonitor-elisa-kits-1053686896837>. [Accessed 15.08.2016].  358. National Institute for Health and Care Excellence. PlGF-based testing to help diagnose suspected pre-eclampsia (Triage PlGF test, Elecsys immunoassay sFlt- /PlGF ratio, DELFIA Xpress PlGF 1-2-3 test, and BRAHMS sFlt-1 Kryptor/BRAHMS PlGF plus Kryptor PE ratio). 2016. Available from: <https://www.nice.org.uk/guidance/dg23/resources/plgfbased-testing-to-help-diagnose-suspected-preeclampsia-triage-plgf-test-elecsys-immunoassay-sflt1plgf-ratio-delfia-xpress-plgf-123-test-and-brahms-sflt1-kryptorbrahms-plgf-plus-kryptor-pe-ratio-1053688576453>. [Accessed 15.08.2016].  359. National Institute for Health and Care Excellence. ImmunoCAP ISAC 112 and Microtest for multiplex allergen testing. 2016. Available from: <https://www.nice.org.uk/guidance/dg24/resources/immunocap-isac-112-and-microtest-for-multiplex-allergen-testing-1053690256069>. [Accessed 15.08.2016].  360. National Institute for Health and Care Excellence. Spectra Optia for automatic red blood cell exchange in patients with sickle cell disease. 2016. Available from: <https://www.nice.org.uk/guidance/mtg28/resources/spectra-optia-for-automatic-red-blood-cell-exchange-in-patients-with-sickle-cell-disease-64371941564101>. [Accessed 02.03.2016].  361. National Institute for Health and Care Excellence. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed. 2016. Available from: <https://www.nice.org.uk/guidance/ta375/resources/adalimumab-etanercept-infliximab-certolizumab-pegol-golimumab-tocilizumab-and-abatacept-for-rheumatoid-arthritis-not-previously-treated-with-dmards-or-after-conventional-dmards-only-have-failed-82602790920133>. [Accessed 16.08.2016].  362. National Institute for Health and Care Excellence. Canagliflflozin, dapagliflflozin and empagliflflozin as monotherapies for treating type 2 diabetes. 2016. Available from: <https://www.nice.org.uk/guidance/ta390/resources/canagliflozin-dapagliflozin-and-empagliflozin-as-monotherapies-for-treating-type-2-diabetes-82602903454405>. [Accessed 16.08.2016].  363. National Institute for Health and Care Excellence. TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis. 2016. Available from: <https://www.nice.org.uk/guidance/ta383/resources/tnfalpha-inhibitors-for-ankylosing-spondylitis-and-nonradiographic-axial-spondyloarthritis-82602848027077>. [Accessed 16.08.2016].  364. National Institute for Health and Care Excellence. Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene. 2016. Available from: <https://www.nice.org.uk/guidance/hst3/resources/ataluren-for-treating-duchenne-muscular-dystrophy-with-a-nonsense-mutation-in-the-dystrophin-gene-1394899207621>. [Accessed 15.08.2016].  365. National Institute for Health and Care Excellence. Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation. 2016. Available from: <https://www.nice.org.uk/guidance/ta398>. [Accessed 15.08.2016].  366. National Institute for Health and Care Excellence. Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts. 2016. Available from: <https://www.nice.org.uk/guidance/ta399>. [Accessed 15.08.2016].  367. National Institute for Health and Care Excellence. Nivolumab in combination with ipilimumab for treating advanced melanoma. 2016. Available from: <https://www.nice.org.uk/guidance/ta400>. [Accessed 15.08.2016].  368. National Institute for Health and Care Excellence. Adalimumab for treating moderate to severe hidradenitis suppurativa. 2016. Available from: <https://www.nice.org.uk/guidance/ta392>. [Accessed 15.08.2016].  369. National Institute for Health and Care Excellence. Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia. 2016. Available from: <https://www.nice.org.uk/guidance/ta393>. [Accessed 15.08.2016].  370. National Institute for Health and Care Excellence. Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia. 2016. Available from: <https://www.nice.org.uk/guidance/ta394>. [Accessed 15.08.2016].  371. National Institute for Health and Care Excellence. Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer. 2016. Available from: <https://www.nice.org.uk/guidance/ta395>. [Accessed 15.08.2016].  372. National Institute for Health and Care Excellence. Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma. 2016. Available from: <https://www.nice.org.uk/guidance/ta396>. [Accessed 15.08.2016].  373. National Institute for Health and Care Excellence. Belimumab for treating active autoantibody-positive systemic lupus erythematosus. 2016. Available from: <https://www.nice.org.uk/guidance/ta397>. [Accessed 15.08.2016].  374. National Institute for Health and Care Excellence. Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes. 2016. Available from: <https://www.nice.org.uk/guidance/ta390>. [Accessed 15.08.2016].  375. National Institute for Health and Care Excellence. Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel. 2016. Available from: <https://www.nice.org.uk/guidance/ta391>. [Accessed 15.08.2016].  376. National Institute for Health and Care Excellence. Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated. 2016. Available from: <https://www.nice.org.uk/guidance/ta387>. [Accessed 15.08.2016].  377. National Institute for Health and Care Excellence. Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction. 2016. Available from: <https://www.nice.org.uk/guidance/ta388>. [Accessed 15.08.2016].  378. National Institute for Health and Care Excellence. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer. 2016. Available from: <https://www.nice.org.uk/guidance/ta389>. [Accessed 15.08.2016].  379. National Institute for Health and Care Excellence. Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis. 2016. Available from: <https://www.nice.org.uk/guidance/ta386>. [Accessed 15.08.2016].  380. National Institute for Health and Care Excellence. Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated. 2016. Available from: <https://www.nice.org.uk/guidance/ta377>. [Accessed 15.08.2016].  381. National Institute for Health and Care Excellence. Nivolumab for treating advanced (unresectable or metastatic) melanoma. 2016. Available from: <https://www.nice.org.uk/guidance/ta384>. [Accessed 15.08.2016].  382. National Institute for Health and Care Excellence. Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia 2016. Available from: <https://www.nice.org.uk/guidance/ta385>. [Accessed 15.08.2016].  383. National Institute for Health and Care Excellence. Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy. 2016. Available from: <https://www.nice.org.uk/guidance/ta378>. [Accessed 15.08.2016].  384. National Institute for Health and Care Excellence. Nintedanib for treating idiopathic pulmonary fibrosis. 2016. Available from: <https://www.nice.org.uk/guidance/ta379>. [Accessed 15.08.2016].  385. National Institute for Health and Care Excellence. Panobinostat for treating multiple myeloma after at least 2 previous treatments. 2016. Available from: <https://www.nice.org.uk/guidance/ta380>. [Accessed 15.08.2016].  386. National Institute for Health and Care Excellence. Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy. 2016. Available from: <https://www.nice.org.uk/guidance/ta381>. [Accessed 15.08.2016].  387. Newton S, Ellery B, Fischer S, et al. Life Saving Drugs Programme Review: Technical Assessment. 2015. Available from: <http://www.pbs.gov.au/reviews/lsdp-technical-assessment-report/lsdp-review-technical-assessment-april-2015.pdf>. [Accessed 02.07.2016].  388. Noble SI, Nelson A, Fitzmaurice D, et al. A feasibility study to inform the design of a randomised controlled trial to identify the most clinically effective and cost-effective length of Anticoagulation with Low-molecular-weight heparin In the treatment of Cancer-Associated Thrombosis (ALICAT). Health Technol Assess. 2015 2015/10/22; 19(83).  389. O'Connor J, McCaughan D, McDaid C, et al. Orthotic management of instability of the knee related to neuromuscular and central nervous system disorders: systematic review, qualitative study, survey and costing analysis. Health Technol Assess. 2016 Jul; 20(55):1-262.  390. Orgeta V, Leung P, Yates L, et al. Individual cognitive stimulation therapy for dementia: a clinical effectiveness and cost-effectiveness pragmatic, multicentre, randomised controlled trial. Health Technol Assess. 2015 2015/08/20; 19(64).  391. Palmer S, Cramp F, Clark E, et al. The feasibility of a randomised controlled trial of physiotherapy for adults with joint hypermobility syndrome. Health Technol Assess. 2016 Jun; 20(47):1-264.  392. Parry SW, Bamford C, Deary V, et al. Cognitive-behavioural therapy-based intervention to reduce fear of falling in older people: therapy development and randomised controlled trial - the Strategies for Increasing Independence, Confidence and Energy (STRIDE) study. Health Technol Assess. 2016 2016/08/01; 20(56).  393. Paton NI, Stöhr W, Oddershede L, et al. The Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) trial: a randomised controlled trial of a protease inhibitor monotherapy strategy for long-term management of human immunodeficiency virus infection. Health Technol Assess. 2016 2016/03/17; 20(21).  394. Paula Cantero M, Lucinda Paz V, Gerardo Atienza M. Efectividad clínica del cribado neonatal de errores congénitos del metabolismo mediante espectrometría de masas en tándem. Parte IV. 2015. Available from: <http://avalia-t.sergas.es/DXerais/564/avalia-t201504CribadoNeonatalParteIV.pdf>. [Accessed 02.07.2016].  395. Peckham E, Man MS, Mitchell N, et al. Smoking Cessation Intervention for severe Mental Ill Health Trial (SCIMITAR): a pilot randomised control trial of the clinical effectiveness and cost-effectiveness of a bespoke smoking cessation service. Health Technol Assess. 2015 2015/03/31; 19(25).  396. Perera R, McFadden E, McLellan J, et al. Optimal strategies for monitoring lipid levels in patients at risk or with cardiovascular disease: a systematic review with statistical and cost-effectiveness modelling. Health Technol Assess. 2015 2015/12/21; 91(0).  397. Pickard R, Starr K, MacLennan G, et al. Use of drug therapy in the management of symptomatic ureteric stones in hospitalised adults: a multicentre, placebo-controlled, randomised controlled trial and cost-effectiveness analysis of a calcium channel blocker (nifedipine) and an alpha-blocker (tamsulosin) (the SUSPEND trial). Health Technol Assess. 2015 2015/08/04; 19(63).  398. Price MJ, Ades AE, Soldan K, et al. The natural history of Chlamydia trachomatis infection in women: a multi parameter evidence synthesis. Health Technol Assess. 2016 2016/03/23; 20(22).  399. Priebe S, Savill M, Wykes T, et al. Clinical effectiveness and cost-effectiveness of body psychotherapy in the treatment of negative symptoms of schizophrenia: a multicentre randomised controlled trial. Health Technol Assess. 2016 2016/02/15; 20(11).  400. Rachaneni S, McCooty S, Middleton LJ, et al. Bladder ultrasonography for diagnosing detrusor overactivity: test accuracy study and economic evaluation. Health Technol Assess. 2016 2016/01/26; 20(7).  401. Raftery J, Young A, Stanton L, et al. Clinical trial metadata: defining and extracting metadata on the design, conduct, results and costs of 125 randomised clinical trials funded by the National Institute for Health Research Health Technology Assessment programme. Health Technol Assess. 2015 2015/02/11; 19(11).  402. Ramsay CR, Adewuyi TE, Gray J, et al. Ablative therapy for people with localised prostate cancer: a systematic review and economic evaluation. Health Technol Assess. 2015 2015/07/02; 19(49).  403. Raquel Barbosa L, Gerardo Atienza M. Estents capturadores de células progenitoras de endotelio en el tratamiento de estenosis coronaria. 2015. Available from: <http://avalia-t.sergas.es/DXerais/617/CT201501_EstentAC_DEF.pdf>. [Accessed 02.07.2016].  404. Red Española de Agencias de Evaluación de Tecnologías y Prestaciones del SNS, Axencia Galega para a Xestión do Coñecemento en Saúde, Unidade de Asesora-mento Científico-técnico a-t. Selección de prioridades sanitarias: criterios, proceso y marco estratégico. Revisión sistemática. 2016. Available from: <http://avalia-t.sergas.es/DXerais/612/avalia-t201508_PrioridadesSanitarias.pdf>. [Accessed 12.08.2016].  405. Reeves BC, Pike K, Rogers CA, et al. A multicentre randomised controlled trial of Transfusion Indication Threshold Reduction on transfusion rates, morbidity and health-care resource use following cardiac surgery (TITRe2). Health Technol Assess. 2016 2016/08/15; 20(60).  406. regionali A-Anpiss. Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment [Core HTA]. 2015. Available from: <http://meka.thl.fi/ViewCover.aspx?id=267>. [Accessed 14.08.2016].  407. Sackley CM, Walker MF, Burton CR, et al. An Occupational Therapy intervention for residents with stroke-related disabilities in UK Care Homes (OTCH): cluster randomised controlled trial with economic evaluation. Health Technol Assess. 2016 2016/02/29; 20(15).  408. Scanlon P H, Aldington S J, Leal J, et al. Development of a cost-effectiveness model for optimisation of the screening interval in diabetic retinopathy screening. Health Technol Assess. 2015 2015/09/17; 19(74).  409. Simpson SA, McNamara R, Shaw C, et al. A feasibility randomised controlled trial of a motivational interviewing-based intervention for weight loss maintenance in adults. Health Technol Assess. 2015 2015/07/14; 19(50).  410. Skapinakis P, Caldwell D, Hollingworth W, et al. A systematic review of the clinical effectiveness and cost-effectiveness of pharmacological and psychological interventions for the management of obsessive-compulsive disorder in children/adolescents and adults. Health Technol Assess. 2016 2016/06/15; 20(43).  411. South Australian Medicines Evaluation Panel (SAMEP). Palivizumab for prevention of serious lower respiratory tract disease caused by Respiratory Syncytial Virus (RSV) in infants at high risk of RSV disease: Evaluation Summary. 2015. Available from: <http://www.sahealth.sa.gov.au/wps/wcm/connect/43ef95804ae1ddb4a6d7fe0b65544981/Palivizumab_RSV_final_web+summary_2015.pdf?MOD=AJPERES&CACHEID=43ef95804ae1ddb4a6d7fe0b65544981&CACHE=NONE>. [Accessed 03.08.2016].  412. Sozialversicherung Hdö. Legasthenie/Dyskalkulie. 2016. Available from: <http://www.hauptverband.at/cdscontent/load?contentid=10008.631763&version=1467622658> [Accessed 05.08.2016].  413. Stein RC, Dunn JA, Bartlett JMS, et al. OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer. Health Technol Assess. 2016 2016/02/11; 20(10).  414. Tandvårds- och läkemedelsförmånsverket (TLV). Cost-effectiveness analysis of thrombectomy for treatment of acute severe ischemic stroke. 2016. Available from: <http://www.tlv.se/Upload/English/Assessment_trombektomi.pdf>. [Accessed 13.08.2016].  415. Thursz M, Forrest E, Roderick P, et al. The clinical effectiveness and cost-effectiveness of STeroids Or Pentoxifylline for Alcoholic Hepatitis (STOPAH): a 2 × 2 factorial randomised controlled trial. Health Technol Assess. 2015 2015/12/21; 91(2).  416. Ussher M, Lewis S, Aveyard P, et al. The London Exercise And Pregnant smokers (LEAP) trial: a randomised controlled trial of physical activity for smoking cessation in pregnancy with an economic evaluation. Health Technol Assess. 2015 2015/10/22; 19(84).  417. Warhurst G, Dunn G, Chadwick P, et al. Rapid detection of health-care-associated bloodstream infection in critical care using multipathogen real-time polymerase chain reaction technology: a diagnostic accuracy study and systematic review. Health Technol Assess. 2015 2015/05/12; 19(35).  418. Williams JG, Alam MF, Alrubaiy L, et al. Comparison Of iNfliximab and ciclosporin in Steroid Resistant Ulcerative Colitis: pragmatic randomised Trial and economic evaluation (CONSTRUCT). Health Technol Assess. 2016 2016/06/21; 20(44).  419. Williams MA, Heine PJ, Williamson EM, et al. Active Treatment for Idiopathic Adolescent Scoliosis (ACTIvATeS): a feasibility study. Health Technol Assess. 2015 2015/07/22; 19(55).  420. Williams MA, Williamson EM, Heine PJ, et al. Strengthening And stretching for Rheumatoid Arthritis of the Hand (SARAH). A randomised controlled trial and economic evaluation. Health Technol Assess. 2015 2015/03/09; 19(19).  421. Williamson I, Vennik J, Harnden A, et al. An open randomised study of autoinflation in 4- to 11-year-old school children with otitis media with effusion in primary care. Health Technol Assess. 2015 2015/09/17; 19(72).  422. Wright B, Marshall D, Adamson J, et al. Social Stories™ to alleviate challenging behaviour and social difficulties exhibited by children with autism spectrum disorder in mainstream schools: design of a manualised training toolkit and feasibility study for a cluster randomised controlled trial with nested qualitative and cost-effectiveness components. Health Technol Assess. 2016 2016/01/20; 20(6). |

Supplementary Table 8 Methods of systematic reviews of economic evaluations in health technology assessment – Scope and literature search (detailed version)

| Category | Characteristics | | All (n=83) | | | Full HTA (n=73) | Rapid HTA (n=10) |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Scope of systematic review** | Exclusively systematic review | | 50 (60%) | | | 40 (55%) | 10 (100%) |
|  | Systematic review accompanied by primary CEA | | 25 (30%) | | | 25 (34%) | 0 |
|  | Systematic review to inform primary CEA | | 8 (10%) | | | 8 (11%) | 0 |
| **Research question/objective** | Stated | | 82 (99%) | | | 72 (99%) | 10 (100%) |
| **Eligibility criteria** | Not specified | | 6 (7%) | | | 3 (4%) | 3 (30%) |
|  | Population | | 61 (73%) | | | 58 (79%) | 3 (30%) |
|  | Intervention(s) | | 70 (84%) | | | 65 (89%) | 5 (50%) |
|  | Comparator(s) | | 52 (63%) | | | 50 (68%) | 2 (20%) |
|  | Outcomes | | 51 (61%) | | | 49 (67%) | 2 (20%) |
|  | Study design | | 57 (69%) | | | 51 (70%) | 6 (60%) |
|  | Specification of economic study types considered | | 57 (69%) | | | 52 (71%) | 5 (50%) |
|  | *Full economic evaluations only* | | *13 (23%)* | | | *12 (23%)* | *1 (20%)* |
|  | *Full economic evaluations and systematic reviews of full economic evaluations* | | *5 (9%)* | | | *5 (10%)* | *0* |
|  | *Other economic study types also considered* | | *39 (68%)* | | | *35 (67%)* | *4 (80%)* |
|  | PICO | | 7 (8%) | | | 7 (10%) | 0 |
|  | PICOS | | 32 (39%) | | | 31 (42%) | 1 (10%) |
|  | Country/Setting | | 14 (17%) | | | 14 (19%) | 0 |
|  | *only domestic studies* | | *6 (43%)* | | | *6 (8%)* | *0* |
|  | Publication type | | 24 (29%) | | | 23 (32%) | 1 (10%) |
|  | Publication date | | 11 (13%) | | | 10 (14%) | 1 (10%) |
|  | Language | | 6 (7%) | | | 4 (5%) | 2 (20%) |
|  | *English only* | | *4 (67%)* | | | *2 (50%)* | *2 (100%)* |
|  | *English + selected other(s)* | | *2 (33%)* | | | *2 (50%)* | *0* |
|  | Human studies | | 2 (2%) | | | 2 (3%) | 0 |
|  | Specified requirements for cost data | | 10 (12%) | | | 10 (14%) | 0 |
| **Literature Search** | |  | |  | | | |
|  | **Number of databases searched** | | 4 (1–14) | | | 5 (1–14) | 4 (1–9) |
| **Information Sources** | **Databases** | |  | | |  |  |
|  | General (medical) databases | | 79 (95%) | | | 69 (95%) | 10 (100%) |
|  | *MEDLINE* | | *79 (95%)* | | | *69 (95%)* | *10 (100%)* |
|  | *EMBASE* | | *71 (86%)* | | | *62 (85%)* | *9 (90%)* |
|  | *Cochrane Central Register of Controlled Trials (CENTRAL)* | | *26 (31%)* | | | *25 (34%)* | *1 (10%)* |
|  | *Web of Science* | | *18 (22%)* | | | *15 (21%)* | *3 (30%)* |
|  | *SCPOUS* | | *3 (4%)* | | | *3 (4%)* | *0* |
|  | *BIOSIS previews* | | *2 (2%)* | | | *2 (3%)* | *0* |
|  | *TRIP Database* | | *2 (2%)* | | | *2 (3%)* | *0* |
|  | *Journals@Ovid Full Text* | | *2 (2%)* | | | *2 (3%)* | *0* |
|  | *Current Contents* | | *1 (1%)* | | | *1 (1%)* | *0* |
|  | *ACP Journal Club* | | *1 (1%)* | | | *1 (1%)* | *0* |
|  | Cochrane Library | | 11 (13%) | | | 9 (12%) | 2 (20%) |
|  | Economic databases | | 51 (61%) | | | 48 (66%) | 3 (30%) |
|  | *National Health System Economic Evaluation Database (NHS EED)* | | *49 (59%)* | | | *46 (63%)* | *3 (30%)* |
|  | *EconLit* | | *10 (12%)* | | | *10 (14%)* | *0* |
|  | *Health Economic Evaluations Database (HEED)* | | *9 (11%)* | | | *8 (11%)* | *1 (10%)* |
|  | *Cost-effectiveness Analysis (CEA) Registry* | | *8 (10%)* | | | *7 (10%)* | *1 (10%)* |
|  | *IDEAS* | | *1 (1%)* | | | *1 (1%)* | *0* |
|  | General (medical) databases and economic databases | | 49 (59%) | | | 46 (63%) | 3 (30%) |
|  | HTA/SR databases | | 53 (64%) | | | 51 (70%) | 2 (20%) |
|  | *Health Technology Assessment (HTA) Database* | | *40 (48%)* | | | *38 (52%)* | *2 (20%)* |
|  | *Cochrane Database of Systematic Reviews (CDSR)* | | *23 (28%)* | | | *22 (30%)* | *1 (10%)* |
|  | *Database of Abstracts of Reviews of Effects (DARE)* | | *23 (28%)* | | | *22 (30%)* | *1 (10%)* |
|  | *Centre for Reviews and Dissemination (CRD) Database* | | *8 (10%)* | | | *8 (11%)* | *0* |
|  | *Cochrane Methodology Register (CMR)* | | *4 (5%)* | | | *4 (5%)* | *0* |
|  | *Evidence-Based Medicine (EBM) Reviews* | | *3 (4%)* | | | *3 (4%)* | *0* |
|  | *Planned and Ongoing Projects (POP) Database* | | *2 (2%)* | | | *2 (3%)* | *0* |
|  | Specific databases | | 27 (33%) | | | 21 (29%) | 6 (60%) |
|  | *CINAHL* | | *23 (28%)* | | | *17 (23%)* | *6 (60%)* |
|  | *PsycINFO* | | *14 (17%)* | | | *14 (19%)* | *0* |
|  | *Applied Social Science Index and Abstracts (ASSIA)* | | *2 (2%)* | | | *2 (3%)* | *0* |
|  | *Global Resource for EczemA Trials (GREAT) Database* | | *1 (1%)* | | | *1 (1%)* | *0* |
|  | *Allied and Complementary Medicine Database (AMED)* | | *1 (1%)* | | | *1 (1%)* | *0* |
|  | *Nursing Database* | | *1 (1%)* | | | *1 (1%)* | *0* |
|  | *International Bibliography for the Social Sciences (IBSS)* | | *1 (1%)* | | | *1 (1%)* | *0* |
|  | *Education Resources Information Center (ERIC)* | | *1 (1%)* | | | *1 (1%)* | *0* |
|  | *Physiotherapy Evidence Database (PEDro)* | | *1 (1%)* | | | *1 (1%)* | *0* |
|  | Citation index (SSCI/SCI) | | 8 (10%) | | | 8 (11%) | 0 |
|  | **Other sources searched** | | 68 (82%) | | | 62 (85%) | 6 (60%) |
|  | Online search | | 41 (49%) | | | 36 (49%) | 5 (50%) |
|  | Hand search in selected journals | | 2 (2%) | | | 2 (3%) | 0 |
|  | Reference lists | | 47 (57%) | | | 46 (63%) | 1 (10%) |
|  | Contact experts or corresponding authors of included studies | | 9 (11%) | | | 9 (12%) | 0 |
|  | Contact manufacturers | | 4 (5%) | | | 4 (5%) | 0 |
| **Economic search terms/filters** | Economic search terms/filters | | 45 (54%) | | | 40 (55%) | 5 (50%) |
|  | *Published economic filter* | | *8 (18%)* | | | *5 (13%)* | *3 (60%)* |
|  | *own Boolean search string with economic term* | | *37 (82%)* | | | *35 (88%)* | *2 (40%)* |
| **Search limits** | **Number of limitations applied** | | 3 (0–6) | | 3 (0–6) | | 3 (0–6) |
|  | At least one limitation applied | | 68 (82%) | | 59 (81%) | | 9 (90%) |
|  | Publication date | | 43 (52%) | | 37 (51%) | | 6 (60%) |
|  | *Update of previews SR* | | *8 (19%)* | | *8 (22%)* | | *0* |
|  | Language | | 46 (55%) | | 39 (53%) | | 7 (70%) |
|  | *English only* | | *33 (72%)* | | *26 (67%)* | | *7 (100%)* |
|  | *English + selected other* | | *13 (28%)* | | *13 (33%)* | | *0* |
|  | Human studies | | 37 (45%) | | 32 (44%) | | 5 (50%) |
|  | Publication type | | 25 (30%) | | 21 (29%) | | 4 (40%) |
|  | Study type | | 11 (13%) | | 7 (10%) | | 4 (40%) |
| **Study Selection** | | | | |  | |  |
| **Reviewers involved in screening** | Duplicate study selection | | 36 (43%) | | 35 (48%) | | 1 (10%) |
|  | *All identified studies screened independently by at least two reviewers* | | *27 (75%)* | | *26 (74%)* | | *1 (100%)* |
|  | *Titles and abstracts screened by one reviewer*  *Full-texts screened by two reviewers* | | *3 (8%)* | | *3 (9%)* | | *0* |
|  | *Titles and abstracts screened by one reviewer, quality assurance by second reviewer*  *Full-texts screened by two reviewers* | | *3 (8%)* | | *3 (9%)* | | *0* |
|  | *Titles and abstracts screened by two reviewers*  *Full-texts screened by one reviewer* | | *1 (3%)* | | *1 (3%)* | | *0* |
|  | *Titles and abstracts screened by two reviewers*  *Full-texts screened by one reviewer, quality assurance by second reviewer* | | *2 (6%)* | | *2 (6%)* | | *0* |
|  | *Mechanism to resolve disagreement reported* | | *22 (61%)* | | *21 (60%)* | | *1 (100%)* |
|  | All identified studies screened by one reviewer | | 21 (25%) | | 20 (27%) | | 1 (10%) |
|  | Not reported | | 26 (31%) | | 18 (25%) | | 8 (80%) |
| **Flow of study selection** | Described and/or presented in flow chart | | 60 (72%) | | 57 (78%) | | 3 (30%) |
|  | Presentation of flow chart | | 53 (64%) | | 51 (70%) | | 2 (20%) |
| CEA: cost-effectiveness analysis; HTA: health technology assessment; PICO: population, intervention(s), comparator(s), outcomes; PICOS: population, intervention(s), comparator(s), outcomes, study design; SCI: Sciences Citation Index; SSCI: Social Sciences Citation Index | | | | | | | |

Supplementary Table 9 Methods of systematic reviews of economic evaluations in health technology assessment – Data extraction, critical appraisal, and synthesis (detailed version)

| Category | Characteristics | All (n=71) | Full HTA (n=62) | Rapid HTA (n=9) |
| --- | --- | --- | --- | --- |
| **Data Extraction** | | | | |
| **Data extraction method** | Use of standardized extraction form | 23 (32%) | 21 (34%) | 2 (22%) |
| **Reviewers involved in data extraction** | Duplicate data extraction | 20 (28%) | 18 (29%) | 2 (22%) |
|  | *All data extracted by at least two reviewers* | *8 (40%)* | *6 (33%)* | *2 (100%)* |
|  | *All data extracted by one reviewer, quality assurance by second reviewer* | *12 (60%)* | *12 (67%)* | *0* |
|  | *Mechanism to resolve disagreement reported* | *6 (30%)* | *5 (28%)* | *1 (50%)* |
|  | All data extracted by one reviewer | 9 (13%) | 8 (13%) | 1 (11%) |
|  | Not reported | 42 (59%) | 36 (58%) | 6 (67%) |
| **Assessment of Methodological Study Quality** | | | | |
|  | Assessment of methodological study quality on study level | 38 (54%) | 35 (56%) | 3 (33%) |
| **Assessment tool** | *Drummond checklist [24]* | *13 (34%)* | *11 (31%)* | *2 (67%)* |
|  | *ICER Integrated Evidence Rating [25]* | *9 (24%)* | *9 (26%)* | *0* |
|  | *CHEERS statement (Husereau et al. 2013 [26])* | *3 (8%)* | *3 (9%)* | *0* |
|  | *Philips et al. 2004 [27]* | *3 (8%)* | *3 (9%)* | *0* |
|  | *CHEC-list (Evers et al. 2005 [28])* | *2 (5%)* | *2 (6%)* | *0* |
|  | *Critical Appraisal Skills Programme Checklist [29]* | *2 (5%)* | *2 (6%)* | *0* |
|  | *Questionnaire to Assess Relevance and Credibility of Modeling Studies for Informing Health Care Decision Making*  *(Jaime Caro et al. 2014 [31])* | *1 (3%)* | *1 (3%)* | *0* |
|  | *Guide to the Methods of Technology Appraisal - reference checklist for economic evaluations (NICE 2013 [30])* | *1 (3%)* | *1 (3%)* | *0* |
|  | *Cochrane 2008 (Handbook for Systematic Reviews of Interventions - Incorporating Economics Evidence [35])* | *1 (3%)* | *1 (3%)* | *0* |
|  | *Internal checklist based on published tools* | *8 (21%)* | *7 (20%)* | *1 (33%)* |
| **Reviewers involved in quality assessment** | Duplicate quality assessment | 15 (39%) | 15 (43%) | 0 |
|  | *Included studies critically appraised by at least two reviewers* | *11 (73%)* | *11 (73%)* | *0* |
|  | *Included studies critically appraised by one reviewer, quality assurance by second reviewer* | *4 (27%)* | *4 (27%)* | *0* |
|  | *Mechanism to resolve disagreement reported* | *9 (60%)* | *9 (60%)* | *0* |
|  | Included studies critically appraised by one reviewer | 4 (11%) | 4 (11%) | 0 |
|  | Not reported | 22 (58%) | 19 (54%) | 3 (100%) |
| **Assessment of Generalizability/Transferability/Applicability** | | | | |
|  | Assessment of generalizability/transferability/applicability | 7 (10%) | 6 (10%) | 1 (11%) |
| **Assessment tool** | *Questionnaire to Assess Relevance and Credibility of Modeling Studies for Informing Health Care Decision Making*  *(Jaime Caro et al. 2014 [31])* | *2 (29%)* | *2 (33%)* | *0* |
|  | *EUnetHTA Adaptation Toolkit [32]* | *1 (14%)* | *1 (17%)* | *0* |
|  | *Internal checklist based on published tools or own criteria* | *4 (57%)* | *3 (50%)* | *1 (100%)* |

| Category | Characteristics | | All (n=71) | | Full HTA (n=62) | Rapid HTA (n=9) |
| --- | --- | --- | --- | --- | --- | --- |
| **Reviewers involved in generalizability/transfer-ability/applicability assessment** | Duplicate assessment of generalizability/transferability/applicability | | 4 (57%) | | 4 (67%) | 0 |
|  | *Included studies critically appraised by at least two reviewers* | | *1 (25%)* | | *1 (25%)* | *0* |
|  | *Included studies critically appraised by one reviewer, quality assurance by second reviewer* | | *3 (75%)* | | *3 (75%)* | *0* |
|  | *Mechanism to resolve disagreement reported* | | *3 (75%)* | | *3 (75%)* | *0* |
|  | Not reported | | 3 (43%) | | 2 (33%) | 1 (100%) |
| **Presentation of cost data** | |  | |  | | |
|  | As reported | | 37 (52%) | | 32 (52%) | 5 (56%) |
|  | As reported and currency converted | | 13 (18%) | | 10 (16%) | 3 (33%) |
|  | As reported and inflated/currency converted | | 6 (8%) | | 6 (10%) | 0 |
|  | Inflated | | 1 (1%) | | 1 (2%) | 0 |
|  | Currency converted | | 4 (6%) | | 3 (5%) | 1 (11%) |
|  | Inflated/currency converted | | 4 (6%) | | 4 (6%) | 0 |
|  | Unclear | | 6 (8%) | | 6 (10%) | 0 |
| **Data synthesis** | |  | |  | | |
|  | Narrative synthesis | | 53 (75%) | | 46 (74%) | 7 (78%) |
|  | Permutation matrix | | 1 (1%) | | 1 (2%) | 0 |
|  | n.a. – only one study included | | 13 (18%) | | 11 (18%) | 2 (22%) |
|  | No synthesis | | 4 (6%) | | 4 (6%) | 0 |
| HTA: health technology assessment; ICER: Institute for Clinical and Economic Review; EUnetHTA: European Network for Health Technology Assessment; n.a.: not applicable | | | | | | |

Supplementary Table 10 Data items extracted (presented in standardized extraction forms or reported for all included studies)

| Category | Data item | All (n=67) | Full HTA (n=58) | Rapid HTA (n=9) |
| --- | --- | --- | --- | --- |
| **Study details** | | **65 (97%)** | **56 (97%)** | **9 (100%)** |
|  | Author(s) | 60 (90%) | 56 (97%) | 4 (44%) |
|  | Year of publication | 56 (84%) | 48 (83%) | 8 (89%) |
|  | Objective | 13 (19%) | 11 (19%) | 2 (22%) |
|  | Country | 52 (78%) | 44 (76%) | 8 (89%) |
|  | Setting | 8 (12%) | 8 (14%) | 0 |
|  | Funding | 13 (19%) | 11 (19%) | 2 (22%) |
| Methods | | 67 (100%) | 58 (100%) | 9 (100%) |
|  | Population | 57 (85%) | 48 (83%) | 9 (100%) |
|  | Intervention(s) | 65 (97%) | 56 (97%) | 9 (100%) |
|  | Comparator(s) | 58 (87%) | 49 (84%) | 9 (100%) |
|  | Outcomes/effects | 30 (45%) | 26 (45%) | 4 (44%) |
|  | Study design | 43 (64%) | 39 (67%) | 4 (44%) |
|  | PICO | 26 (39%) | 22 (38%) | 4 (44%) |
|  | PICOS | 20 (30%) | 19 (33%) | 1 (11%) |
|  | Methods for valuing outcomes/benefits | 8 (12%) | 8 (14%) | 0 |
|  | Model type | 29 (43%) | 23 (40%) | 6 (67%) |
|  | Perspective | 38 (57%) | 32 (55%) | 6 (67%) |
|  | Time horizon | 47 (70%) | 39 (67%) | 8 (89%) |
|  | Cost/ressource items included | 35 (52%) | 30 (52%) | 5 (56%) |
|  | Data sources for costs | 24 (36%) | 18 (31%) | 6 (67%) |
|  | Data sources for clinical data | 27 (40%) | 21 (36%) | 6 (67%) |
|  | Data sources for utility data | 14 (21%) | 11 (19%) | 3 (33%) |
|  | Discounting | 25 (37%) | 22 (38%) | 3 (33%) |
|  | Currency | 32 (48%) | 31 (53%) | 1 (11%) |
|  | Analysis of uncertainty | 28 (42%) | 22 (38%) | 6 (67%) |
| **Results** | | **62 (93%)** | **53 (91%)** | **9 (100%)** |
|  | Costs/resources | 51 (76%) | 42 (72%) | 9 (100%) |
|  | Outcomes/benefits | 36 (54%) | 28 (48%) | 8 (89%) |
|  | Incremental | 47 (70%) | 39 (67%) | 8 (89%) |
|  | Analysis of uncertainty | 29 (43%) | 23 (40%) | 6 (67%) |
|  | Author’s conclusion | 24 (36%) | 23 (40%) | 1 (11%) |
| PICO: population, intervention(s), comparator(s), outcomes; PICOS: population, intervention(s), comparator(s), outcomes, study design | | | | |